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ABSTRACT 
Healthy mitochondria are essential for cell survival. Described herein is 
the synthesis of a family of novel aminoquinone antioxidants designed to alleviate 
oxidative stress and prevent the impairment of cellular function. In addition, a 
library of bleomycin disaccharide analogues has also been synthesized to better 
probe the tumor targeting properties of bleomycin. 
The first study involves the synthesis of a benzoquinone natural product 
and analogues that closely resemble the redox core of the natural product 
geldanamycin. The synthesized 5-amino-3-tridecyl-1,4-benzoquinone 
antioxidants were tested for their ability to protect Friedreich’s ataxia (FRDA) 
lymphocytes from induced oxidative stress. Some of the analogues synthesized 
conferred cytoprotection in a dose-dependent manner in FRDA lymphocytes at 
micromolar concentrations. The biological assays suggest that the modification of 
the 2-hydroxyl and N-(3-carboxypropyl) groups in the natural product can 
improve its antioxidant activity and significantly enhance its ability to protect 
mitochondrial function under conditions of oxidative stress.  
The second project focused on the synthesis of a library of bleomycin 
disaccharide-dye conjugates and monitored their cellular uptake by fluorescence 
microscopy. The studies reveal that the position of the carbamoyl group plays an 
important role in modulating the cellular uptake of the disaccharide. It also led to 
the discovery of novel disaccharides with improved tumor selectivity. 
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CHAPTER 1 
1. INTRODUCTION 
The mitochondria are cellular organelles that play a vital role in 
maintaining cellular function and are essential for cell survival.1,2 In addition to 
the generation of ATP, mitochondria play a key role in many cellular processes 
such as ion homeostasis,3 innate immune response4 and programmed cell death.5 
Impaired mitochondrial function is associated with several pathological 
conditions such as Alzheimer’s disease,6 Parkinson’s disease,7 cancer,8 diabetes,9 
epilepsy,10 Huntington’s disease11 and obesity.12  
Mitochondrial dysfunction can arise from either a primary or secondary 
mitochondrial disorder.13 A primary disorder is caused by a mutation of any one 
of the genes encoding mitochondrial proteins while a secondary disorder is 
attributed to external effects like viral infections14 and off-target drug effects.15,16 
Mitochondrial DNA (mtDNA) is particularly susceptible to damage by reactive 
oxygen species (ROS) as the mitochondrion is the main source of ROS in cells.17  
In healthy mitochondria ROS is generated by tightly regulated cellular 
enzymes like NADPH oxidase and NO synthase.18 As a result in normal cells 
ROS is always present in low concentrations and plays a crucial role in 
physiological processes like cell signaling and immune response.19 In diseased 
cells, however, disruptions in the mitochondrial electron transport chain can cause 
overproduction of ROS leading to oxidative stress, exposing cellular components 
to oxidative damage.20-25 In neuronal degenerative diseases such as Alzheimer’s 
disease,26 Parkinson disease27-29 and amyotrophic lateral sclerosis (ALS),30 this 
exposure to oxidative stress has been found to cause mutations and deletions in 
the mitochondrial DNA (mtDNA) causing mtDNA damage. 
Mitochondrial DNA encodes for 13 of the approximately 100 proteins that 
make up the electron transport chain machinery located in the inner membrane of 
mitochondria.31 The machinery works by electron transport, driven by the 
generation of an electrochemical gradient across the mitochondrial inner 
membrane. In a dysfunctional mitochondria, the flow of electrons through 
complex I is interrupted and electrons are redirected to oxygen, generating 
superoxide (O2−•). Superoxide by itself is relatively inert towards biological 
molecules like lipid membranes, proteins and DNA; however, it can undergo a 
spontaneous or enzyme catalyzed (superoxide dismutase) disproportionation 
reaction with itself to form hydrogen peroxide (H2O2) and molecular oxygen (O2). 
The peroxide can undergo the Fenton reaction (Figure 1.1) in presence of Fe2+ 
ions to produce a hydroxyl radical and a hydroxide ion. 
2O2-. + 2H+ H2O2 + O2
H2O2 + Fe2+ Fe3+ + OH· + OH-  
Figure 1.1. Formation of hydroxyl radical by the Fenton reaction. 
  
The hydroxyl radicals diffuse through cells readily and are capable of 
reacting with virtually any biological molecule like DNA, proteins and lipids. It 
can also react with superoxide to generate the highly reactive singlet oxygen 
(1O2). 
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A particularly deleterious and damaging reaction mediated by hydroxyl 
radicals involves the abstraction of hydrogen atoms (H•) from lipid membranes to 
form a carbon centered radical (R•).32 This radical reacts readily with oxygen to 
form the highly reactive peroxyl radical (ROO•) which is capable of abstracting a 
hydrogen atom from the lipid membrane to further generate R•. This ultimately 
leads to a chain reaction producing multiple oxidative lesions from a single 
hydroxyl radical.32 
 
Figure 1.2. Reaction sequence of lipid peroxidation. (modified from ref. 32) 
 
1.1 Mitochondrial diseases 
Friedreich’s ataxia is a neurodegenerative disease characterized by the 
progressive ataxia of the limbs, muscle weakness, skeletal deformities and 
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cardiomyopathy. The biochemical basis of the disease is attributed to a deficiency 
in frataxin, a mitochondrial protein33 essential for the assembly of Fe-S clusters, 
resulting in a compromised mitochondrial respiratory chain. Frataxin deficiency, 
therefore, leads to higher levels of H2O2 and Fe2+, resulting in increased 
generation of ROS. Oxidative stress has been found to play an important role in 
the progression of the disease;34 therefore, strategies to overcome oxidative stress 
may have therapeutic potential.  
Huntington’s disease is a neurodegenerative genetic disorder clinically 
characterized by chorea, ataxia and dementia. The biochemical basis of the 
disease is attributed to an abnormally expanded cytidine-adenosine-guanosine 
(CAG) repeat in the huntington gene on chromosome 4.35 Biochemical analyses 
have shown a deficiency of complexes II, III and IV coupled with a decrease in 
aconitase acitivity.36-38 These findings suggest that antioxidant therapy may be 
helpful in treating patients with Huntington’s disease. 
Alzheimer’s disease is another neurodegenerative disease linked to 
mitochondrial dysfunction. Several complementary studies have shown that 
mitochondrial function is severely compromised in Alzheimer’s disease cells. It 
has been observed that complex IV activity is significantly reduced in the brain of 
patients with Alzheimer’s disease.39-41 Another distinct pathological feature of 
Alzheimer’s disease cells is the decrease in the expression of nuclear and mtDNA 
encoded COX subunits.42  
Amyotrophic lateral sclerosis (ALS) is a motor neuron disease arising 
from a dysfunctional mitochondrion. Mutations in the gene for superoxide 
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dismutase 1 (SOD-1) is observed in about 20% of patients suffering from the 
disease, causing neuronal damage by enhanced peroxidation.43,44 Increased 
concentration of 8-hydroxy-2-deoxyguanosine, an indicator of oxidative DNA 
damage, has also been observed in the plasma and urine of ALS patients, and its 
amount has been found to increase progressively with time.45 
The mitochondrion plays a central role in diverse cellular functions. It is 
therefore hardly surprising that mitochondrial damage cripples cellular function. 
Evidence is emerging that mitochondrial dysfunction is a common pathogenic 
feature in several neurodegenerative diseases. The development of therapeutic 
strategies to alleviate mitochondrial defects may provide novel drugs for the 
treatment of neurodegenerative disorders 
1.2 Cancer 
Cancer is a deadly disease causing one out of every eight deaths 
worldwide.46 It is actually a collection of more than 100 distinct diseases 
originating from most of the cell types and organs of the human body.47 A 
common characteristic of cancerous cells is their ability to proliferate in an 
unrestrained manner and to invade beyond normal tissue boundaries and 
metastasize to other organs.47 
Chemotherapeutic agents capable of inflicting damage specifically to 
cancer cells are potent tools in fighting unregulated cell growth. They restrict cell 
proliferation by inhibiting crucial cellular functions like cell division,48-50 protein 
synthesis51 and deoxyribonucleic acid (DNA) replication and transcription.52 The 
discovery of DNA as the hereditary material53 and the subsequent finding that 
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chemical agents capable of causing DNA damage and mutations can cause 
cancer,54 led to the increased scrutiny of cancer cell chromosomes.55,56 The 
identification and the isolation of the first oncogene further validated the role of 
DNA mutations in enabling cells to proliferate and metastasize.57,58 These 
findings, which implicated DNA damage as a key cause for the development of 
human cancer, also underlined its importance as a therapeutic target. 
The two major categories of drug-DNA interactions are intercalation and 
groove binding.59 Intercalation requires the insertion of a planar molecule 
between DNA base pairs resulting in a decrease of DNA helical twist and 
lengthening of DNA.60 Groove binders do not induce conformational changes in 
the DNA. They bind to the minor groove of the DNA and are stabilized by 
intermolecular interactions.61 
Therapeutic agents that affect DNA function by modulating its interaction 
with DNA processing enzymes like endonucleases, topoisomerases or 
polymerases are subjects of intense study.62,63 Disruptions in the function of DNA 
processing enzymes have a profound effect on cancer cells as compared to normal 
cells owing to their rapid division. For left uncorrected, this would lead to the 
accumulation of DNA mutations, causing cell death.64-68  
The design and synthesis of small molecules capable of targeting DNA in 
cancer cells is an active field of research in the pharmaceutical industry. The 
anticancer effects of radiation therapy and many chemotherapeutic agents can be 
attributed to the cytotoxicities arising from DNA damage, which cripples vital 
cellular processes such as transcription and replication.69 Targeting particular 
7 
 
components of DNA repair pathways in cancer cells like DNA double-strand 
break repair, base excision repair and nucleotide excision repair would improve 
the efficacy of anticancer treatments.69 
The bleomycins (BLMs), first discovered by Umezawa et al.,70,71 are a 
family of water soluble glycopeptidic antibiotics used in anticancer chemotherapy 
owing to their cytotoxicity towards cancer cells. Different structural variants of 
naturally occurring BLMs, differing primarily at the C-terminus of the 
glycopeptide, have been identified from fermentation broths. The initially 
proposed structure of BLM was revised in 197872 and confirmed by total 
synthesis in 1982.73,74 Many natural products like phleomycins (PLMs),75-78 
tallysomycins (TLMs)79,80 and zorbamycin (ZBM),81 which are structurally and 
biosynthetically related to the BLMs, have been isolated (Figure 1.3).82 
 Figure 1.3. Structures of bleomycins (BLMs) and structurally related antitumor 
antibiotics: tallysomycin (TLM), phleomycin (PLM) and zorbamycin (ZBM). 
Structural differences between the different natural products and BLMs are 
highlighted in red. (adapted from ref. 82) 
 
The structure of BLMs can be dissected into four functional domains 
(Figure 1.4).83 The metal binding domains comprised of the pyrimidoblamic acid 
subumit along with the adjacent β−hydroxyhistidine moiety. This domain 
provides the coordination sites required for Fe2+ complexation and molecular 
oxygen activation responsible for DNA cleavage.84 The bithiazole and C-terminal 
domain is responsible for the affinity of BLM towards DNA. In addition, it is also 
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believed to play a crucial role in polynucleotide recognition and DNA cleavage 
selectivity.84 The (2S, 3S, 4R)-4-amino-3-hydroxy-2-methylpentanoic acid 
(AHM) subunit acts as a linker between the DNA and metal binding sites of 
bleomycin and is essential for efficient cleavage of DNA by BLMs.84 
 
Figure 1.4. Core structure of BLMs. The nitrogen atoms involved in metal-
complexation appear in bold. (adapted from ref. 83) 
 
The biological activities of BLMs arise from their ability to cleave nucleic 
acids in a sequence selective, metal-dependent manner in presence of 
oxygen.83,85-88 Bleomycins sold under the trade name Blenoxane are used 
clinically in combination with etoposide and cisplatin for the treatment of 
testicular cancer and certain types of lymphomas.89,90 The low myelosuppression, 
and immunosuppression of BLM promotes its widespread use in combination 
chemotherapy;83-86 however, BLM-induced pneumonitis causing extensive 
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damage of lung vasculature is a major dose-limiting side effect.83 The favourable 
features of BLM have prompted continued efforts targeted at the synthesis of 
analogues with improved clinical efficacy and lower toxicity. 
The disaccharide moiety of BLM has remained largely unexplored mainly 
because of the lack of BLM analogues containing different sugars. Preliminary 
studies however indicate that the carbohydrate domain plays a crucial role in 
BLM activity.91-93 Modification of the disaccharides in BLM has resulted in 
analogues with modified selectivity and improved DNA cleavage activity.94 A 
major portion of this thesis describes efforts directed towards the modification of 
the disaccharide moiety in BLM. These studies have led to the identification of 
novel disaccharides with better cellular targeting profiles. 
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CHAPTER 2 
2. SYNTHESIS OF AMINOQUINONE ANTIOXIDANTS 
2.1 Introduction 
Mitochondria are cellular organelles essential for the normal functioning 
of eukaryotic cells. The primary function of the mitochondria is to support aerobic 
respiration and generate enough ATP to support cellular metabolism.1,2 In 
addition to being the powerhouse of the cell, the mitochondria also play an 
important role in immune response,4 production of reactive oxygen species 
(ROS)95,96 and apoptosis.5 Owing to their fundamental role in several cellular 
processes, mitochondrial dysfunction can endanger cell survival. Unsurprisingly, 
mitochondrial defects have been linked to the pathogenesis of a number of human 
diseases.13,97  
Mitochondrial density varies from one tissue to another and depends on 
the dependence of that tissue on oxidative phosphorylation for its energy needs. 
Consequently, neuronal, cardiac and skeletal muscle cells, which have a high 
density of mitochondria, have been found to be the most sensitive to energy-
linked defects arising from defective mitochondria.97 
Mitochondrial proteins are encoded by two distinct genetic systems: 
mitochondrial DNA (mtDNA) and nuclear DNA (nDNA). Mitochondrial DNA is 
a circular, double stranded DNA that codes for 13 proteins and 24 nucleic acids 
(two ribosomal RNAs (rRNAs) and 22 transfer RNAs (tRNAs), that are essential 
for intramitochondrial protein synthesis.13 The majority of the mitochondrial 
12 
 
respiratory chain polypeptides are encoded by nuclear DNA.98,99 These peptides, 
synthesized in the cytoplasm with a mitochondrial targeting sequence, are 
translocated into the mitochondria. The targeting sequence is cleaved before the 
protein is assembled on the inner mitochondrial membrane.100 The replication, 
repair, transcription and translation of mtDNA remain entirely dependent on 
proteins encoded by nDNA.98,99 This dependency ensures that damage to nuclear 
or mitochondrial genes can cause mitochondrial dysfunction and human disease.97  
New strategies need to be developed and implemented to tackle the effects 
of mitochondrial dysfunction. Novel drugs capable of restoring mitochondrial 
electron transport chain and ATP production might be effective in preventing the 
progression of organelle degradation. As the underlying biochemistries of a 
number of mitochondrial diseases are similar and can be alleviated by lowering 
oxidative stress,101 studies leading to the development of potent antioxidants offer 
great potential. 
Natural electron carriers like α-tocopherol102 and coenzyme Q10103 (Figure 
2.1) have recently received attention as potential therapeutic agents to prevent 
mitochondrial damage. The utility of coenzyme Q10 has been limited by its poor 
water solubility; however, given its favorable safety profile efforts have been 
directed at improving its pharmacokinetic properties. Idebenone is an analogue of 
coenzyme Q10 that can restore respiration in ubiquinone-deficient and rotenone-
blocked mitochondria. It is not specifically targeted to the mitochondria, but is 
capable of accepting electrons from complex I and reducing oxidative stress. 
 Figure 2.1. Structures of α-tocopherol and coenzyme Q10. 
 
Our research efforts were directed towards the synthesis of coenzyme Q 
analogues capable of transporting single electrons. As the reductive stress 
encountered in mitochondrial dysfunction is initially a one electron process, 
molecules in which the one-electron reduced intermediate is stabilized by dipole 
interactions, substituent effects, resonance or captodative effects should be better 
equipped to deal with cellular reductive stress. These molecules are denoted as 
multifunctional radical quenchers (MRQs) and should be capable of accepting 
electrons from superoxide, donating electrons to complex III and quench carbon-
centered radicals as a consequence of trafficking single electrons. 
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Figure 2.2. Structures of benzoquinone antioxidants.prepared for evaluation. 
 
Compound 2.3 is a natural product, first isolated from Embelia ribes 
Burm. (Myrsinaceae)−a species used in traditional Chinese medicine.104 The 
synthesis of compound 2.3, which closely resembles the redox active core of the 
natural product geldanamycin, has been reported.105 Geldanamycin is a 
benzoquinone ansamycin which exhibits antiproliferative activities against a 
broad range of human tumor cell lines.106 It has been reported that an analogue of 
geldanamycin (17-AAG) possessing the same redox core undergoes reduction in 
normal epithelial cells under physiological conditions.107 The reduced 
hydroquinone is formed in situ and binds to its target protein Hsp 90 with greater 
affinity than the quinone. Considering the structural similarities between the 
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redox cores of 2.3 and geldanamycin, it seemed likely that 2.3 would also undergo 
reduction under physiological conditions to the corresponding hydroquinone, 
potentially enabling it to protect cells from oxidative stress. 
 
Figure 2.3. Structures of 2.3, geldanamycin and 17-AAG. 
 
2.2 Results  
2.2.1 Synthesis of natural product 2.3 
A retrosynthetic analysis of aminoquinones is shown in Figure 2.4.  
 
Figure 2.4. Retrosynthetic analysis of natural product 2.3. 
 
Natural product 2.3 and its analogues could be synthesized from 2,4,5-
trimethoxybenzaldehyde by appropriate functional group transformations. As 
outlined in Scheme 2.1, the synthesis of compound 2.3 began with the H2O2-
mediated oxidation of commercially available 2,4,5-trimethoxybenzaldehyde to 
yield 2,4,5-trimethoxyphenol (2.20) in 78% yield.108 Deprotonation of phenol 
15 
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2.20 with sodium hydride and subsequent alkylation with methyl iodide 
proceeded smoothly to afford 1,2,4,5-tetramethoxybenzene (2.21) in 95% yield.109 
The n-butyllithium-mediated alkylation of compound 2.21 with purified 1-
bromotridecane yielded compound 2.22 in 73% yield.109 The alkylated 
tetramethoxybenzene 2.22 was then subjected to cerium(IV) ammonium nitrate 
oxidation to give a crude mixture containing quinones 2.23 and 2.24, which 
underwent perchloric acid-catalyzed selective demethylation to afford 
hydroxyquinone 2.24 exclusively in 54% yield over two steps.109 The selective 
demethylation has been reported to take place regioselectively with the removal 
of the more hindered methoxy group.109 The aminocarboxypropyl group was 
introduced by treating hydroxyquinone 2.24 with γ-aminobutyric acid tert-butyl 
ester hydrochloride salt in the presence of a large excess of sodium bicarbonate to 
yield the tert-butyl ester 2.1 in 45% yield. The tert-butyl ester was cleaved upon 
treatment with trifluoroacetic acid in the presence of anisole,110 which on 
precipitation from methanol afforded natural product 2.3 in 88% yield. The tert-
butyl ester 2.1 was further methylated with dimethyl sulfate in dry acetone to 
yield methoxyquinone 2.2 in 91% yield which, upon treatment with trifluoroacetic 
acid in the presence of a catalytic amount of anisole, gave the acid 2.4 in 76% 
yield. 
 Scheme 2.1. Synthesis of aminoquinone 2.3 and analogues. 
 
2.2.2 Synthesis of N-carboxypropyl esters of 2.3. 
As shown in Scheme 2.2, the key step in the synthesis involved the 
conjugate addition of the different esters of γ-aminobutyric acid to the 
methoxyquinone 2.24. The benzyl ester of γ-aminobutyric acid was synthesized 
according to a reported procedure111 to yield the ester 2.25 in 93% yield. The 
butyl and hexyl esters 2.26 and 2.27 were synthesized as their tosylate salts in 
92% and 72% yields, respectively, by the same procedure. The esters were then 
coupled to the hydroxyquinone 2.24 in presence of potassium tert-butoxide to 
obtain hydroxy quinone esters 2.5, 2.6 and 2.7 in 9%, 30% and 50% yields 
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respectively. The quinone esters thus obtained were methylated with dimethyl 
sulfate in dry acetone to yield methoxyquinones 2.8, 2.9 and 2.10 in 45%, 93% 
and 27% yields respectively. 
 
Scheme 2.2. Synthesis of N-carboxypropyl esters of quinone 2.3. 
 
2.2.3 Synthesis of N-alkylaminoquinones 
The synthesis of the N-alkylamine analogues of compound 2.3 was carried 
out to better understand the importance of the ester moiety to the overall 
antioxidant activity. As outlined in Scheme 2.3, methoxyquinone 2.24 was 
coupled to hexylamine to yield the corresponding hydroxyquinone 2.11 in 17% 
yield. The hydroxyquinone 2.11 thus obtained was methylated with dimethyl 
sulfate in dry acetone to yield methoxyquinone 2.12 in 58% yield. 
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 Scheme 2.3. Synthesis of N-alkylaminoquinone analogues.  
 
2.2.4 Synthesis of N,N-dialkylaminoquinones 
As a part of the structure-activity relationship (SAR) study, N,N-
dialkylated analogues were synthesized to ascertain the importance of the −NH 
moiety to the antioxidant activity of the quinones. The synthesis of the N-
methylated analogues, shown in Scheme 2.4, began with the hydrolysis of N-
methyl-2-pyrrolidone to yield 4-(methylamino)butanoic acid (2.28) in 45% yield 
according to a reported procedure.112 The acid 2.28 was converted to hexyl ester 
2.29 which was then coupled to benzoquinone 2.24 to afford hydroxyquinone 
2.13 in 43% yield. The hydroxyquinone was then methylated to afford 
methoxyquinone 2.15 in 51% yield. The synthesis of quinone 2.16 began with the 
N-CBz protection of the acid 2.28 followed by its esterification to afford the tert-
butyl ester 2.30 in 29% yield over two steps. The CBz group was then deprotected 
by catalytic hydrogenation to yield ester 2.31 in 43% yield, which when coupled 
to benzoquinone 2.24 afforded quinone 2.14 in 74% yield. The hydroxyquinone 
2.14 was then subjected to dimethyl sulfate-mediated methylation to yield 
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methoxyquinone 2.16 in 42% yield. The synthesis of 2.17 was achieved by 
coupling of the benzoquinone 2.24 with dimethylamine, which proceeded in 69% 
yield. The methylation of the hydroxyquinone 2.17 provided the methoxyquinone 
2.18 in 93% yield. 
 
Scheme 2.4. Synthesis of N,N-dialkylaminoquinone analogues.  
 
2.2.5 Synthesis of a cyclic geldanamycin analogue 2.19 
The synthesis of cyclic geldanamycin analogue 2.19 is outlined in Scheme 
2.5. Hex-5-en-1-amine hydrochloride (2.34) was synthesized according to a 
reported procedure.113 The synthesis of compound 2.19 began with the alkylation 
of tetramethoxybenzene (2.21) with purified 11-bromo-1-undecene to yield 2.35 
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in 82% yield. The oxidation of compound 2.35 with cerium(IV) ammonium 
nitrate provided a crude mixture of quinones 2.36 and 2.37, respectively, which 
upon treatment with HClO4-SiO2114 led to regioselective demethylation to form 
hydroxyquinone 2.37 in 26% yield over two steps. Attempts to carry out HClO4-
mediated demethylation to generate quinone 2.37, as in the synthesis of 
hydroxyquinone 2.24 (Scheme 2.1) led to the formation of an inseparable mixture 
of products. The quinone 2.37 was coupled with hex-5-en-1-amine hydrochloride 
(2.34) to form hydroxyquinone 2.38 in 75% yield. Quinone 2.38 was methylated 
to protect the phenolic hydroxyl group to yield methoxyquinone 2.39 in 74% 
yield. Compound 2.39 was subjected to ring closing metathesis in presence of 
Grubb’s catalyst to yield alkene 2.40 as a mixture of diastereomers in 52% yield. 
The reduction of alkene by catalytic hydrogenation followed by air oxidation 
provided 2.19 in 38% yield over two steps.115,116  
 
Scheme 2.5. Synthesis of cyclic analogue 2.19. 
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2.2.6 Biochemical results 
2.2.6.1 Cytoprotection 
The synthesized analogues were tested for their ability to confer 
cytoprotection to cultured cells as shown in Table 2.1. Cell viability was 
determined by trypan blue exclusion assay in Friedreich’s ataxia lymphoblast cell 
line GM15850 (Coriell Institute). This technique was used to assess the 
cytoprotective effects of the compounds in cultured cells treated with diethyl 
maleate (DEM) to induce cell death by glutathione (GSH) depletion.117 The 
viability of DEM-treated FRDA cells was determined by their ability to exclude 
the dye trypan blue. Viable cells exclude trypan blue, whereas non-viable cells 
take up the dye and stain blue. As outlined in Table 2.1, compound 2.2 was the 
most efficient, exhibiting 80% cytoprotection at 0.5 μM concentration. 
Benzoquinone analogue 2.4 afforded greater cyoprotection to FRDA lymphocytes 
at 5 μM concentration than did the tert-butyl ester 2.1 (74 vs 50%). The natural 
product 2.3 afforded the least protection when tested at this concentration. 
As shown below, the methoxyquinones 2.2, 2.4, 2.8, 2.9, 2.10, 2.12, 2.16 
and 2.18 offered greater cytoprotection when compared to their corresponding 
hydroxyquinones 2.1, 2.3, 2.5, 2.6, 2.7, 2.11, 2.14 and 2.17. The N-methylated 
compound 2.16 exhibited similar activity to unmethylated 2.2 at a concentration 
of 2.5 μM. The alkyl esters 2.9 and 2.10 also exhibited similar activities at tested 
concentrations. The cyclic analogue 2.19 offered concentration-dependent 
cytoprotection, affording 83% protection at 2.5 μM concentration.  
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Table 2.1. Cytoprotection of cultured FRDA lymphocytes from the effects of 
oxidative stressa   
 Compounds Concentration of test compounds 5 μM 2.5 μM 1 μM 0.5 μM 0.1 μM 
2.1 50 ± 2.9     
2.2 93 ± 4.0 84 ± 5.0 80 ± 4.0 80 ± 2.0  
2.3 36 ± 7.3     
2.4 74 ± 5.5     
2.5 48 ± 5.8     
2.6 58 ± 9.0     
2.7 49 ± 9.9     
2.8 71 ± 6.4     
2.9 82 ± 2.9     
2.10 90 ± 2.0     
2.11 70 ± 4.8     
2.12 80 ± 3.2     
2.14  74 ± 4.0 21 ± 6.0   
2.16  82 ± 5.0 64 ± 15   
2.17  24 ± 3.0  18 ± 4.0 21 ± 3.0 
2.18  90 ± 3.0  66 ± 3.0 53 ± 9.0 
2.19  83 ± 5.4  69 ± 2.3 36 ± 4.3 
a The viability of untreated cells was defined as 100%; cells treated with DEM 
alone had 18 ± 10% viability.  
This experiment was performed by Jennifer Jaruvangsanti. 
24 
 
2.2.6.2 Inhibition of lipid peroxidation 
The ability of the synthesized analogues to quench lipid peroxidation was 
evaluated in FRDA lymphocytes. These cells were placed under oxidative stress 
by depleting them of glutathione (GSH) using diethyl maleate (DEM).117-119 The 
extent of lipid peroxidation was quantified using a fatty acid sensitive fluorescent 
reporter C11-BODIPY581/591 (Molecular Probes).120,121 Upon oxidation of the 
phenylbutadiene moiety of the fluorophore, the red emitting form of the dye (595 
nm) is converted into a green emitting form (520 nm). Increased C11-
BODIPY581/591-green (oxidized) fluorescence, a measure of peroxyl radical 
production, was determined by flow cytometric analysis, which is expressed as % 
scavenging activity. The results in Table 2.2 show that analogue 2.16 was very 
effective in suppressing lipid peroxidation at 5 and 10 μM concentrations (97 and 
100% suppression of lipid peroxidation), while the natural product 2.3 was much 
less active (24% suppression at 10 μM concentration). Methoxyquinones 2.2, 2.10 
and 2.12 also exhibited concentration-dependent suppression of lipid 
peroxidation, affording 86, 98 and 94% suppression, respectively, at 10 μM 
concentration.  
 
Table 2.2. Suppression of lipid peroxidation by 3-alkyl-1,4-benzoquinone 
derivatives of N-(3-carboxylpropyl)-5-amino-2-hydroxy-3-tridecyl-1,4-
benzoquinone (2.3) antioxidants in cultured FRDA lymphocytes treated with 
diethyl maleate (DEM)a  
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Compound 
Scavenging activity (%)  
 5 μM 10 μM 
untreated controlb  100 100 
treated controlc  0 0 
2.1  26 ± 6.7 37 ± 1.4 
2.2  72 ± 1.8 86 ± 1.8 
2.3      8.0 ± 6.6  24 ± 7.4 
2.4                  41 ± 7.2 51 ± 5.0 
2.7                 9.0 ± 2.5 40 ± 9.9 
2.10                  81 ± 1.6 98 ± 1.2 
2.11                  27 ± 11 50 ± 1.2 
2.12                  79 ± 1.9 94 ± 1.4 
2.16                  97 ± 2.1       100 ±1.60 
2.19                  66 ± 5.1 81 ± 4.6 
a Values have been calculated as [(100 - % mean) / (100-% mean of the untreated 
control)] × 100. 
b No DEM treatment. 
c DEM treatment. 
The experiment was carried out by Dr. Omar Khdour. 
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2.2.6.3 Inhibition of mitochondrial complex I and NADH oxidase activity 
As shown in Tables 2.3 and 2.4, the methoxy hydroquinones were 
generally found to be much less inhibitory than the corresponding 
hydroxyquinones. The hydroxyquinones 2.1, 2.5, 2.6, 2.7 and 2.11 exhibits 
significantly higher inhibitory activities as compared to their corresponding 
methoxyquinones 2.2, 2.8, 2.9, 2.10 and 2.12. Compounds 2.2 (540 μM), 2.10 
(513 μM) and 2.12 (482 μM) had the least inhibitory effect on complex I activity. 
The effect of varying the length of the ester side chains on the ability of 
methoxyquinones 2.8, 2.9 and 2.10 to inhibit complex I, is not well understood. 
N-methylation significantly increases the inhibitory activity of methoxyquinones. 
N-methylated methoxyquinone 2.15 is a potent inhibitor of complex I while 
unmethylated 2.10 is not (1.9 μM vs 513 μM)  
Methoxyquinone 2.2 exhibited the least inhibition of NADH oxidase 
activity (77% at 5 μM). Methoxyquinones 2.8 (27% vs >85% at 5 μM) and 2.10 
(47% vs >85% at 5 μM) were more potent inhibitors of NADH oxidase activity as 
compared to complex I. The effect of O-methylation and N-methylation on the 
NADH inhibitory activities of compounds needs to be studied further.  
 
Table 2.3. Complex I inhibition by test compounds. 
Compound 
Complex I inhibition 
IC50 (µM) Imax (%) 
2.1  10 ± 0.6          64 ± 13 
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2.2  540 ± 17.0        >85 ± 2.3 
2.3          2.0 ± 0.1 84 ± 1.3 
2.4 1.9 ± 0.1 98 ± 2.8 
2.5 1.7 ± 0.1 70 ± 0.3 
2.6 11 ± 0.6 58 ± 4.0 
2.7 2.0 ± 0.4 51 ± 1.4 
2.8 34 ± 2.5        ≥53 ± 1.5 
2.9 98 ± 8.0       ≥ 60 ± 4.7 
2.10 513 ± 38.0        >85 ± 3.2 
2.11 20 ± 1.7          77 ± 6.2 
2.12 482 ± 24.0        >85 ± 3.6 
2.13 3.4 ± 0.1 78 ± 0.8 
2.15 1.9 ± 0.1 90 ± 0.7 
2.17 1.5 ± 0.1 90 ± 3.4 
2.18 1.60 ± 0.03 90 ± 1.1 
 
Table 2.4: NADH oxidase activity (complexes I, III and IV) 
Compound 
NADH oxidase activity (Complex I, III, IV) % 
10 μM 5 μM 1 μM 
2.2  77 ± 4.0 84 ± 1.0 
2.3  62 ± 3.0 77 ± 4.0 
2.8  48 ± 3.0 67 ± 6.0 
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2.10  27 ± 3.0 54 ± 5.0 
2.11  39 ± 1.0 67 ± 6.0 
2.12  47 ± 3.0         74 ± 16 
2.13         18 ± 0.5 36 ± 1.0         82 ± 2.4 
           2.15       17 ± 0.4       33 ± 0.9       81 ± 1.5 
2.17        5.0 ± 0.1        6.6 ± 0.1         18 ± 0.5 
2.18         15 ± 0.4         34 ± 0.6         70 ± 2.1 
 
The experiment was carried out by Dr. Valerie C. Collin and Sriloy Dey. 
 
2.2.6.4 Preservation of mitochondrial membrane potential (Δψm) 
The ability of the test compounds to preserve mitochondrial membrane 
potential under conditions of oxidative stress was studied. Assessment of Δψm is 
an important indicator of cellular function during stress-induced cell death. 
Changes in mitochondrial membrane potential (Δψm) were measured using two 
different fluorescent dyes, tetramethylrhodamine methyl ester (TMRM) and 
5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolocarbocyanine iodide (JC-1). 
TMRM is a potentiometric, cell-permeable fluorescent indicator that accumulates 
in the highly negatively charged interior of mitochondria inner membrane in a 
Nernstian manner. The fluorescence signal of TMRM can be directly co-related to 
Δψm across the inner mitochondrial membrane. Therefore the accumulation of dye 
into mitochondria and the intensity of signal is a direct function of mitochondrial 
potential. Loss of mitochondrial membrane potential is indicated by a reduction in 
TMRM red fluorescence. The detection of mitochondrial depolarization using 
TMRM was accomplished by flow cytometry. Figure 2.5 illustrates representative 
two-dimensional density dot plots of TMRM-stained lymphocyte cells showing 
the percentage of cells with intact Δψm (TMRM fluorescence in top right 
quadrant) vs. the percentage of cells with reduced Δψm (TMRM fluorescence in 
bottom left and right quadrants). The results show that DEM treatment decreased 
the percentage of cells with TMRM fluorescence in the top right quadrant, 
indicating that DEM treatment caused depolarization of Δψm. Compound 2.2 
preserved mitochondrial membrane potential as compared to the natural product 
2.3. The methoxy hydroquinone esters 2.9, 2.10 and the cyclic analogue 2.19 
prevented the loss of Δψm, consistent with the cytoprotection results.  
 
untreated control DEM FCCP 2.1 (5 µM) 
 
 
 
 
2.2 (5 µM) 2.3 (5 µM) 2.4 (5 µM) 2.5 (5 µM) 
 
 
  
2.6 (5 µM) 2.7 (5 µM) 2.8 (5 µM) 2.9 (5 µM) 
    
2.10 (5 µM) 2.11 (5 µM) 2.12 (5 µM) 2.19 (5 µM) 
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Figure 2.5 Effect of nitrogen-containing 1,4-benzoquinone derivatives on 
mitochondrial membrane potential of cultured FRDA cells. Representative flow 
cytometric two dimensional color density dot plot analyses of mitochondrial 
membrane potential Δψm in FRDA lymphocytes stained with TMRM and 
analyzed using the FL2-H channel. The cells were washed twice in phosphate 
buffered saline, and suspended in phosphate buffered saline containing 20 mM 
glucose. The percentage of cells with intact Δψm is indicated in the top right 
quadrant of captions. In each analysis, 10,000 events were recorded. Data are 
expressed as means ± SEM of three independent experiments run in duplicate. 
The experiment was carried out by Dr. Omar Khdour. 
 
These results were further confirmed with JC-1 dye in primary FRDA 
fibroblasts treated with buthionine sulfoximine (BSO) (Figure 2.6). BSO was used 
in this cellular model to induce an oxidative insult by inhibiting de novo 
glutathione synthesis.122 JC-1 is a lipophilic, cationic dye that can selectively 
enter into mitochondria and reversibly change color from green to red as the 
membrane potential increases by forming aggregates.123 The dye fluoresces red 
when it aggregates in the matrix of healthy energized mitochondria, whereas it 
fluoresces green in cells with depolarized Δψm. In untreated FRDA cells and cells 
treated with compounds 2.2 and 2.19, JC-1 probe was mainly in the aggregated 
state (red−orange), suggesting that compound 2.2, and to a lesser extent 2.19, 
preserved mitochondrial membrane potential in BSO−treated primary FRDA 
fibroblasts. Treatment with 1 mM BSO prevented JC-1 mitochondrial 
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accumulation, resulting in a pronounced green fluorescence due to complete loss 
of mitochondrial membrane potential. A significant mitochondrial membrane 
depolarization was observed with natural product 2.3 in BSO−treated cells. 
Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), a commonly 
used uncoupler of oxidative phosphorylation in mitochondria, was employed to 
dissipate the chemiosmotic proton gradient (ΔμH+). The pronounced green 
fluorescence resulting from FCCP treatment reflects the depolarization of 
mitochondrial inner membrane potential. These data indicate that compound 2.2 is 
able to prevent oxidative−stress induced collapse of Δψm, an event indicating 
mitochondrial function disruption that occurs prior to cell death. The results show 
that compound 2.2 is able to prevent ROS−induced damage of intracellular lipids, 
and is able to maintain mitochondrial function and confer cytoprotection in FRDA 
lymphocytes despite severe oxidative stress.  
 Figure 2.6. Representative fluorescence microscopy images of JC-1-stained 
primary FRDA fibroblasts were examined under Zeiss fluorescent microscope in 
control FRDA fibroblasts. Red indicates JC-1 aggregates, which are formed in the 
mitochondria when a sufficiently high membrane potential is reached. When the 
Δψm collapses as a result of glutathione depletion, the reagent (JC-1) no longer 
accumulates inside the mitochondria. Instead, it is distributed throughout the cell 
in the monomeric form which fluoresces green. Hoechst 33342 was used to 
identify all nuclei. (A) untreated primary FRDA fibroblasts (B) FRDA fibroblasts 
treated for 2 hours with 25 µM of the uncoupler FCCP (C) FRDA fibroblasts 
treated for 24 hours with 1 mM BSO (D) compound 2.2 (5 µM) (E) compound 
2.19 (5 µM) (F) compound 2.3 (5 µM). The experiment was carried out by Dr. 
Omar Khdour. 
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2.3 Discussion 
2.3.1 Synthesis of natural product 2.3 and its analogues 
The alkylation of tetramethoxybenzene (2.21) carried out according to a 
published procedure109 initially failed to give any product of interest. To ascertain 
the reason for the failure of the reaction, the reaction mixture was quenched with 
D2O after treatment with n-BuLi. The NMR spectrum of the purified product 
confirmed the incorporation of deuterium in 2.21. It was therefore concluded that 
the reaction was being quenched by the addition of 1-bromotridecane. 
Consequently the commercial sample of 1-bromotridecane was purified by flash 
column chromatography before use in the reaction, which enhanced the yield of 
the reaction significantly.  
The penultimate step in the synthesis of the natural product 2.3 was based 
on an NaHCO3-mediated conversion of vinylogous ester into the corresponding 
vinylogous amide124 involving conjugate addition of α-amino acid to the ester. 
The reaction did not proceed well in the presence of the unprotected  
γ-aminobutyric acid, possibly due to γ-butyrolactam formation. This 
problem was solved by using γ-aminobutyric acid t-butyl ester hydrochloride salt 
for conjugate addition to the hydroxyquinone 2.24.  
The deprotection of the Boc ester 2.1 to afford 2.3 could not be carried out 
with trifluroacetic acid alone and required the addition of an equivalent amount of 
anisole to the reaction mixture. Anisole is believed to act as a carbonium ion 
scavenger, thereby facilitating the deprotection of the t-Boc group. 
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The ROS scavenging activity of natural antioxidants like α-tocopherol and 
coenzyme Q10 depend not only on its redox core but also on the length of its 
lipophilic side chain. For α-TOH, the lipophilic side chain facilitates the insertion 
of the redox core into the liposomes and suppresses its migration between 
liposomal membranes. The design of the different N-carboxypropyl esters 2.5, 
2.6, 2.7, 2.8, 2.9 and 2.10 was directed towards optimizing the lipophilic 
character, and thereby increasing the antioxidant activities of the synthesized 
aminoquinones. 
A key step in the synthesis of the cyclic analogue 2.19 involved the 
oxidation of 2.35 with cerium(IV) ammonium nitrate to provide a crude mixture 
of quinones 2.36 and 2.37. The demethylation of 2.36 to yield 2.37 in presence of 
70% HClO4 led to the formation of a significant amount of byproducts which 
could not be separated from the product of interest. The formation of the 
byproducts was attributed to the oxidation of the alkene functional group by 
perchloric acid. This led to the use of a milder reagent HClO4-SiO2114 to carry out 
the regioselective demethylation of 2.36 to form hydroquinone 2.37. 
The successful synthesis of 2.19 involved a key ring closing metathesis 
reaction. Repeated attempts to subject 2.38 to a ring closing metathesis reaction 
with Grubb’s catalyst were met with failure. Amino groups have been reported to 
deactivate the Grubb’s catalyst by substituting the ligands on the catalyst .We 
hypothesized that the phenolic group, albeit less nucleophilic, was deactivating 
the catalyst by a similar mechanism. To circumvent this problem the hydroxyl 
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group was methylated and the corresponding methoxyquinone 2.39 was subjected 
to a ring closing metathesis reaction which proceeded smoothly as anticipated. 
2.3.2 Discussion of biochemical results 
2.3.2.1 Cytoprotection 
The ability of the synthesized quinones to protect cultured Friedreich’s 
ataxia lymphocyte from cell death by oxidative stress was measured (Table 2.1). 
For all the analogues synthesized the conversion of the hydroxyl group to the 
methoxy group was found to increase their ability to confer cytoprotection in a 
dose dependent manner. The improved activity of the methoxyquinones over the 
hydroxyquinones could be attributed to their greater stability under physiological 
conditions. The effect of N-methylation on the cytoprotective ability is not well 
understood and needs to be studied further. Hydroxyquinone 2.14 and the 
corresponding methoxyquinone 2.16 exhibited similar activities. The slight 
increase in activity of methoxyquinone 2.10 containing a hexyl side chain as 
compared to quinone 2.9 bearing a butyl side chain at 5 μM concentration 
suggested that synthesizing analogues with longer lipophilic ester side chains 
might improve activity. Initial biological results suggest that the ester moiety in 
the amine side chain might not be essential for activity. This conclusion is 
supported by the similar cytoprotective activities of methoxyquinone 2.9 and 
hexyl analogue 2.12 and needs to be studied in greater detail. The cyclic analogue 
2.19 with a lipophilic chain exhibits similar cytoprotection to the tert-butyl ester 
2.2. 
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2.3.2.2 Inhibition of lipid peroxidation 
The ability of the synthesized quinones to suppress lipid peroxidation in 
cultured Friedreich’s ataxia lymphocytes treated with diethyl maleate (DEM) was 
measured (Table 2.2). Consistent with the results observed for cytoprotection, the 
methoxyquinones offered greater protection against lipid peroxidation as 
compared to the corresponding hydroxyquinones. The presence of the ester 
moiety in the amine side chain might not be essential to quench lipid 
peroxidation. This conclusion, which is in agreement with the results for 
cytoprotection, is based on the result that 2.12, which lacks an ester group, 
exhibits similar activities as esters 2.2 and 2.10 in quenching lipid peroxidation. 
Preliminary results suggest that N-methylation improves the ability of the 
compounds to quench lipid peroxidation, as suggested by the improved activity of 
compound 2.16 as compared to 2.2 (97 vs 72%) at 5 μM concentration. 
2.3.2.3 Mitochondrial complex I and NADH oxidase Activity 
As shown in Tables 2.3 and 2.4, methoxy hydroquinones were generally 
found to be much less inhibitory than the corresponding hydroxyquinones. O-
methylation was found to have a profound impact on complex I inhibitory 
activities of the synthesized analogues. The inhibitory concentrations of 
methoxyquinones 2.8, 2.9, 2.10 and 2.12 are much higher than those of the 
corresponding hydroxyquinones 2.5, 2.6, 2.7 and 2.11, respectively. The lack of 
the ester moiety in the amine side chain decreases the ability of the compound to 
inhibit complex I, as observed for compound 2.12 which has a higher IC50 value 
as compared to most synthesized methoxyquinones studied. The presence of the 
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-NH moiety is crucial for preventing complex I inhibition as all the tested N,N-
dialkylamino quinones (2.13, 2.15, 2.17 and 2.18) exhibited low inhibitory 
concentrations for complex I. Compound 2.2 exhibited the highest IC50 value for 
complex I and NADH oxidase activity, in agreement with its ability to protect 
FRDA lymphocytes from oxidative stress. 
2.3.2.4 Preservation of mitochondrial membrane potential 
The ability of the synthesized quinones to preserve mitochondrial 
membrane potential in cultured Friedreich’s ataxia lymphocytes was measured 
(Figures 2.5 and 2.6). The methoxyquinones 2.8, 2.9, 2.10, 2.12 and 2.19 were 
more effective at preserving loss of Δψm than the corresponding hydroxyquinones 
2.5, 2.6, 2.7 and 2.11. Compound 2.2 was most effective at preserving 
mitochondrial membrane potential. These results were further confirmed with JC-
1 dye in primary FRDA fibroblasts treated with buthionine sulfoximine (BSO) 
which showed that compound 2.2 and 2.19 are able to prevent ROS-induced 
damage of intracellular lipids, and maintain mitochondrial function in FRDA 
lymphocytes despite severe oxidative stress.  
2.4 Experimental 
General Methods. The chemicals were all ACS reagent grade and were used 
without further purification, except for 1-bromotridecane and undecyl bromide 
which were purified by silica gel flash column chromatography prior to use. The 
reactions were carried out under an atmosphere of argon. Flash column 
chromatography was carried out using silica gel (Silicycle R10030B, 60 particle 
size, 230-400 mesh), applying a low pressure stream of nitrogen. Analytical thin 
layer chromatographic separations were carried out on glass plates coated with 
silica gel (60 particle size F254, SiliCycle TLG-R10011B-323). The TLC 
chromatograms were developed by immersing the plates in 2.5% potassium 
permanganate in ethanol or 2% anisaldehyde + 5% sulfuric acid + 1.5% glacial 
acetic acid in ethanol, followed by heating, or else visualized by UV irradiation 
(254 nm). Melting points were recorded on a MelTemp apparatus and are 
uncorrected. Tetrahydrofuran was distilled from sodium/benzophenone ketyl and 
dichloromethane from calcium hydride. 1H and 13C NMR spectra were recorded 
on a Gemini 300 or Varian Inova 400, or on a Varian Inova 500 spectrometer, 
using CDCl3 as solvent and internal standard, unless otherwise indicated. 1H 
NMR chemical shifts were reported relative to residual CHCl3 at 7.26 ppm, or to 
residual DMSO-d5 at 2.50 ppm; 13C NMR shifts were reported relative to the 
central line of CDCl3 at 77.16 ppm, or to 13C DMSO-d6 at 39.51 ppm. Splitting 
patterns are designated as s, singlet; br s, broad singlet; d, doublet; dd, doublet of 
doublets; dt, doublet of triplets; m, multiplet; q, quartet; quin, quintet. High 
resolution mass spectrometric data were obtained at the Michigan State Mass 
Spectrometry Facility or at the Arizona State University CLAS High Resolution 
Mass Spectrometry Facility. 
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2,4,5-Trimethoxyphenol (2.20).108,109 To a solution containing 10 g (51 mmol) of 
2,4,5-trimethoxybenzaldehyde and 6.4 mL of H2O2 (35% wt solution in H2O) in 
102 mL of methanol was added 1.0 mL (18 mmol) of concentrated H2SO4 
dropwise under an atmosphere of argon at room temperature. The reaction 
mixture was heated to reflux for 2 h, diluted with water and extracted with three 
100-mL portions of dichloromethane. The combined organic layer was washed 
with brine, dried (MgSO4) and concentrated under diminished pressure. The crude 
residue was applied to a silica gel column (12 × 4 cm). Step gradient elution with 
1:4Æ1:2 ethyl acetate−hexanes afforded compound 2.20 as a yellow solid: yield 
7.34 g (78%); silica gel TLC Rf 0.45 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 3.48 (s, 6H), 3.52 (s, 3H), 6.08 (br s, 1H), 6.33 (s, 1H) and 6.36 (s, 1H); 
13C NMR (CDCl3) δ 56.4, 57.0, 57.2, 99.6, 100.9, 139.6, 142.1 and 143.8. 
 
 
1,2,4,5-Tetramethoxybenzene (2.21).109 To a solution of 1.38 g (60% oil 
dispersion, 57.5 mmol) of sodium hydride washed with several portions of hexane 
in 32 mL of anh N,N-dimethylformamide was added a solution of 7.06 g (38.3 
mmol) of phenol 2.20 in 32 mL of anh N,N-dimethylformamide. The reaction 
mixture was stirred at 0 °C for 30 min under an argon atmosphere and 4.78 mL 
(10.9 g, 76.6 mmol) of methyl iodide was added dropwise. The reaction mixture 
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was then stirred at room temperature for 13 h and quenched by addition of 10 mL 
of methanol. The solvent was concentrated under diminished pressure to afford a 
crude residue. The residue was extracted with five 10-mL portions of 
dichloromethane, was washed successively with 50 mL of 3% aq HCl, distilled 
water and brine, and then dried (MgSO4). The solvent was concentrated under 
diminished pressure to afford a crude residue. The residue was applied to a silica 
gel column (8 × 4 cm). Elution with 1:4 ethyl acetate−hexanes gave compound 
2.21 as a colorless solid: yield 7.21 g (95%); mp 102-103 °C, lit109 mp 101-102 
°C; silica gel TLC Rf 0.32 (1:2 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 3.70 
(s, 12H) and 6.47 (s, 2H); 13C NMR (CDCl3) δ 57.1, 100.7 and 143.2. 
 
 
1,2,4,5-Tetramethoxy-3-tridecylbenzene (2.22).109 
To a solution containing 1.0 g (5.0 mmol) of 1,2,4,5-tetramethoxybenzene (2.21) 
and 87 μL (90 mg, 0.5 mmol) of hexamethylphosphoramide in 25 mL of anh THF 
was added 3.4 mL (1.6 M in hexanes, 5.5 mmol) of n-butyllithium dropwise at 
−40 ºC over a period of 5 min. The reaction mixture was warmed to 0 °C over a 
period of 2 h, then 1.4 mL (1.4 g, 5.5 mmol) of purified 1-bromotridecane was 
added and the reaction mixture was stirred at room temperature under an argon 
atmosphere for 15 h. The reaction mixture was quenched by the addition of 20 
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mL of saturated NH4Cl and extracted with five 10-mL portions of ether. The 
combined organic layer was washed with distilled water and brine and then dried 
(MgSO4). The solvent was concentrated under diminished pressure to afford a 
crude residue. The residue was applied to a silica gel column (6 × 3 cm). Elution 
with 1:9 ethyl acetate−hexanes afforded compound 2.22 as a colorless solid: yield 
1.4 g (73%); silica gel TLC Rf 0.45 (1:1 ethyl ether−hexanes); mp 31-32 oC, lit109 
mp 31-32 oC; 0.2 g (20%) of unreacted 1,2,4,5-tetramethoxybenzene (2.21) was 
recovered; 1H NMR (CDCl3) δ 0.87 (t, 3H, J = 6.8 Hz), 1.14-1.46 (m, 20H), 1.47-
1.58 (m, 2H), 2.61 (dd, 2H, J = 8.8 and 6.9 Hz), 3.76 (s, 6H), 3.82 (s, 6H) and 
6.40 (s, 1H); 13C NMR (CDCl3) δ 14.1, 22.7, 24.7, 29.4, 29.5, 29.6, 29.70, 29.75, 
29.76, 30.0, 30.8, 32.0, 56.2, 60.4, 60.9, 96.7, 131.1, 141.1 and 148.8. 
 
 
2-Hydroxy-5-methoxy-3-tridecylcyclohexa-2,5-diene-1,4-dione (2.24).109 To a 
solution containing 0.10 g (0.26 mmol) of 1,2,4,5-tetramethoxy-3-tridecylbenzene 
(2.22) in 2.60 mL of acetonitrile was added dropwise a solution containing 0.28 g 
(0.52 mmol) of cerium(IV) ammonium nitrate in 2.6 mL of 7:3 acetonitrile−water 
at −7 °C (salt−ice bath) over a period of 30 min. The reaction mixture was stirred 
at room temperature for 3 h and then diluted with 10 mL of ether. The organic 
layer was washed successively with distilled water and brine and then dried 
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(MgSO4). The solvent was concentrated under diminished pressure to afford a 
mixture of quinones 2.23 and 2.24. To a solution of this mixture in 2.60 mL of 
dichloromethane was added 1.10 mL (13.0 mmol) of 70% perchloric acid 
dropwise at 0 °C. The reaction mixture was then stirred at 0 °C for 9 h and diluted 
with 10 mL of dichloromethane. The organic layer was washed successively with 
distilled water and brine and then dried (MgSO4). The solvent was concentrated 
under diminished pressure to afford a crude residue. The residue was applied to a 
silica gel column (7 × 2 cm). Elution with 1:4 ethyl acetate−hexanes gave 
compound 2.24 as a yellow−orange solid: yield 48 mg (54%); mp 90-92 °C, lit125 
mp 90-91°C; silica gel TLC Rf 0.58 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 0.85 (t, 3H, J = 6.8 Hz), 1.17-1.33 (m, 20H), 1.39-1.49 (m, 2H), 2.41 
(t, 2H, J = 8.0 Hz), 3.84 (s, 3H), 5.82 (s, 1H) and 7.32 (s, 1H); 13C NMR (CDCl3) 
δ 14.2, 22.7, 22.8, 28.1, 29.48, 29.54, 29.68, 29.69, 29.77, 29.78, 29.79, 29.80, 
32.0, 56.9, 102.3, 119.4, 151.7, 161.2, 181.8, and 183.0. 
 
 
tert-Butyl 4-(4-hydroxy-3,6-dioxo-5-tridecylcyclohexa-1,4-
dienylamino)butanoate (2.1).105 To a solution of 42.0 mg (0.13 mmol) of 2-
hydroxy-5-methoxy-3-tridecyl-(1,4)-benzoquinone (2.24) and 1.00 g (13.0 mmol) 
of sodium bicarbonate in 9.70 mL of ethanol was added 39.0 mg (0.19 mmol) of 
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γ-aminobutyric acid tert-butyl ester hydrochloride salt. The reaction mixture was 
stirred at 45 °C for 27 h under an argon atmosphere and quenched by the addition 
of 5 mL of water. The aqueous layer was extracted with seven 2-mL portions of 
dichloromethane. The combined organic layer was washed with distilled water 
and brine and then dried (Na2SO4). The solvent was concentrated under 
diminished pressure to afford a crude residue. The residue was applied to a silica 
gel column (5 × 2 cm). Elution with dichloromethane gave compound 2.1 as a 
dark red solid: yield 27 mg (45%); mp 96-97 °C, lit105 mp 82-85 °C; silica gel 
TLC Rf 0.38 (dichloromethane); 1H NMR (CDCl3) δ 0.86 (t, 3H, J = 6.5 Hz), 
1.20-1.32 (m, 20H), 1.38-1.46 (m, 11H), 1.94 (quin, 2H, J = 6.9 Hz), 2.31 (t, 2H, 
J = 7.0 Hz), 2.34-2.40 (m, 2H), 3.21 (dd, 2H, J = 12.9 and 6.6 Hz), 5.35 (s, 1H) 
and 6.58 (s, 1H); 13C NMR (CDCl3) δ 14.3, 22.79, 22.84, 23.5, 28.23, 28.24, 29.5, 
29.6, 29.73, 29.75, 29.81, 29.83, 29.84, 32.1, 32.8, 42.4, 81.2, 91.9, 115.9, 149.9, 
155.1, 172.1, 179.0 and 182.6; mass spectrum (LCT electrospray), m/z 486.3181 
(M + Na)+ (C27H45NO5Na requires m/z 486.3195). 
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tert-Butyl 4-(4-methoxy-3,6-dioxo-5-tridecylcyclohexa-1,4-
dienylamino)butanoate (2.2). To a solution containing 22.0 mg (47.0 μmol) of 
quinone 2.1 and 0.25 g (1.80 mmol) of potassium carbonate in 1.2 mL of anh 
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acetone was added 23.0 µL (31.0 mg, 0.23 mmol) of dimethyl sulfate. The 
reaction mixture was heated to reflux overnight, cooled to room temperature and 
concentrated under diminished pressure. The crude reaction mixture was 
redissolved in 10 mL of dichloromethane and washed with 5 mL of 1 N HCl. The 
aqueous layer was extracted with three 10-mL portions of dichloromethane. The 
combined organic layer was dried (MgSO4) and concentrated under diminished 
pressure to afford a crude residue. The residue was applied to a silica gel column 
(24 × 2 cm). Elution with 1:5 ethyl acetate−hexanes gave compound 2.2 as a 
bright red amorphous solid: yield 21 mg (91%); silica gel TLC Rf 0.60 (1:2 ethyl 
acetate−hexanes); 1H NMR (CDCl3) δ 0.87 (t, 3H, J = 6.8 Hz), 1.16-1.42 (m, 
22H), 1.45 (s, 9H), 1.82-2.03 (quin, 2H, J = 9.0 Hz), 2.31 (t, 2H, J = 7.2 Hz), 
2.35-2.39 (m, 2H), 3.14 (dd, 2H, J = 13.0 and 6.8 Hz), 4.10 (s, 3H), 5.28 (s, 1H) 
and 5.94 (t, 1H, J = 5.6 Hz); 13C NMR (CDCl3) δ 14.3, 22.8, 23.1, 23.6, 28.20, 
28.24, 28.8, 29.5, 29.6, 29.7, 29.81, 29.83, 32.1, 32.9, 42.1, 61.8, 81.1, 96.1, 
127.6, 146.9, 158.5, 172.18, 172.20, 181.8 and 183.9; mass spectrum (APCI), m/z 
478.3532 (M + H)+ (C28H48NO5 requires m/z 478.3532). 
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4-(4-Hydroxy-3,6-dioxo-5-tridecylcyclohexa-1,4-dienylamino)butanoic Acid 
(2.3).105 To a solution containing 28 mg (60 µmol) of ester 2.1 in 0.4 mL of 
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dichloromethane were added 6.5 μL (6.5 mg, 60 µmol) of anisole and 0.4 mL (0.6 
g, 5.4 mmol) of trifluoroacetic acid. The reaction mixture was stirred at room 
temperature for 24 h under an argon atmosphere. The reaction mixture was 
concentrated under diminished pressure and the excess trifluoroacetic acid was 
removed by co-evaporation three times with cyclohexane to afford a crude 
residue. The residue was precipitated from methanol to give compound 2.3 as a 
red amorphous solid: yield 21 mg (88%); mp 194-195 °C, lit105mp 177-180 °C; 1H 
NMR (DMSO-d6) δ 0.85 (t, 3H, J = 6.8 Hz), 1.15-1.42 (m, 22H), 1.74 (quin, 2H, 
J = 14.4 and 7.2 Hz), 2.26 (q, 4H, J = 6.9Hz), 3.14 (dd, 2H, J = 13.8 and 6.7 Hz), 
5.32 (s, 1H), 7.78 (t, 1H, J = 6.2 Hz), 10.5 (br s, 1H), and 12.2 (br s, 1H); 13C 
NMR (DMSO-d6) δ 14.0, 22.1, 22.2, 22.8, 27.6, 28.8, 28.9, 29.0, 29.02, 29.06, 
29.08, 29.1, 30.9, 31.3, 41.4, 91.8, 115.6, 149.3, 156.7, 174.2, 178.5 and 182.5; 
mass spectrum (LCT electrospray), m/z 430.2564 (M + Na)+ (C23H37NO5Na 
requires m/z 430.2569). 
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4-(4-Methoxy-3,6-dioxo-5-tridecylcyclohexa-1,4-dienylamino)butanoic 
Acid (2.4). To a solution containing 9.0 mg (19 µmol) of ester 2.2 in 120 μL of 
dichloromethane was added 2.0 µL (2.0 mg, 19 µmol) of anisole, and 130 μL (0.2 
g, 1.7 mmol) of trifluoroacetic acid. The reaction mixture was stirred at room 
temperature for 24 h under an argon atmosphere. The reaction mixture was co-
evaporated with six 5-mL portions of cyclohexane and the solvent was 
concentrated under diminished pressure to afford a crude residue. The residue was 
applied to a silica gel column (22 × 2 cm). Elution with 100:1 
chloroform−methanol gave compound 2.4 as a red amorphous solid: yield 6.0 mg 
(76%); silica gel TLC Rf 0.32 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
0.88 (t, 3H, J = 6.9 Hz), 1.22-1.41 (m, 22H), 1.98 (quin, 2H, J = 6.9 Hz), 2.33-
2.40 (m, 2H), 2.47 (t, 2H, J = 6.9 Hz), 3.20 (q, 2H, J = 6.6 Hz), 4.11 (s, 3H), 5.29 
(s, 1H), and 5.97 (s, 1H); 13C NMR (CDCl3) δ 14.3, 18.5, 22.8, 23.1, 23.2, 28.8, 
29.5, 29.6, 29.7, 29.81, 29.84, 31.3, 32.1, 42.0, 51.0, 58.6, 61.8, 96.2, 127.7, 
146.9, 158.5, 176.6, 181.8, and 184.0; mass spectrum (APCI), m/z 422.2898 (M + 
H)+ (C24H40NO5 requires 422.2906). 
 
 
4-(Benzyloxy)-4-oxobutan-1-aminium 4-Methylbenzenesulfonate (2.25).111 A 
solution of 1.00g (9.70 mmol) of 4-aminobutanoic acid, 2.02 g (1.08 mmol) of p-
toluenesulfonic acid monohydrate and 1.24 mL (1.29 g, 1.24 mmol) of benzyl 
alcohol in 20 mL of toluene was heated to reflux for 24 h, using a Dean-Stark 
distilling receiver. The reaction mixture was cooled to room temperature and 
diluted with 20 mL of anh diethyl ether to afford p-toluenesulfonate 2.25 as a 
crystalline, colorless solid: yield 3.30 g (93%); silica gel TLC Rf 0.47 (9:1 
chloroform−methanol); 1H NMR (CDCl3) δ 1.89 (quin, 2H, J = 7.3 Hz), 2.28-2.40 
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(m, 5H), 2.87 (dt, 2H, J = 12.8 and 6.3 Hz), 5.04 (s, 2H), 7.11 (d, 2H, J = 7.9 Hz), 
7.27-7.37 (m, 5H) and 7.76-7.85 (m, 5H); 13C NMR (CDCl3) δ 21.4, 22.6, 30.9, 
39.3, 66.5, 126, 128.30, 128.35, 128.6, 129.2, 135.9, 140.9, 141.2 and 172.3. 
 
 
Benzyl 4-((4-Hydroxy-3,6-dioxo-5-tridecylcyclohexa-1,4-dien-1-
yl)amino)butanoate (2.5). To a solution containing 57.0 mg (0.17 mmol) of 2-
hydroxy-5-methoxy-3-tridecyl-(1,4)-benzoquinone (2.24) in 8 mL of 
dichloromethane was added a solution containing 185 mg (0.51 mmol) of p-
tolunesulfonate salt 2.25 and 60.0 mg (97%, 0.51 mmol) of potassium tert-
butoxide in 8 mL of dichloromethane dropwise over a period of 10 min. The 
reaction mixture was stirred at room temperature for 20 h under an argon 
atmosphere, then washed with 5 mL of 1 N HCl. The aqueous layer was extracted 
with seven 2-mL portions of dichloromethane. The combined organic layer was 
washed successively with water and brine and then dried (MgSO4). The solvent 
was concentrated under diminished pressure to afford a crude residue. The residue 
was applied to a silica gel column (24 × 3 cm). Elution with diethyl ether gave 
compound 2.5 as a dark red solid: yield 11.0 mg (9%); silica gel TLC Rf 0.25 (1:1 
ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.90 (t, 3H, J = 6.8 Hz), 1.21-1.36 
(m, 20H), 1.38-1.52 (m, 2H), 1.96-2.09 (m, 2H), 2.31-2.45 (m, 3H), 2.44-2.61 (m, 
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2H), 3.15-3.34 (m, 2H), 5.15 (s, 2H), 5.37 (s, 1H), 6.56 (s, 1H) and 7.13-7.46 (m, 
5H); 13C NMR (CDCl3) δ 14.3, 21.6, 22.8, 23.4, 28.2, 29.5, 29.6, 29.7, 29.80, 
29.83, 31.6, 32.1, 42.2, 66.8, 92.0, 125.4, 128.3, 128.5, 128.6, 128.8, 129.2, 
135.68, 135.72, 138.00, 138.02, 149.8, 155.1, 172.6, 179 and 182.5; mass 
spectrum (APCI), m/z 498.3206 (M + H)+ (C30H44NO5 requires 498.3219). 
 
 
Benzyl 4-((4-Methoxy-3,6-dioxo-5-tridecylcyclohexa-1,4-dien-1-
yl)amino)butanoate (2.8). To a solution containing 12.0 mg (24.0 μmol) of 
quinone 2.5 and 125 mg (0.91 mmol) of potassium carbonate in 0.6 mL of anh 
acetone was added 45.0 µL (60.0 mg, 0.48 mmol) of dimethyl sulfate. The 
reaction mixture was heated to reflux overnight, then allowed to cool to room 
temperature and concentrated under diminished pressure. The crude mixture was 
redissolved in 10 mL of dichloromethane and washed with 5 mL of 1 N HCl. The 
aqueous layer was extracted with three 10-mL portions of dichloromethane. The 
combined organic layer was dried (MgSO4) and concentrated under diminished 
pressure to afford a crude residue. The residue was applied to a silica gel column 
(23 × 2 cm). Elution with 20% diethyl ether in hexane gave compound 2.8 as a 
bright red solid: yield 8 mg (45%); silica gel TLC Rf 0.40 (1:1 ethyl 
acetate−hexanes); 1H NMR (CDCl3) δ 0.81-0.97 (m, 3H), 1.15-1.34 (m, 20H), 
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1.32-1.45 (m, 2H), 1.98 (quin, 2H, J = 7.0 Hz), 2.29-2.41 (m, 2H), 2.45 (t, 2H, J = 
7.1 Hz), 3.15 (q, 2H, J = 6.7 Hz), 4.11 (s, 3H), 5.14 (s, 2H), 5.25 (s, 1H), 5.92 (t, 
1H, J = 5.5 Hz) and 7.19-7.44 (m, 5H); 13C NMR (CDCl3) δ 14.3, 22.8, 23.1, 
23.5, 28.8, 29.5, 29.6, 29.7, 29.81, 29.84, 31.7, 32.1, 42.0, 61.8, 66.8, 96.2, 127.7, 
128.50, 128.55, 128.8, 135.8, 146.8, 158.5, 172.7, 181.8 and 183.9; mass 
spectrum (APCI), m/z 512.3379 (M + H)+ (C31H46NO5 requires 512.3376). 
 
 
4-Butoxy-4-oxobutan-1-aminium 4-Methylbenzenesulfonate (2.26).126 A 
solution of 1.00g (9.70 mmol) of 4-aminobutanoic acid, 2.02 g (1.08 mmol) of p-
toluenesulfonic acid monohydrate and 1.10 mL (891 mg, 1.24 mmol) of 1-butanol 
in 20 mL of toluene was heated to reflux for 24 h, using a Dean-Stark distilling 
receiver. The reaction mixture was allowed to cool to room temperature and 
diluted with 20 mL of anh diethyl ether to afford the p-toluenesulfonate salt 2.26 
as a crystalline, colorless solid: yield 2.96 g (92%); silica gel TLC Rf 0.25 (9:1 
chloroform−methanol); 1H NMR (CD3OD) δ 0.94 (t, 3H, J = 7.4 Hz), 1.33-1.46 
(m, 2H), 1.55-1.67 (m, 2H), 1.88-1.96 (m, 2H), 2.37 (s, 3H), 2.44 (t, 2H, J = 7.2 
Hz), 2.92-3.02 (m, 2H), 4.09 (t, 2H, J = 6.6 Hz), 4.86 (s, 3H), 7.24 (d, 2H, J= 
10.5 Hz) and 7.71 (d, 2H, J = 10.0 Hz); 13C NMR (CD3OD) δ 14.0, 20.1, 21.4, 
23.7, 31.6, 31.8, 40.1, 65.6, 126.8, 129.5, 141.6, 143.3 and 174.1. 
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Butyl 4-((4-Hydroxy-3,6-dioxo-5-tridecylcyclohexa-1,4-dien-1-
yl)amino)butanoate (2.6). To a solution containing 82.0 mg (0.24 mmol) of 2-
hydroxy-5-methoxy-3-tridecyl-(1,4)-benzoquinone (2.24) in 11.5 mL of 
dichloromethane was added a solution containing 241 mg (0.73 mmol) of p-
tolunesulfonate salt 2.26 and 72.0 mg (97%, 0.73 mmol) of potassium tert-
butoxide in 11.5 mL of dichloromethane dropwise over a period of 10 min. The 
reaction mixture was stirred at room temperature for 20 h under an argon 
atmosphere. The reaction mixture was then washed with 5 mL of 1 N HCl and the 
aqueous layer was extracted with seven 2-mL portions of dichloromethane. The 
combined organic layer was washed with water and brine and then dried 
(MgSO4). The solvent was concentrated under diminished pressure to afford a 
crude residue. The residue was applied to a silica gel column (24 × 3 cm). Elution 
with diethyl ether gave compound 2.6 as a dark red solid: yield 34 mg (30%); 
silica gel TLC Rf 0.16 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.87 (t, 
3H, J = 6.8 Hz), 0.93 (t, 3H, J = 7.4 Hz), 1.11-1.52 (m, 24H), 1.53-1.68 (m, 2H), 
1.99 (quin, 2H, J = 6.9 Hz), 2.32-2.54 (m, 4H), 3.23 (q, 2H, J = 6.6 Hz), 4.10 (t, 
2H, J = 6.7 Hz), 5.36 (s, 1H), 6.58 (s, 1H) and 8.09 (s, 1H); 13C NMR (CDCl3) δ 
13.8, 14.3, 19.3, 22.79, 22.84, 23.3, 28.2, 29.5, 29.6, 29.7, 29.80, 29.82, 30.7, 
31.6, 32.1, 42.3, 64.9, 91.9, 116, 149.8, 155.1, 172.9, 179 and 182.6; mass 
spectrum (APCI), m/z 464.3374 (M + H)+ (C27H46NO5 requires 464.3376). 
 Butyl 4-((4-Methoxy-3,6-dioxo-5-tridecylcyclohexa-1,4-dien-1-
yl)amino)butanoate (2.9). To a solution containing 8.0 mg (16 μmol) of 
hydroxyquinone 2.6 and 84 mg (0.6 mmol) of potassium carbonate in 1.0 mL of 
anh acetone was added dropwise 30 µL (0.3 mmol) of dimethyl sulfate. The 
reaction mixture was heated to reflux overnight and allowed to cool to room 
temperature. The crude reaction mixture was concentrated under diminished 
pressure and redissolved in 10 mL of dichloromethane. The organic layer was 
washed with 5 mL of 1 N HCl and the aqueous layer was extracted with three 10-
mL portions of dichloromethane. The combined organic layer was dried (MgSO4) 
and concentrated under diminished pressure to afford a crude residue. The residue 
was applied to a silica gel column (24 × 2 cm). Step gradient elution with 20% 
diethyl etherÆ30% diethyl ether in hexane gave compound 2.9 as a bright red 
solid: yield 7.7 mg (93%); silica gel TLC Rf 0.67 (1:1 ethyl acetate−hexanes); 1H 
NMR (CDCl3) δ 0.88 (t, 3H, J = 6.8 Hz), 0.93 (t, 3H, J = 7.4 Hz), 1.16-1.46 (m, 
23H), 1.51-1.71 (m, 3H), 1.96 (quin, 2H, J = 7.0 Hz), 2.31-2.49 (m, 4H), 3.16 (dd, 
2H, J = 13.0 and 6.7 Hz), 4.02-4.15 (m, 5H), 5.28 (s, 1H) and 5.95 (t, 1H, J = 5.6 
Hz); 13C NMR (CDCl3) δ 13.9, 14.3, 19.3, 22.8, 23.1, 23.5, 28.8, 29.5, 29.6, 
29.73, 29.81, 29.84, 30.8, 31.7, 32.1, 42.1, 61.8, 64.9, 96.2, 127.7, 146.9, 158.5, 
173, 181.8 and 184; mass spectrum (APCI), m/z 478.3516 (M + H)+ (C28H48NO5 
requires 478.3532). 
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 4-(Hexyloxy)-4-oxobutan-1-ammonium 4-Methylbenzenesulfonate (2.27).126 
A solution of 1.00g (9.70 mmol) of 4-aminobutanoic acid, 2.02 g (1.08 mmol) of 
p-toluenesulfonic acid monohydrate and 1.51 mL (1.23 g, 1.24 mmol) of 1-
hexanol in 20 mL of toluene was heated to reflux for 24 h, using a Dean-Stark 
distilling receiver. The reaction mixture was allowed to cool to room temperature 
and diluted with 20 mL of anh diethyl ether to afford p-toluenesulfonate salt 2.27 
as a crystalline, colorless solid: yield 2.50 g (72%); silica gel TLC Rf 0.22 (9:1 
chloroform−methanol); 1H NMR (CDCl3) δ 0.88 (t, 3H, J = 7.2 Hz), 1.21-1.35 
(m, 6H), 1.55 (quin, 2H, J = 14.0 and 7.2 Hz), 1.85 (quin, 2H, J = 14.8 and 7.3 
Hz), 2.27 (t, 2H, J = 7.3 Hz), 2.36 (s, 3H), 2.80-2.92 (m, 2H), 3.98 (t, 2H, J = 6.9 
Hz), 7.18 (d, 2H, J = 7.9 Hz) and 7.72-7.83 (m, 5H); 13C NMR (CDCl3) δ 14.2, 
21.5, 22.67, 22.71, 25.7, 28.6, 31.0, 31.6, 39.4, 65.0, 126.1, 129.2, 140.9, 141.2 
and 172.6. 
 
 
Hexyl 4-((4-Hydroxy-3,6-dioxo-5-tridecylcyclohexa-1,4-dien-1-
yl)amino)butanoate (2.7). To a solution containing 37.0 mg (0.11 mmol) of 2-
hydroxy-5-methoxy-3-tridecyl-(1,4)-benzoquinone (2.24) in 5.2 mL of 
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dichloromethane was added a solution containing 119 mg (0.33 mmol) of p-
tolunesulfonate salt 2.27 and 33.0 mg (97%, 0.33 mmol) of potassium tert-
butoxide dropwise in 5.2 mL of dichloromethane. The reaction mixture was 
stirred at room temperature for 20 h under an argon atmosphere. The reaction 
mixture was then washed with 5 mL of 1 N HCl and the aqueous layer was 
extracted with seven 2-mL portions of dichloromethane. The combined organic 
layer was washed with water and brine and then dried (Na2SO4). The solvent was 
concentrated under diminished pressure to afford a crude residue. The residue was 
applied to a silica gel column (24 × 3 cm). Elution with diethyl ether gave 
compound 2.7 as a dark red solid: yield 27 mg (50%); silica gel TLC Rf 0.40 (1:1 
ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.85-0.90 (m, 6H), 1.18-1.51 (m, 
28H), 1.58-1.65 (m, 2H), 1.99 (quin, 2H, J = 14.0 and 7.2 Hz), 2.35-2.43 (m, 4H), 
3.23 (q, 2H, J = 6.7 Hz), 4.09 (t, 2H, J = 6.8 Hz), 5.36 (s, 1H), 6.58 (s, 1H) and 
8.08 (s, 1H); 13C NMR (CDCl3) δ 14.1, 14.3, 22.70, 22.79, 22.83, 23.3, 25.7, 28.2, 
28.7, 29.5, 29.6, 29.7, 29.80, 29.82, 31.5, 31.6, 32.1, 42.3, 65.2, 91.9, 116, 149.8, 
155.1, 172.9, 179 and 182.6; mass spectrum (APCI), m/z 492.3684 (M + H)+ 
(C29H50NO5 requires 492.3689). 
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Hexyl 4-((4-Methoxy-3,6-dioxo-5-tridecylcyclohexa-1,4-dien-1-
yl)amino)butanoate (2.10). To a solution containing 29 mg (59 μmol) of 
hydroxyquinone 2.7 and 0.3 g (2.2 mmol) of potassium carbonate in 1.5 mL of 
anh acetone was added dropwise 28 µL (37 mg, 0.3 mmol) of dimethyl sulfate. 
The reaction mixture was heated to reflux overnight, allowed to cool to room 
temperature and concentrated under diminished pressure to afford a crude residue. 
The residue was redissolved in 10 mL of dichloromethane and washed with 5 mL 
of 1 N HCl. The aqueous layer was then extracted with three 10-mL portions of 
dichloromethane. The combined organic layer was dried (MgSO4) and 
concentrated under diminished pressure to afford a crude residue. The residue was 
applied to a silica gel column (23 × 2 cm). Step gradient elution with 20% diethyl 
etherÆ30% diethyl ether in hexane gave compound 2.10 as a bright red solid: 
yield 8 mg (27%); silica gel TLC Rf 0.40 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 0.81-0.97 (m, 6H), 1.15-1.45 (m, 28H), 1.54-1.70 (m, 2H), 1.96 (quin, 
2H, J = 11.2 and 5.6 Hz), 2.31-2.48 (m, 4H), 3.16 (q, 2H, J = 6.6 Hz), 4.02-4.21 
(m, 5H), 5.26 (s, 1H) and 5.87-6.06 (m, 1H); 13C NMR (CDCl3) δ 14.1, 14.3, 
15.4, 22.7, 22.8, 23.1, 23.5, 25.7, 28.7, 28.8, 29.5, 29.6, 29.7, 29.80, 29.84, 31.6, 
31.8, 32.1, 42.1, 61.7, 65.2, 66.0, 96.2, 127.6, 146.9, 158.5, 173.0, 181.7 and 
183.9; mass spectrum (APCI), m/z 506.3836 (M + H)+ (C30H52NO5 requires 
506.3845). 
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5-(Hexylamino)-2-hydroxy-3-tridecylcyclohexa-2,5-diene-1,4-dione (2.11). To 
a solution containing 49.0 mg (0.15 mmol) of 2-hydroxy-5-methoxy-3-tridecyl-
(1,4)-benzoquinone (2.24) in 12 mL of EtOH was added 97.0 μL (74.0 mg, 0.73 
mmol) of hexylamine dropwise followed by 1.20 g (14.6 mmol) of NaHCO3. The 
reaction mixture was stirred at room temperature for 20 h under an argon 
atmosphere and then washed with 5 mL of 1 N HCl. The aqueous layer was 
extracted with seven 2-mL portions of dichloromethane. The combined organic 
layer was washed with water and brine and then dried (Na2SO4). The solvent was 
concentrated under diminished pressure to afford a crude residue. The residue was 
applied to a silica gel column (24 × 3 cm). Elution with 10% diethyl ether in 
hexane gave compound 2.11 as a dark red solid: yield 10.0 mg (17%); silica gel 
TLC Rf 0.53 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.81-0.96 (m, 6H), 
1.16-1.50 (m, 28H), 1.65 (quin, 2H, J = 14.4 and 6.8 Hz), 2.30-2.43 (m, 2H), 3.15 
(dd, 2H, J = 12.8 and 6.4 Hz), 3.22-3.34 (br s, 1H), 5.32 (s, 1H) and 6.41 (s, 1H); 
13C NMR (CDCl3) δ 14.1, 14.3, 22.6, 22.79, 22.84, 26.8, 28.2, 28.3, 29.51, 29.56, 
29.6, 29.7, 29.81, 29.83, 31.4, 31.5, 32.0, 32.1, 43.0, 91.6, 115.8, 149.8, 155.3, 
178.8 and 182.7; mass spectrum (APCI), m/z 406.3313 (M + H)+ (C25H44NO3 
requires 406.3321). 
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5-(Hexylamino)-2-methoxy-3-tridecylcyclohexa-2,5-diene-1,4-dione (2.12). To 
a solution containing 15 mg (40 μmol) of quinone 2.11 and 84 mg (1.4 mmol) of 
potassium carbonate in 1.0 mL of anh acetone was added 20 µL (27 mg, 0.2 
mmol) of dimethyl sulfate. The reaction mixture was heated to reflux for 3h and 
stirred at room temperature overnight. The reaction mixture was then 
concentrated under diminished pressure and the crude residue was redissolved in 
10 mL of dichloromethane and washed with 5 mL of 1 N HCl. The aqueous layer 
was extracted with three 10-mL portions of dichloromethane. The combined 
organic layer was dried (MgSO4) and concentrated under diminished pressure to 
afford a crude residue. The residue was applied to a silica gel column (24 × 2 cm). 
Elution with 10% diethyl ether in hexane gave compound 2.12 as a bright red 
solid: yield 9.0 mg (58%); silica gel TLC Rf 0.76 (1:1 ethyl acetate−hexanes); 1H 
NMR (CDCl3) δ 0.82-0.98 (m, 6H), 1.18-1.46 (m, 27H), 1.51-1.73 (m, 3H), 2.27-
2.46 (m, 2H), 3.07 (dd, 2H, J = 13.2 and 6.4 Hz), 4.11 (s, 3H), 5.25 (s, 1H) and 
5.81 (s, 1H); 13C NMR (CDCl3) δ 14.1, 14.3, 22.7, 22.8, 23.1, 26.8, 28.3, 28.8, 
29.5, 29.6, 29.7, 29.81, 29.83, 31.5, 32.1, 42.7, 61.8, 95.9, 127.5, 146.9, 158.7, 
181.7 and 184.1; mass spectrum (APCI), m/z 420.3470 (M + H)+ (C26H46NO3 
requires 420.3478). 
 
 
4-(N-Methylamino)butanoic Acid (2.28).112 To a solution containing 9.70 g (104 
mmol) of N-methyl-2-pyrrolidone in 111 mL of distilled water was added 10.9 g 
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(63.5 mmol) of Ba(OH)2. The heterogeneous mixture was heated to reflux for 5 h 
and then cooled to 0 °C and saturated with CO2 gas (dry ice). The resulting white 
precipitate was collected by filtration and washed with cold water. The clear 
filtrate was concentrated under diminished pressure and the resulting moist 
residue was triturated with acetonitrile, filtered and washed with ether. The crude 
residue thus obtained was further dried by co-evaporating three times with toluene 
and triturated with methanol to yield N-methyl butyric acid (2.28) as a colorless 
solid: yield 5.45 g (45%); 1H NMR (DMSO-d6) δ 1.09 (quin, 2H, J = 13.6 and 6.8 
Hz), 1.41-1.59 (m, 2H), 1.86 (d, 3H, J = 0.9 Hz), 2.20 (t, 2H, J = 6.9 Hz), 2.50-
2.57 (m, 1H) and 4.67 (s, 1H); 13C NMR (DMSO-d6) δ 14.0, 23.2, 27.0, 41.0 and 
171.3. 
 
 
Hexyl 4-(N-Methylamino)butanoate (2.29). A solution containing 3.52 g (30.0 
mmol) of 4-(N-methylamino)butanoic acid (2.28), 6.25 g (32.4 mmol) of p-
toluenesulfonic acid hydrate and 4.70 mL (3.82 g, 37.2 mmol) of 1-hexanol in 62 
mL of toluene was heated to reflux for 12 h using a Dean-Stark distilling receiver. 
The cooled reaction mixture was concentrated under diminished pressure to afford 
a crude residue. The residue was dissolved in 10 mL of hexane and the resulting 
solution cooled to −72 °C for 40 min and filtered to yield the amine 2.29 as its 
tosylate salt. The tosylate salt obtained was dissolved in 100 mL of 
dichloromethane and washed with 1 M K2CO3. The organic layer was dried 
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(MgSO4) and concentrated under diminished pressure to generate the free amine 
2.29 as a colorless oil: yield 5.50 g (91%); 1H NMR (CDCl3) δ 0.73-0.87 (m, 3H), 
1.15-1.34 (m, 6H), 1.48-1.60 (m, 2H), 1.73 (quin, 2H, J = 14.4 and 7.2 Hz), 2.22-
2.32 (m, 2H), 2.35 (d, 3H, J = 10.7 Hz), 2.52 (t, 2H, J = 7.1 Hz) and 3.88-4.07 (m, 
2H); 13C NMR (CDCl3) δ 14.0, 22.5, 25.1, 25.6, 28.6, 31.4, 32.1, 36.3, 50.9, 64.6 
and 173.6. 
 
 
Hexyl 4-((4-Hydroxy-3,6-dioxo-5-tridecylcyclohexa-1,4-dien-1-
yl)(methyl)amino)butanoate (2.13). To a solution containing 60.0 mg (0.18 
mmol) of 2-hydroxy-5-methoxy-3-tridecyl-(1,4)-benzoquinone (2.24) in ethanol 
was added 360 mg (1.79 mmol) of amine 2.29. The reaction mixture was stirred at 
room temperature for 12 h and then washed with brine and dried (MgSO4). The 
organic layer was concentrated under diminished pressure to afford the crude 
residue. The residue was applied to a silica gel column (24 × 2 cm). Elution with 
60:1 dichloromethane−methanol gave compound 2.13 as a red solid: yield 39.0 
mg (43%); silica gel TLC Rf 0.32 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) 
δ 0.81-0.95 (m, 6H), 1.19-1.28 (m, 14H), 1.27-1.37 (m, 12H), 1.36-1.48 (m, 2H), 
1.51-1.68 (m, 2H), 2.00 (quin, 2H, J = 15.0 and 7.5 Hz), 2.38 (t, 4H, J = 7.5 Hz), 
3.14 (s, 3H), 3.63 (t, 3H, J = 7.0 Hz), 4.07 (t, 2H, J = 7.0 Hz) and 5.49 (s, 1H); 
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13C NMR (CDCl3) δ 14.1, 14.3, 22.7, 22.8, 23.2, 25.6, 25.7, 28.5, 28.7, 29.5, 29.6, 
29.78, 29.79, 29.81, 29.83, 29.87, 31.2, 31.6, 31.8, 32.1, 32.9, 54.4, 63.2, 65.0, 
98.0, 117.5, 153.0, 172.9, 178.7 and 184.6; mass spectrum (APCI), m/z 506.3848 
(M + H)+ (C30H51NO5 requires 506.3845). 
 
 
Hexyl 4-((4-Methoxy-3,6-dioxo-5-tridecylcyclohexa-1,4-dien-1-
yl)(methyl)amino)butanoate (2.15). To a solution containing 19 mg (40 μmol) 
of hydroxyquinone 2.13 in anh acetone was added 0.2 g (1.4 mmol) of potassium 
carbonate and 20 μL (27 mg, 0.2 mmol) of dimethyl sulfate dropwise. The 
reaction mixture was heated to reflux for 1.5 h and cooled to room temperature 
and stirred at 23 °C for 12 h. The reaction mixture was concentrated under 
diminished pressure and redissolved in 50 mL of dichloromethane. The organic 
layer was washed with brine, dried (MgSO4) and concentrated under diminished 
pressure to afford a crude red residue. The residue was applied to a silica gel 
column (24 × 2 cm). Elution with 60:1 dichloromethane−methanol gave 
compound 2.15 as a red solid: yield 10 mg (51%); silica gel TLC Rf 0.61 (1:1 
ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.84-0.91 (m, 6H), 1.20-1.40 (m, 
26H), 1.55-1.68 (m, 4H), 1.97 (2H, quin, J = 14.5 and 7.0 Hz), 2.31-2.39 (m, 4H), 
2.99 (s, 3H), 3.50-3.59 (m, 2H), 4.00-4.19 (m, 5H) and 5.40 (s, 1H); 13C NMR 
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(CDCl3) δ 22.7, 22.8, 23.3, 23.6, 25.7, 28.7, 29.1, 29.5, 29.6, 29.72, 29.76, 29.81, 
29.83, 29.92, 29.98, 31.3, 31.6, 32.1, 40.6, 53.6, 61.3, 65.0, 95.8, 102.4, 129.6, 
150.9, 156.6, 173.1, 181.5 and 185.7; mass spectrum (APCI), m/z 520.4002 (M + 
H)+ (C31H54NO5 requires 520.4002). 
 
 
tert-Butyl 4-(((Benzyloxy)carbonyl)(methyl)amino)butanoate (2.30).127-129 To 
a solution containing 900 mg (7.68 mmol) of acid 2.28 in 10.3 mL of 3 M aq 
KOH was added 1.14 mL (1.36 g, 7.68 mmol) of 95% benzyl chloroformate 
dropwise over a period of 10 min under an argon atmosphere. The reaction 
mixture was stirred at room temperature for 2 h and quenched by the addition of 
7.9 mL of 5 M aq HCl solution dropwise. The aqueous layer was extracted with 
three 30-mL portions of ethyl acetate. The combined organic extract was washed 
with water and brine and then dried (MgSO4). The solvent was concentrated 
under diminished pressure to afford a crude residue. The residue was dissolved in 
8.5 mL of tert-butylacetate and 130 μL (1.48 mmol) of 70% perchloric acid was 
added dropwise. The reaction mixture was stirred at room temperature for 18 h 
and quenched by the addition of 20 mL of satd aq NaHCO3. The aqueous layer 
was extracted with three 30-mL portions of dichloromethane. The combined 
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organic layer was washed with water and brine and then dried (MgSO4). The 
solvent was concentrated under diminished pressure to afford a crude residue. The 
residue was applied to a silica gel column (20 × 3 cm). Elution with 1:5 ethyl 
acetate−hexanes afforded compound 2.30 as a colorless oil: yield 372 mg (29% 
over two steps); silica gel TLC Rf 0.52 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 1.42 (s, 9H), 1.81 (dd, 2H, J = 15.6 and 6.8 Hz), 2.15-2.26 (m, 2H), 
2.91 (s, 3H), 3.20 (br s, 2H), 5.11 (s, 2H) and 7.25-7.38 (m, 5H); 13C NMR 
(CDCl3) δ 22.8, 27.8, 32.2, 34.0, 47.9, 66.7, 79.9, 127.5, 127.6, 128.2, 136.7, 
155.9 and 171.9. 
 
 
tert-Butyl 4-(N-methylamino)butanoate (2.31).129 To a solution containing 372 
mg (1.21 mmol) of ester 2.30 in 4.4 mL of methanol was added 40.0 mg of 10% 
Pd/C. Hydrogen gas was bubbled through the solution for 2 h under atmospheric 
pressure. The catalyst was removed by filtration through a pad of Celite and the 
filtrate was concentrated under diminished pressure carefully (as the product is 
volatile) to afford compound 2.31 as a colorless oil: yield 91 mg (43%); 1H NMR 
(CDCl3) δ 1.40 (s, 9H), 2.01-2.11 (m, 2H), 2.31 (t, 2H, J = 7.1 Hz), 2.64 (s, 3H), 
2.95 (dd, 2H, J = 13.0 and 5.1 Hz) and 8.48 (br s, 1H); 13C NMR (CDCl3) δ 21.7, 
28.2, 32.4, 33.2, 48.9, 81.0 and 171.7. 
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 tert-Butyl 4-((4-Hydroxy-3,6-dioxo-5-tridecylcyclohexa-1,4-dien-1-
yl)(methyl)amino)butanoate (2.14). To a solution containing 71.0 mg (0.21 
mmol) of 2-hydroxy-5-methoxy-3-tridecyl-(1,4)-benzoquinone (2.24) in ethanol 
was added 730 mg (4.21 mmol) of the amine 2.31. The reaction mixture was 
stirred at room temperature for 12 h, concentrated under diminished pressure and 
diluted by the addition of 20 mL of dichloromethane. The organic layer was 
washed with brine and dried (MgSO4), then concentrated under diminished 
pressure to afford the crude residue as a red solid. The residue applied to a silica 
gel column (20 × 3 cm). Elution with 9:1 hexane−ethyl acetate gave compound 
2.14 as a red solid: yield 75 mg (74%); silica gel TLC Rf 0.45 (1:1 ethyl 
acetate−hexanes); 1H NMR (CDCl3) δ 0.85 (t, 3H, J = 6.7 Hz), 1.18-1.31 (m, 
22H), 1.43 (s, 9H), 1.94 (dt, 2H, J = 14.0 and 6.9 Hz), 2.27 (t, 2H, J = 7.0 Hz), 
2.32-2.39 (m, 2H), 3.08 (br s, 3H), 3.59 (br s, 2H) and 5.48 (s, 1H); 13C NMR 
(CDCl3) δ 14.2, 22.8, 23.1, 28.2, 28.4, 29.4, 29.6, 29.73, 29.75, 29.77, 29.78, 
29.8, 32.0, 32.4, 41.4, 54.5, 80.8, 97.6, 117.4, 153.0, 153.3, 172.1, 178.6 and 
184.8; mass spectrum (APCI), m/z 478.3533 (M + H)+ (C28H48NO5 requires 
478.3532). 
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 tert-Butyl 4-((4-Methoxy-3,6-dioxo-5-tridecylcyclohexa-1,4-dien-1-
yl)(methyl)amino)butanoate (2.16). To a solution containing 43.0 mg (0.09 
mmol) of hydroxyquinone 2.14 in 2.5 mL of anh acetone was added 473 mg (3.42 
mmol) of potassium carbonate and 50.0 μL (66.0 mg, 0.45 mmol) of dimethyl 
sulfate dropwise. The reaction mixture was heated to reflux for 3h and allowed to 
cool to room temperature, then concentrated under diminished pressure to afford a 
crude residue. The residue was dissolved in 50 mL of dichloromethane, washed 
with brine and then dried (MgSO4). The organic layer was concentrated under 
diminished pressure to afford a crude red residue. The residue was applied to a 
silica gel column (20 × 3 cm). Elution with 60:1 dichloromethane−methanol gave 
compound 2.16 as a red solid: yield 30 mg (42%); silica gel TLC Rf 0.58 (1:1 
ethyl acetate−hexanes); 1H NMR (CDCl3) δ 0.87 (t, 3H, J = 6.9 Hz), 1.22-1.32 
(m, 20H), 1.33-1.39 (m, 2H), 1.44 (s, 9H), 1.92 (dt, 2H, J = 14.8 and 7.3 Hz), 2.26 
(t, 2H, J = 7.2 Hz), 2.33-2.39 (m, 2H), 2.99 (s, 3H), 3.48-3.55 (m, 2H), 4.05 (s, 
3H) and 5.40 (s, 1H); 13C NMR (CDCl3) δ 14.2, 22.8, 23.4, 23.6, 28.20, 28.24, 
29.0, 29.5, 29.6, 29.74, 29.79, 29.81, 29.83, 30.0, 32.1, 32.5, 40.6, 53.7, 61.3, 
80.7, 102.3, 129.6, 150.9, 156.6, 172.3, 181.4 and 185.7; mass spectrum (APCI), 
m/z 492.3695 (M + H)+ (C29H50NO5 requires 492.3689). 
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 5-(N,N-Dimethylamino)-2-hydroxy-3-tridecylcyclohexa-2,5-diene-1,4-dione 
(2.17). To a solution containing 38.0 mg (0.11 mmol) of 2-hydroxy-5-methoxy-3-
tridecyl-(1,4)-benzoquinone (2.24) in 12 mL of ethanol was added 470 mg (5.65 
mmol) of NaHCO3 and 140 μL (126 mg, 1.12 mmol) of a 40% by wt solution of 
dimethylamine in water dropwise. The reaction mixture was stirred at room 
temperature for 20 h and then concentrated under diminished pressure to afford a 
crude residue. The residue was diluted with 50 mL of dichloromethane. The 
organic layer was washed with two 10-mL portions of 1 N HCl, dried (MgSO4) 
and then concentrated under diminished pressure to afford a red solid. The crude 
residue was applied to a silica gel column (20 × 2 cm). Elution with 60:1 
dichloromethane−methanol gave compound 2.17 as a red solid: yield 27 mg 
(69%); silica gel TLC Rf 0.36 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
0.87 (t, 3H, J = 7.2 Hz), 1.20-1.35 (m, 16H), 1.36-1.48 (m, 4H), 2.34-2.47 (m, 
4H), 3.23 (br s, 6H), 3.85 (s, 1H) and 5.48 (s, 1H); 13C NMR (CDCl3) δ 14.3, 
22.8, 23.2, 28.4, 29.51, 29.56, 29.6, 29.71, 29.78, 29.81, 29.82, 29.83, 29.85, 32.1, 
43.7, 56.9, 97.6, 102.3, 117.2, 153.7 and 185.0; mass spectrum (APCI), m/z 
350.2692 (M + H)+ (C21H36NO3 requires 350.2695). 
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 5-(N,N-Dimethylamino)-2-methoxy-3-tridecylcyclohexa-2,5-diene-1,4-dione 
(2.18). To a solution containing 26.0 mg (74.0 μmol) of hydroxyquinone 2.17 in 
7.4 mL of anh acetone was added 388 mg (2.81 mmol) of potassium carbonate 
and 35.0 μL (47.0 mg, 0.37 mmol) of dimethyl sulfate dropwise. The reaction 
mixture was heated to reflux for 1.5 h and allowed to cool to room temperature 
and then stirred for another 12 h. The reaction mixture was concentrated under 
diminished pressure and then diluted with 50 mL of dichloromethane. The organic 
layer was washed with 10 mL brine and dried (Na2SO4), then concentrated under 
diminished pressure to afford a crude residue. The residue was applied to a silica 
gel column (20 × 2 cm). Elution with dichloromethane gave compound 2.18 as a 
red solid: yield 25 mg (93%); silica gel TLC Rf 0.50 (1:1 ethyl acetate−hexanes); 
1H NMR (CDCl3) δ 0.87 (t, 3H, J = 6.8 Hz), 1.20-1.32 (m, 20H), 1.33-1.45 (m, 
2H), 2.29-2.44 (m, 2H), 3.12 (s, 6H), 4.06 (s, 3H) and 5.38 (s, 1H); 13C NMR 
(CDCl3) δ 14.3, 22.8, 23.6, 29.0, 29.5, 29.6, 29.7, 29.80, 29.82, 29.83, 29.9, 32.1, 
42.8, 61.3, 102.3, 129.5, 151.4, 156.8, 181.4 and 185.9; mass spectrum (APCI), 
m/z 364.2859 (M + H)+ (C22H38NO3 requires 364.2852). 
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Hex-5-en-1-yl 4-Methylbenzenesulfonate (2.32).130 To a solution containing 2.0 
g (20 mmol) of 5-hexen-1-ol and 3.1 mL (2.2 g, 5.5 mmol) of triethylamine in 60 
mL of anh dichloromethane was added 4.2 g (22 mmol) of p-toluenesulfonyl 
chloride at 0 °C. The reaction mixture was allowed to warm to room temperature 
and stirred for 12 h. The reaction mixture was then diluted with 100 mL of 
dichloromethane and washed with two 30-mL portions of 10% aq NaHCO3 and 
brine. The organic layer was dried (MgSO4) and then concentrated under 
diminished pressure to afford a crude residue. The residue was purified by flash 
column chromatography on a silica gel column (24 × 3 cm). Elution with 4:1 
hexanes−ethyl acetate gave compound 2.32 as a colorless oil: yield 5.07 g 
(100%); silica gel TLC Rf 0.65 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
1.41 (quin, 2H, J = 15.2 and 7.6 Hz), 1.60-1.71 (m, 2H), 1.97 (q, 2H, J = 14.4 and 
7.2 Hz), 2.45 (s, 3H), 4.03 (t, 2H, J = 6.4 Hz), 4.89-4.95 (m, 2H), 5.65-5.78 (m, 
1H), 7.34 (d, 2H, J = 8.4 Hz) and 7.79 (d, 2H, J = 8.4 Hz); 13C NMR (CDCl3) δ 
21.8, 24.7, 28.3, 33.0, 70.6, 115.2, 128.0, 129.9, 133.3, 138.0 and 144.8. 
 
 
2-(Hex-5-en-1-yl)isoindoline-1,3-dione (2.33).113 To a solution containing 5.1 g 
(20 mmol) of tosylate 2.32 in 40 mL of DMF was added 4.4 g (24 mmol) of 
potassium phthalimide and the mixture heated at 60 °C for 24h. The reaction 
mixture was allowed to cool to room temperature and then the solution was 
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filtered. The filtrate was then washed with brine and extracted with three 30-mL 
portions of ether. The combined organic layer was washed with brine and dried 
(MgSO4), then concentrated under diminished pressure to afford 2.33 as colorless 
oil. The crude residue was used for the next reaction. 
 
 
Hex-5-en-1-ammonium Chloride (2.34).113 To a solution containing 3.10 g (13.3 
mmol) of the crude phthalimide 2.33 in 16 mL of ethanol was added 400 μL (13.3 
mmol) of hydrazine hydrate. The reaction mixture was heated at 60 °C for 12 h. 
The cooled reaction mixture was treated dropwise with 4.7 mL of conc HCl and 
then again heated to reflux for an additional 2 h. The cooled reaction mixture was 
filtered to remove a white precipitate. The filtrate was concentrated under 
diminished pressure to afford a crude residue. The residue was triturated 
successively with chloroform and ether to afford amine hydrochloride 2.34 as a 
yellow solid: yield 686 mg (25% over two steps); 1H NMR (CDCl3) δ 1.50 (quin, 
2H, J = 15.2 and 7.6 Hz), 1.79 (quin, 2H, J = 15.2 and 7.2 Hz), 2.09 (dd, 2H, J = 
14.4 and 7.2 Hz), 3.00 (br s, 2H), 4.93-5.07 (m, 2H), 5.70-5.85 (m, 1H) and 8.25 
(br s, 3H); 13C NMR (CDCl3) δ 25.8, 27.1, 33.1, 40.0, 115.5 and 137.7. 
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 1,2,4,5-Tetramethoxy-3-(undec-10-en-1-yl)benzene (2.35). To a solution 
containing 630 mg (3.18 mmol) of 1,2,4,5-tetramethoxybenzene (2.21) and 56.0 
µL (58.0 mg, 0.32 mmol) of hexamethyl phosphoramide in 16 mL of anh THF 
was added 1.40 mL (2.5 M in hexanes, 3.50 mmol) of n-butyllithium dropwise at 
−40 °C over a period of 1 h. The reaction mixture was allowed to warm to −10 °C 
over a period of 2 h and 770 μL (0.82 g, 3.50 mmol) of purified 11-bromoundec-
1-ene was added. The reaction mixture was stirred at room temperature under an 
argon atmosphere for 15 h and quenched by the addition of 20 mL of satd aq 
NH4Cl solution. The aqueous layer was extracted with five 10-mL portions of 
diethyl ether. The combined organic layer was washed with water and brine and 
then dried (MgSO4). The solvent was concentrated under diminished pressure to 
afford a crude residue. The residue was applied to a silica gel column (6 × 3 cm). 
Step gradient elution with hexaneÆ2:1 hexane−ethyl acetate afforded 2.35 as a 
colorless oil: yield 0.91 g (82%); silica gel TLC Rf 0.83 (1:1 ethyl 
acetate−hexanes); 1H NMR (CDCl3) δ 1.23-1.43 (m, 12H), 1.49-1.56 (m, 2H), 
2.03 (q, 2H, J = 14.4 and 6.8 Hz), 2.59-2.63 (m, 2H), 3.77 (s, 6H), 3.84 (s, 6H), 
4.90-5.00 (m, 2H), 5.76-5.86 (m, 1H) and 6.41 (s, 1H); 13C NMR (CDCl3) δ 24.8, 
29.1, 29.3, 29.59, 29.64, 29.65, 30.1, 30.9, 33.9, 56.3, 61.0, 96.7, 114.2, 131.2, 
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139.4, 141.2 and 148.9; mass spectrum (EI), m/z 350.2451 (M)+ (C21H34O4 
requires 350.2457). 
 
 
2-Hydroxy-5-methoxy-3-(undec-10-en-1-yl)cyclohexa-2,5-diene-1,4-dione 
(2.37). To a solution containing 3.33 g (9.50 mmol) of alkenyltetramethoxy 
benzene 2.35 in 95 mL of acetonitrile was added dropwise a solution containing 
10.4 g (19.0 mmol) of cerium(IV) ammonium nitrate in 95 mL of 7:3 
acetonitrile−water at −7 °C (salt−ice bath) over a period of 30 min. The reaction 
mixture was allowed to warm to room temperature and stirred for 3 h and was 
then quenched by the addition of 300 mL of ether. The organic layer was washed 
with distilled water and brine and then dried (MgSO4). The solvent was 
concentrated under diminished pressure to afford a crude mixture of quinones 
2.36 and 2.37. To the solution of the crude residue dissolved in 95 mL of 
dichloromethane was added 9.50 g (4.75 mmol) of HClO4-SiO2 and the reaction 
mixture was stirred at room temperature for 12 h. The reaction mixture was 
filtered and then concentrated under diminished pressure to afford a crude residue. 
The residue was applied to a silica gel column (23 × 3 cm). Elution with 9:1 
hexane−ethyl acetate gave compound 2.37 as a yellow−orange solid; silica gel 
TLC Rf 0.46 (1:1 ethyl acetate−hexanes): yield 745 mg (26% over two steps); 1H 
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NMR (CDCl3) δ 1.06-1.24 (m, 12H), 1.24-1.35 (m, 2H), 1.86 (q, 2H, J = 14.4 and 
7.6 Hz), 2.23-2.33 (m, 2H), 3.71 (s, 3H), 4.72-4.88 (m, 2H) and 5.58-5.72 (m, 
2H); 13C NMR (CDCl3) δ 22.6, 28.0, 28.9, 29.1, 29.40, 29.48, 29.50, 29.57, 33.8, 
56.8, 102.2, 114.1, 119.3, 139.2, 151.6, 161.1, 181.7 and 182.9; mass spectrum 
(APCI), m/z 306.1836 (M)+ (C18H26O4 requires 306.1831). 
 
 
2,5-Dimethoxy-3-(undec-10-en-1-yl)cyclohexa-2,5-diene-1,4-dione (2.36). 
Yellow solid; silica gel TLC Rf 0.61 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 1.20-1.44 (m, 14H), 1.97-2.05 (m, 2H), 2.41 (dd, 2H, J = 13.4 and 6.2 
Hz), 3.79 (s, 3H), 4.03 (s, 3H), 4.87-5.01 (m, 2H), 5.71 (s, 1H) and 5.74-5.84 (m, 
1H) ; 13C NMR (CDCl3) δ 23.2, 28.8, 29.0, 29.2, 29.46, 29.55, 29.57, 29.7, 33.9, 
56.5, 61.4, 105.5, 114.2, 130.8, 139.3, 156.0, 158.9, 182.5 and 183.7; mass 
spectrum (APCI), m/z 320.1977 (M)+ (C19H28O4 requires 320.1988). 
 
O
O
OH
N
H
 
5-(Hex-5-en-1-ylamino)-2-hydroxy-3-(undec-10-en-1-yl)cyclohexa-2,5-diene-
1,4-dione (2.38). To a solution containing 141 mg (1.04 mmol) of amine 
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hydrochloride 2.34 in 35 mL of ethanol was added 123 mg (96%, 1.04 mmol) of 
potassium t-butoxide and the reaction mixture stirred at room temperature for 30 
min. To the reaction mixture was added a solution of 107 mg (0.35 mmol) of 
hydroxyquinone 2.37 in 35 mL of ethanol dropwise over a period of 15 min. The 
reaction mixture was stirred for 12 h. The reaction mixture was concentrated 
under diminished pressure to afford a crude residue. The resulting residue was 
dissolved in 30 mL of dichloromethane and washed with 10 mL of 1 N HCl. The 
organic layer was dried (MgSO4) and then concentrated under diminished 
pressure to afford a crude residue. The residue was applied to a silica gel column 
(24 × 2 cm). Elution with 50:1 dichloromethane−methanol gave compound 2.38 
as a bright red solid: yield 126 mg (75%); silica gel TLC Rf 0.13 (chloroform); 1H 
NMR (CDCl3) δ 1.17-1.38 (m, 12H), 1.39-1.53 (m, 4H), 1.60-1.76 (m, 2H), 2.01 
(dd, 2H, J = 14.1 and 6.9 Hz), 2.08 (dd, 2H, J = 13.6 and 6.8 Hz), 2.32-2.41 (m, 
2H), 3.15 (d, 2H, J = 4.5 Hz), 4.86-5.07 (m, 4H), 5.33 (s, 1H), 5.68-5.86 (m, 2H), 
6.46 (s, 1H) and 8.25 (s, 1H); 13C NMR (CDCl3) δ 22.7, 26.2, 27.6, 28.2, 29.02, 
29.22, 29.53, 29.57, 29.62, 29.67, 33.3, 33.9, 42.8, 91.7, 114.2, 115.4, 115.8, 
137.9, 139.3, 149.8, 155.4, 178.8 and 182.6; mass spectrum (APCI), m/z 374.2694 
(M + H)+ (C23H36NO3 requires 374.2695). 
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5-(Hex-5-en-1-ylamino)-2-methoxy-3-(undec-10-en-1-yl)cyclohexa-2,5-diene-
1,4-dione (2.39). To a solution containing 144 mg (0.39 mmol) of quinone 2.38 
and 2.00 g (38.0 mmol) of potassium carbonate in 9.6 mL of anh acetone was 
added 190 µL (253 mg, 1.93 mmol) of dimethyl sulfate. The reaction mixture was 
heated to reflux for 3 h and allowed to cool to room temperature and stirred 
overnight. The solvent was concentrated under diminished pressure to afford a 
crude product. The crude product was dissolved in 20 mL of dichloromethane and 
washed with 5 mL of 1 N HCl. The aqueous layer was extracted with three 10-mL 
portions of dichloromethane. The combined organic layer was dried (MgSO4) and 
concentrated under diminished pressure to afford a crude residue. The residue was 
applied to a silica gel column (24 × 2 cm). Elution with 20% diethyl ether in 
hexane gave compound 2.39 as a bright red solid: yield 110 mg (74%); silica gel 
TLC Rf 0.36 (dichloromethane); 1H NMR (CDCl3) δ 1.18-1.39 (m, 14H), 1.45 
(quin, 2H, J = 15.2 and 7.6 Hz), 1.63 (quin, 2H, J = 14.8 and 7.2 Hz), 1.97-2.11 
(m, 4H), 2.34 (t, 2H, J = 7.6 Hz), 3.08 (dd, 2H, J = 13.2 and 6.0 Hz), 4.09 (s, 3H), 
4.86-5.05 (m, 4H), 5.23 (s, 1H) and 5.69-5.87 (m, 3H); 13C NMR (CDCl3) δ 23.0, 
26.3, 27.7, 28.7, 29.0, 29.2, 29.5, 29.6, 29.7, 33.3, 33.9, 42.5, 61.7, 95.8, 114.2, 
115.3, 127.4, 138.0, 139.3, 146.8, 158.5, 181.6 and 184.0; mass spectrum (APCI), 
m/z 388.2858 (M + H)+ (C24H38NO3 requires 388.2852). 
 19-Methoxy-2-azabicyclo[16.3.1]docosa-1(21),7,18-triene-20,22-dione (2.40). 
To a solution containing 31 mg (80 μmol) of quinone 2.39 in toluene was added 
7.0 mg (8.0 μmol) of Grubb’s 2nd generation catalyst. The reaction mixture was 
heated at 80 oC for 12 h and then allowed to cool to room temperature. The 
solvent was concentrated under diminished pressure to afford crude residue. The 
residue was applied to a silica gel column (30 × 3 cm). Elution with 1:9 ethyl 
acetate−hexane afforded compound 2.40 as a purple-red solid (mixture of 
diastereomers): yield 15 mg (52%); silica gel TLC Rf 0.23 (dichloromethane); 
major diastereomer 1H NMR (CDCl3) δ 1.08-1.35 (m, 12H), 1.35-1.53 (m, 4H), 
1.57-1.70 (m, 2H), 1.92-2.04 (m, 4H), 2.42-2.52 (m, 2H), 3.08-3.21 (m, 3H), 
4.08-4.14 (m, 2H), 5.24-5.31 (m, 2H), 5.31-5.43 (m, 1H) and 5.82-5.92 (m,1H); 
mixture of diastereomers 13C NMR (CDCl3) δ 22.2, 26.6, 26.85, 26.97, 26.98, 
27.11, 27.15, 27.2, 27.38, 27.44, 27.7, 28.2, 28.3, 28.4, 28.5, 28.6, 28.8, 28.9, 
29.1, 29.3, 29.8, 30.0, 31.6, 32.3, 42.1, 53.6, 61.7, 62.9, 95.7, 95.9, 127.5, 128.6, 
129.5, 131.5, 132.3, 147.0, 158.8, 158.9, 181.6 and 184.2; mass spectrum (APCI), 
m/z 360.2546 (M + H)+ (C22H34NO3 requires 360.2539). 
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 19-Methoxy-2-azabicyclo[16.3.1]docosa-1(21),18-diene-20,22-dione (2.19). To 
a solution containing15.5 mg (0.04 mmol) of quinone 2.40 in 5 mL of ethyl 
acetate was added 23 mg of 10% Pd/C and H2 gas was bubbled through the 
solution at room temperature for 4h. The reaction mixture was then diluted with 1 
mL of methanol and stirred at room temperature overnight. The reaction mixture 
was purged by bubbling air and then concentrated under diminished pressure to 
afford a crude residue. The residue was applied to a silica gel column (20 × 3 cm). 
Step gradient elution with dichloromethaneÆ100: 1 dichloromethane−methanol 
afforded compound 2.19 as a purple-red solid: yield 6 mg (38% over two steps); 
silica gel TLC Rf 0.3 (dichloromethane); 1H NMR (CDCl3) δ 1.06-1.39 (m, 22H), 
1.43-1.53 (m, 2H), 1.60-1.69 (m, 2H), 2.43-2.53 (m, 2H), 3.12-3.22 (m, 2H), 4.12 
(s, 3H), 5.28 (s, 1H) and 5.89 (s, 1H); 13C NMR (CDCl3) δ 22.2, 26.3, 27.4, 27.69, 
27.75, 27.81, 27.87, 28.0, 28.2, 28.49, 28.53, 28.55, 28.63, 29.1, 42.2, 61.8, 95.8, 
127.3, 146.9, 158.9, 181.6 and 184.1; mass spectrum (APCI), m/z 362.2702 (M + 
H)+ (C22H36NO3 requires 362.2695). 
 
Cytoprotection 
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FRDA lymphocytes were grown in RPMI 1640 medium (Gibco) 
supplemented with 15% fetal calf serum, 2 mM glutamine (HyClone) and 1% 
penicillin-streptomycin mix (Cellgro). Cells were seeded at a density of 5×105 
cells/mL and treated with different concentrations of the indicated compounds. 
Cells were incubated at 37 °C in a humidified atmosphere of 5% CO2 in air for 17 
h. After pre-incubation, the cells were treated with 5 mM DEM. Cell viability was 
determined by staining cells with 0.4% trypan blue and counting the cells using a 
hemacytometer. At least 500 cells were counted in each experimental group. At 
the time of assay, < 20% of DEM treated cells were viable (trypan blue negative), 
whereas in non DEM-treated controls, > 90% of the cells were viable. Cell 
viability was expressed as the percentage of control. Data are expressed as means 
± S.E.M. (n = 3). 
Inhibition of lipid peroxidation 
Lipid peroxidation was determined in FRDA lymphocyte cells depleted of 
glutathione. Following pretreatment with the indicated compounds at 5 µM or 10 
µM concentration for 16 h, the cells were treated with 500 nM C11-BODIPY581/591 
in the dark at 37 °C for 30 min before inducing lipid peroxidation with 5 mM 
diethyl maleate (DEM) for 140 min, and then subjected to flow cytometry 
analysis using the FL1-H channel for C11-BODIPY581/591 – green (oxidized form). 
In each analysis, 10,000 events were recorded. Increased C11-BODIPY581/591 – 
green fluorescence, a measure of intracellular lipid peroxidation, was determined 
by a shift in BODIPY581/591 – green fluorescence to the right on the x-axis of the 
FACS histogram relative to the untreated control. 
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Inhibition of mitochondrial complex I and NADH oxidase activity 
Beef heart mitochondria were obtained by a large-scale procedure.131 
Inverted submitochondrial particles (SMP) were prepared by the method of 
Matsuno-Yagi and Hatefi132 and stored in a buffer containing 0.25 M sucrose and 
10 mM Tris–HCl, pH 7.4, at −80 °C. Inhibitory effects of quinone analogues on 
bovine heart mitochondrial complex I (NADH: ubiquinone oxidoreductase) were 
evaluated by modification of a method described previously.133 Stock solutions (2 
mg/mL in ethanol) of quinone analogues were prepared and kept in the dark at 
−80 °C. Maximal ethanol concentration never exceeded 2% and had no influence 
on the control enzymatic activity. The enzymatic activities were assayed at 30 °C 
and monitored spectrophotometrically with a Molecular Devices SPECTRA Max-
M5 (340 nm, ε = 6.22 mM-1 cm-1). NADH oxidase activity was determined in a 
reaction medium (2.5 mL) containing 50 mM Hepes, pH 7.5, containing 5 mM 
MgCl2. The final amount of mitochondrial protein was 30 μg. The reaction was 
initiated by adding 50 μM NADH after the pre-equilibration of SMP with 
inhibitor for 5 min. The initial rates were calculated from the linear portion of the 
traces. The inhibition of NADH-Q1 oxidoreductase (complex I) activity was also 
determined under the same experimental conditions except that the reaction 
medium (2.5 mL) contained 0.25 M sucrose, 1 mM MgCl2, 2 μM antimycin A, 2 
mM KCN, 50 μM ubiquinone Q1 and 50 mM phosphate buffer, pH 7.4. IC50 
values were taken as the final compound concentrations in the assay cuvette that 
yielded 50% inhibition of the enzymatic activity. 
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CHAPTER 3 
3. SYNTHESIS OF A BLEOMYCIN DISACCHARIDE LIBRARY 
 
3.1 Introduction 
Carbohydrates are an important class of biomolecules that play a pivotal 
role in mediating various biological processes. Glycopeptides, glycolipids and 
other glycoconjugates are known to participate in signal transduction,134 
inflammation,135 cell-cell interactions,136 fertility and development.137 
Extracellular communication is crucial to a wide range of cellular 
processes that are essential for cell viability including growth, reproduction and 
motility. Such communication involves the interaction of cell surface receptors 
and their respective substrates, a process first described by Emil Fischer with his 
“lock-and-key” hypothesis.138 A comprehensive understanding of cell surface 
interactions would enable the manipulation of these communications and the 
processes they control. Cell surface glycoconjugates have been found to play an 
important role in cellular communication. 
Carbohydrate residues are recognized by specific cell surface 
carbohydrate-binding proteins called lectins and are then internalized into the cell 
by receptor-mediated endocytosis.139 This mechanism is believed to play a crucial 
role in mediating the cellular uptake of many glycosylated natural products and 
controls their biological activity. Glycotargeting is a strategy that utilizes the 
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highly specific carbohydrate−lectin interactions to improve the bioavailability of 
biologically active molecules by conjugation to sugar residues.140,141  
The bleomycins, originally isolated from Streptomyces verticillus in 1966 
by Umezawa and colleagues142 are a family of glycopeptides antibiotics that are 
used clinically in combination with other agents to treat several tumors.143-148 The 
antitumor activity of bleomycin is attributed to its ability to cleave DNA 
specifically at 5’-GC-3’ and 5’-GT-3’ sequences.149 The specific cytotoxicity of 
bleomycin towards tumor cells has led to their clinical use in the treatment of 
squamous cell carcinomas and malignant lymphomas.86,150 All the members of the 
bleomycin family share essentially the same core structure which can be dissected 
into several functional domains as shown in Figure 1.3.83 
The therapeutic utility of bleomycin is enhanced by its low 
myelosuppression and immunosuppression properties and underscored by its low 
therapeutic dose. The major hindrance to its widespread use, however, is the 
appearance of lung fibrosis in a significant percentage of patients treated with the 
drug.83,89,151 This limitation highlights the need to understand the molecular 
mechanisms of bleomycin activity which could lead to the development of more 
highly selective and potent analogues with improved pharmocological properties. 
Synthetic methods to evaluate the functional role of the bleomycin 
domains have shown that altering any position within the metal binding domain, 
the linker region or bithiazole moiety severely reduced the ability of the drug to 
mediate dsDNA cleavage, putatively its main source of cytotoxicity.83,85,86,152-154 
In terms of function the carbohydrate domain is the least well understood. The 
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role of the sugars in bleomycin activity is still unclear although in vitro and in 
vivo studies have shown reduced efficacy of deglycobleomycin in mediating 
dsDNA cleavage.91-93 
The natural disaccharide moeity in bleomycin consists of the 
monosaccharide subunits D-mannose and L-gulose. The 3-position of the D-
mannose moiety has a carbamoyl functional group which has been shown to play 
an important role in coordination of a variety of metal ions.155-158 Although 
bleomycin and deglycobleomycin show analogous DNA cleavage properties in 
vitro,159 differences in the behaviour of BLM and deglyco BLM have become 
more evident when in vivo assays were performed.91-93 The importance of the 
carbohydrate residue to the tumor selectivity of BLM was further validated by the 
imaging studies carried out with 111In-BLEDTA complex (Figure 3.1).91,160,161 
These studies included the findings that radionuclide derivatives of deglyco BLM 
failed to produce images comparable to those observed for the corresponding 
BLM derivative.91,160,161 In summary, these results strongly suggest that the 
carbohydrate moiety in bleomycin may play an important role in cellular 
recognition and possible uptake. 
 Figure 3.1. Chemical structure of BLEDTA. 
 
To fully understand the importance of the carbohydrate domain in 
bleomycin to its overall potency, a library of bleomycin disaccharides which are 
structural analogues of the natural bleomycin disaccharide were synthesized. Our 
preliminary studies had shown that the carbamoyl functional group, which plays a 
crucial role in metal chelation (Figure 3.2), was essential for cellular recognition 
and uptake.162 Thus the carbamoyl group was modified and its position was 
altered systematically to afford a library of disaccharides which were then 
conjugated to a fluorophore to monitor its cellular distribution and uptake by 
fluorescence microscopy (Figure 3.3). These studies would potentially provide 
conclusive evidence regarding the role of the carbohydrate moiety in tumor cell 
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binding and targeting by BLM and also help in identifying tumor targeting 
disaccharides capable of improving the therapeutic index of BLM.  
 
Figure 3.2. Proposed mode of coordination of Fe2+ with BLM.156 
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 Figure 3.3. Structures of disaccharide-dye conjugates prepared for evaluation. 
 
3.2 Results  
3.2.1 Synthesis of gulose acceptor  
The synthesis of gulose acceptor 3.16 was carried out according to a 
published procedure.163 As outlined in Scheme 3.1, the synthesis began with the 
commercially available L-xylose which was first converted to the corresponding 
fully protected dithioacetal 3.9 in 75% yield. The Hg(II) promoted hydrolysis of 
the dithioacetal 3.9 afforded the aldehyde 3.10 which was then coupled to 2-
(trimethylsilyl)thiazole164 (3.11) followed by a desilylative workup to afford the 
alcohol 3.12 in 64% yield over two steps. The hydroxyl group of 3.12 was then 
benzylated to yield ether 3.13 in 91% yield. Ether 3.13 was converted to the 
corresponding aldehyde 3.14 through a one-pot sequence of transformations 
involving the cleavage of the thiazole ring to afford the formyl group. Aldehyde 
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3.14 was then subjected to acid hydrolysis followed by exhaustive acetylation to 
yield tetra-O-acetyl-2-O-benzyl-L-gulopyranoside (3.15) in 64% yield over two 
steps. The benzylated gulose 3.15 was then subjected to debenzylation by 
hydrogenolysis over palladium-on-carbon to yield the gulose acceptor 3.16 in 
87% yield. 
 
Scheme 3.1 Synthesis of gulose acceptor 3.16. 
 
3.2.2 Synthesis of mannose and altrose donors 
The synthetic strategy adopted for the synthesis of the library of 
disaccharides required the generation of mannose and altrose monosaccharides 
with benzyl group at C2, C3 or C4 positions respectively. The benzyl groups were 
used to mask the positions at which the carbamoyl or methylcarbamoyl groups 
were later introduced into the disaccharide. 
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3.2.2.1 Synthesis of mannose donor 3.20 
As shown in Scheme 3.2, the synthesis of the mannose donor 3.20 with a 
C2 benzyl group, began with the commercially available α-D-
methylmannopyranoside, which was converted to 2-benzyl benzylidene acetal 
3.17 in 41% yield over two steps.165 The benzylidene acetal was then cleaved and 
subjected to exhaustive acetylation to yield tetra-O-acetyl-2-O-benzyl-D-
mannopyranoside (3.18) in 80% yield. Mannopyranoside 3.18 was converted to 
3.19 by the selective hydrazine acetate-mediated deacetylation of the anomeric 
acetate in 73% yield. The activation of pyranoside 3.19 as a glycosyl donor was 
accomplished through treatment of 3.19 with diphenyl chlorophosphate in 
presence of DMAP and Et3N to yield the α-glycosyl diphenyl phosphate 3.20 in 
40% yield.166 
 
Scheme 3.2 Synthesis of C2 benzyl mannose donor 3.20. 
  
3.2.2.2 Synthesis of mannose donor 3.25 
The synthesis of the mannose donor 3.25 with a C3 benzyl group is 
outlined in Scheme 3.3. The synthesis began with the conversion of commercially 
available α-D-methylmannopyranoside to the diol 3.21 in 70% yield.167 The 
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alkylation of the 2,3-O-dibutylstannylene derived from the reaction of the diol 
3.21 and Bu2SnO with benzyl bromide resulted in exclusive benzylation of the 
equatorial C3 alcohol to provide acetal 3.22 in 73% yield.167 The benzylidene 
acetal 3.22 was then cleaved and subjected to exhaustive acetylation to yield tetra-
O-acetyl-3-O-benzyl-D-mannopyranoside (3.23) in 85% yield. The 
mannopyranoside 3.23 was converted to 3.24 by the selective hydrazine acetate-
mediated deacetylation of the anomeric acetate in 76% yield. The activation of 
pyranoside 3.24 as a donor was accomplished through treatment of 3.24 with 
diphenyl chlorophosphate in presence of DMAP and Et3N to yield the α-glycosyl 
diphenyl phosphate 3.25 in 48% yield.166 
 
Scheme 3.3 Synthesis of C3 benzyl mannose donor 3.25.  
 
3.2.2.3 Synthesis of mannose donor 3.28 
The synthesis of the mannose donor 3.28 with a C4 benzyl group, began 
with the conversion of commercially available α-D-methylmannopyranoside to 
the diol 3.21167 in 70% yield as shown in Scheme 3.4. The diol was then subjected 
to a regioselective reductive ring-opening in presence of CoCl2 and BH3·THF to 
yield the 4-benzyl pyranoside. The latter was subjected to exhaustive acetylation, 
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affording tetra-O-acetyl-4-O-benzyl-D-mannopyranoside (3.26) in 22% yield over 
two steps.168 Mannopyranoside 3.26 was converted to pyranoside 3.27 by the 
selective hydrazine acetate-mediated deacetylation of the anomeric acetate in 90% 
yield. The activation of pyranoside 3.27 as a glycosyl donor was accomplished 
through treatment of 3.27 with diphenyl chlorophosphate in presence of DMAP 
and Et3N to yield the α-glycosyl diphenyl phosphate 3.28 in 66% yield.166 
 
Scheme 3.4 Synthesis of C4 benzyl mannose donor 3.28.  
 
3.2.2.4 Synthesis of altrose donor 3.35 
The synthesis of the altrose donor 3.35 with a C3 benzyl group, began 
with the conversion of commercially available α-D-methylglucopyranoside to the 
methyl 4,6-di-O-benzylidene-D-glucopyranoside (3.29)169 in 65% yield as 
outlined in Scheme 3.5. A two-step protocol involved the conversion of 3.29 to 
the corresponding 2,3-anhydromannopyranoside 3.30170 in 24% yield, followed 
by the regioselective opening of the oxirane at C3 with sodium benzyloxide was 
adopted to obtain the altropyranoside 3.31171 in 48% yield. The benzylidene acetal 
of 3.31 was then cleaved in 96% yield and the product was subjected to 
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exhaustive acetylation to yield tetra-O-acetyl-3-O-benzyl-D-altropyranoside 
(3.33) as a mixture of anomers in 86% yield. Altropyranoside 3.33 was converted 
to pyranoside 3.34 by the selective hydrazine acetate-mediated deacetylation of 
the anomeric acetate in 48% yield. The activation of 3.34 as a glycosyl donor was 
accomplished through treatment of 3.34 with diphenyl chlorophosphate in 
presence of n-BuLi to yield the α-glycosyl diphenyl phosphate 3.35 in 32% yield. 
 
Scheme 3.5 Synthesis of C3 benzyl altrose donor 3.35.  
 
3.2.3 Synthesis of disaccharides 
3.2.3.1 Syntheses of C2 modified mannose disaccharide-dye conjugates 
The syntheses of the C2 modified mannose disaccharide-dye conjugates 
3.1 and 3.2 (Scheme 3.6) began with the coupling of gulose acceptor 3.16 and 
mannose donor 3.20 to yield the C2 benzylated disaccharide 3.36 in 62% yield.163 
Disaccharide 3.36 was subjected to hydrogenolysis over palladium-on-carbon and 
then converted to the p-nitrophenyl carbonate 3.37 in 96% yield over two steps.167 
The p-nitrophenyl carbonate 3.37 was then subjected to aminolysis with 
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methylamine to yield 3.38 in 77% yield. Disaccharide 3.38 was converted to 
glycosyl donor 3.39 by a selective hydrazine acetate-mediated deacetylation of 
the anomeric acetate, followed by activation with diphenyl chlorophosphate in 
presence of DMAP and Et3N to yield the α-glycosyl diphenyl phosphate 3.39 in 
56% yield over two steps.166 The glycosyl donor 3.39 was then coupled with CBz-
protected linker 3.40172 to yield linker coupled disaccharide 3.42 in 63% yield. 
The linker−disaccharide conjugate 3.41 was synthesized in an analogous fashion 
by Chandrabali Bhattacharya from α-D-methylmannopyranoside and L-xylose 
monosaccharides (Scheme 3.1 and 3.2). The key step was the ammonolysis of 
nitrophenyl ester 3.37 to introduce the carbamoyl group at C2 position of the D-
mannose moiety. The linker coupled disaccharide 3.41 was synthesized as shown 
in Scheme 3.7. The disaccharides 3.41173 and 3.42 were then subjected to a one-
pot deacetylation and hydrogenolysis to afford the fully deprotected linker 
disaccharide conjugates 3.43 and 3.44, which were then coupled to Cy5**COOSu 
(3.8)174 (Figure 3.3) to afford the dye-disaccharide conjugates 3.1 and 3.2 in 35% 
and 37% yields over two steps respectively.  
Scheme 3.6 Synthesis of C2 modified mannose disaccharide-dye conjugates. 
 
 
Scheme 3.7 Synthesis of C2 modified mannose disaccharide-linker conjugate 
3.41. The synthesis was carried out by Chandrabali Bhattacharya. 
 
3.2.3.2 Synthesis of C3 modified mannose disaccharide-dye conjugate 
The synthesis of the C3 modified mannose disaccharide-dye conjugate 3.3 
is outlined in Scheme 3.8. It began with the coupling of gulose acceptor 3.16 and 
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mannose donor 3.25 to yield the C3 benzylated disaccharide 3.45 in 57% yield.163 
Disaccharide 3.45 was subjected to hydrogenolysis over palladium-on-carbon and 
then converted to the p-nitrophenyl carbonate 3.46 in 71% yield over two steps.167 
The p-nitrophenyl carbonate 3.46 was then subjected to aminolysis with 
methylamine to yield 3.47 in 86% yield. Disaccharide 3.47 was converted to 
glycosyl donor 3.48 by selective hydrazine acetate-mediated deacetylation of the 
anomeric acetate, followed by activation with diphenyl chlorophosphate in 
presence of DMAP and Et3N to yield the α-glycosyl diphenyl phosphate 3.48 in 
76% yield over two steps.166 Glycosyl donor 3.48 was then coupled with CBz-
protected linker 3.40172 to yield linker coupled disaccharide 3.49 in 73% yield. 
The disaccharide was then subjected to a one-pot deacetylation and 
hydrogenolysis to afford the fully deprotected linker disaccharide conjugate 3.50 
which was then coupled to Cy5**COOSu (3.8)174 (Figure 3.3) to afford the dye-
disaccharide conjugate 3.3 in 23% yield over two steps. 
Scheme 3.8 Synthesis of C3 modified mannose disaccharide-dye conjugate 
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3.2.3.3 Syntheses of C4 modified mannose disaccharide-dye conjugates 
The syntheses of the C4 modified mannose disaccharide-dye conjugates 
3.4 and 3.5 are outlined in Scheme 3.9. They began with the coupling of gulose 
acceptor 3.16 and mannose donor 3.28 to yield the C4 benzylated disaccharide 
3.51 in 73% yield.163 Disaccharide 3.51 was subjected to hydrogenolysis over 
palladium-on-carbon and then converted to the p-nitrophenyl carbonate 3.52 in 
78% yield over two steps.167 The p-nitrophenyl carbonate 3.52 was then subjected 
to aminolysis with methylamine to yield 3.53 in 86% yield. Disaccharide 3.53 
was converted to glycosyl donor 3.54 by selective hydrazine acetate-mediated 
deacetylation of the anomeric acetate, followed by activation with diphenyl 
chlorophosphate in presence of DMAP and Et3N to yield the α-glycosyl diphenyl 
phosphate 3.54 in 69% yield over two steps.166 The glycosyl donor 3.54 was then 
coupled with CBz-protected linker 3.40172 to yield linker coupled disaccharide 
3.56 in 51% yield. The linker−disaccharide conjugate 3.55 was synthesized by 
Chandrabali Bhattacharya from α-D-methylmannopyranoside and L-xylose 
monosaccharides (Scheme 3.1 and Scheme 3.10). The disaccharides 3.55173 and 
3.56 were then subjected to a one-pot deacetylation and hydrogenolysis to afford 
the fully deprotected linker disaccharide conjugates 3.57 and 3.58 respectively, 
which were then coupled to Cy5**COOSu (3.8)174 (Figure 3.3) to afford the dye-
disaccharide conjugates 3.4 and 3.5 in 32% and 33% yields, over two steps 
respectively. 
Scheme 3.9 Synthesis of C4 modified mannose disaccharide-dye conjugates. 
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Scheme 3.10 Synthesis of C4 modified mannose disaccharide-linker conjugate 
3.55. The synthesis was carried out by Chandrabali Bhattacharya. 
 
3.2.3.4 Syntheses of C3 modified altrose disaccharide-dye conjugates 
The syntheses of the C3 modified altrose disaccharide-dye conjugates 3.6 
and 3.7 are shown in Scheme 3.11. They began with the coupling of gulose 
acceptor 3.16 and altrose donor 3.35 to yield the C3 benzylated disaccharide 3.59 
in 40% yield.163 Disaccharide 3.59 was subjected to hydrogenolysis over 
palladium-on-carbon and then converted to the p-nitrophenyl carbonate 3.60 in 
71% yield over two steps.167 The p-nitrophenyl carbonate 3.60 was then treated 
with ammonia or methylamine to yield 3.61 in 71% and 3.62 in 42% yields 
respectively. Disaccharides 3.61 and 3.62 were converted to the glycosyl donors 
3.63 and 3.64, respectively, by a selective hydrazine acetate-mediated 
deacetylation of the anomeric acetate, followed by activation with diphenyl 
chlorophosphate in presence of DMAP and Et3N to yield the α-glycosyl diphenyl 
phosphate 3.63 in 55% yield and 3.64 in 17% yield over two steps.166 Glycosyl 
donors 3.63 and 3.64 were then coupled with CBz-protected linker 3.40172 to yield 
linker coupled disaccharides 3.65 and 3.66 in 48% and 59% yields, respectively. 
The linker coupled disaccharides were then subjected to a one-pot deacetylation 
and hydrogenolysis to afford the fully deprotected linker disaccharide conjugates 
3.67 and 3.68, which were then coupled to Cy5**COOSu (3.8)174 (Figure 3.3) to 
afford the dye-disccharide conjugates 3.6 and 3.7 in 33% and 48% yields, over 
two steps, respectively. 
 Scheme 3.11 Synthesis of C3 modified altrose disaccharide-dye conjugates. 
 
3.2.4 Biological evaluation of fluorescent carbohydrate analogues 
Cells were cultured on 16-well glass chamber slides for 48 h, and 
incubated with a 25 μM solution of the appropriate disaccharide-dye conjugate at 
37 oC for 1 h. The cells were then fixed with a 4% solution of paraformaldehyde 
and washed twice with PBS buffer. Fluorescence microscopy imaging was carried 
out with a Zeiss Axiovert 200M inverted microscope with 40x oil objective. 
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 Figure 3.4. Chemical structures of Cy5** conjugates and Cy5**dye. 
 
Fluorescent probe Cy5** was chosen to circumvent the problems of 
autofluorescence and non-specific cell surface binding. It is a member of the 
cyanine dye family and has emission wavelengths in the red or near-infrared 
region. The cell binding/uptake of the dye (Cy5**), BLM disaccharide-Cy5** 
conjugate, BLM-Cy5** conjugate and deglyco BLM-Cy5** conjugate in human 
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prostate cancer cell (DU-145) was compared to its uptake in normal human 
prostate cells (PZ-HPV-7). As shown in Figure 3.5, the free dye exhibits very low 
uptake by either human cancer or normal prostate cell lines. The high uptake of 
the BLM disaccharide-Cy5** conjugate and BLM-Cy5** conjugate in the tumor 
cell line highlights the importance of the disaccharide moiety to tumor cell 
uptake. This is further validated by the low binding and uptake of deglyco BLM-
Cy5** conjugate in the human prostate cancer cell line studied.  
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Figure 3.5. Quantification of the binding/uptake of BLM-Cy5**, deglycoBLM-
Cy5**, BLM disaccharide-Cy5** and Cy5** by DU-145 prostate carcinoma cells 
and PZ-HPV-7 normal prostate cells (Figures 3.3 and 3.4). The DU-145 and PZ-
HPV-7 cells were treated with 25 μM dye conjugates and exposed for 1 sec prior 
to imaging. The experiment was carried out by Dr. Zhiqiang Yu. 
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Figure 3.6. Quantification of the binding/uptake of BLM disaccharide-Cy5**, 
decarbamoyl disaccharide-Cy5**and disaccharide-Cy5** conjugates (Figures 3.3 
and 3.4) by A549 lung carcinoma cells and WI-38 normal lung cells. The A549 
and WI-38 cells were treated with 25 μM dye conjugates and exposed for 1 sec 
prior to imaging. The experiment was carried out by Dr. Zhiqiang Yu. 
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Figure 3.7. Quantification of the binding/uptake of BLM disaccharide-Cy5**, 
decarbamoyl disaccharide-Cy5**and disaccharide-Cy5** conjugates (Figures 3.3 
and 3.4) by DU-145 prostate carcinoma cells and PZ-HPV-7 normal prostate 
cells. The DU-145 and PZ-HPV-7 cells were treated with 25 μM dye conjugates 
and exposed for 1 sec prior to imaging. The experiment was carried out by Dr. 
Zhiqiang Yu. 
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Figure 3.8. Quantification of the binding/uptake of BLM disaccharide-Cy5**, 
decarbamoyl disaccharide-Cy5**and disaccharide-Cy5** conjugates (Figures 3.3 
and 3.4) by SW480 colon carcinoma cells and CCD-112CoN normal colon cells. 
The SW480 and CCD-112CoN cells were treated with 25 μM dye conjugates and 
exposed for 1 sec prior to imaging. The experiment was carried out by Dr. 
Zhiqiang Yu. 
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The binding uptake of decarbamoyl disaccharide-Cy5** conjugate, BLM 
disaccharide-Cy5** conjugate and the different synthesized disaccharide-Cy5** 
conjugates by A549 lung carcinoma cells and WI-38 normal lung cells (Figure 
3.6) or by DU-145 prostate carcinoma cells and PZ-HPV-7 normal prostate cells 
(Figure 3.7) or by SW480 colon carcinoma cells and CCD-112CoN normal colon 
cells (Figure 3.8) were quantified by fluorescence imaging. As shown (Figures 
3.6-3.8), the decarbamoylated BLM disaccharide exhibits very low binding and 
uptake in all tumor and normal cell lines tested highlighting the importance of the 
carbamoyl moiety to effective cell binding and uptake. The binding and uptake of 
the disaccharide-dye conjugates in human colon cells was lower relative to that in 
human prostate and lung cancer cells; however, the binding and uptake profiles 
were similar. Disaccharides having a carbamoyl group modified with the 
methylamino group (3.2, 3.3 and 3.7) exhibited greater binding and uptake as 
compared to the disaccharides with unmodified carbamoyl group (3.1 and 3.6). 
Disaccharides with carbamoyl and methylcarbamoyl group at C4 position of the 
D-mannose subunit (3.4 and 3.5) exhibited low binding and uptake in all the 
tumor cell lines tested. The binding and uptake was generally higher for 
disaccharides 3.2 and 3.7 containing the modified carbamoyl group at C2 and C3 
position respectively. All the disaccharide-dye conjugates exhibited very low 
uptake in normal cells, highlighting the role of the disaccharide moiety in the 
cancer cell specificity of BLM 
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3.3 Discussion 
3.3.1 Synthesis of the disaccharide dye conjugates 
The natural disaccharide moiety in bleomycin made up of L-gulose and D-
mannose monosaccharide subunits has been found to play an important role in its 
tumor selectivity. Preliminary studies carried out by our group had highlighted the 
importance of the carbamoyl group present in the BLM disaccharide, towards the 
tumor cell binding and uptake of BLM.175 To better study the importance of the 
carbamoyl moiety, a library of disaccharide-dye conjugates were synthesized 
(Schemes 3.6-3.11).  
All the synthesized disaccharides had a L-gulose monosaccharide subunit, 
however in comparison to the natural BLM disaccharide which has a carbamoyl 
group at the 3-position of the D-mannose moiety, the synthesized disaccharides 
had  
1) A carbamoyl group at C-2 or C-4 positions of the D-mannose moiety. 
or 
2) A methylcarbamoyl group at C-2, C-3 or C-4 positions of the D-mannose 
moiety 
or 
3) A carbamoyl or methylcarbamoyl group at C-3 positions of the D-altrose 
moiety, which is a C3 epimer of D-mannose.  
The L-gulose pyranoside 3.16 was synthesized according to a published 
procedure from L-xylose in 24% yield over seven steps. The diethyl dithioacetal 
3.9 prepared from L-xylose was subjected to a Hg(II)-promoted hydrolysis to 
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afford crude aldehyde 3.10. The aldehyde was then coupled to thiazole 3.11, 
which on treatment with tetrabutylammonium fluoride underwent desilylation to 
afford the alcohol 3.12. The alcohol was converted to the benzyl ether 3.13 and 
subjected to the standard thiazole-to-formyl deblocking protocol to yield crude 
aldehyde 3.14. The removal of isopropyldiene protecting groups and subsequent 
cyclization followed by exhaustive acetylation afforded benzylated pyranoside 
3.15. Compound 3.15 was then subjected to debenzylation by hydrogenolysis 
over palladium to afford the tetraacetylated gulose subunit 3.16. 
The synthetic strategy adopted also required the syntheses of C2, C3, C4 
benzylated mannose and C3 benzylated altrose pyranosides, respectively. The 
benzylated mannose and altrose pyranosides 3.20, 3.25, 3.28 and 3.35 were 
coupled to gulose monosaccharide 3.16 to yield the corresponding benzylated 
disaccharides 3.36, 3.45, 3.51 and 3.59, respectively. The latter was then 
debenzylated and activated as the nitrophenyl ester to facilitate the incorporation 
of carbamoyl or methylcarbamoyl moiety. 
The synthesis of phosphate ester 3.20 (Scheme 3.2) was accomplished 
from commercially available α-D-methylmannopyranoside in 10% overall yield 
over four steps. Methylmannopyranoside was converted to benzylidene acetal 
3.17, via a two step reaction involving a dibenzyldiene intermediate. The reaction 
of α-D-methylmannopyranoside with benzaldehyde dimethyl acetal gave a 
mixture of endo and exo dibenzyldiene derivatives which underwent cleavage in 
presence of di-iso-butyl-aluminium hydride to afford acetal 3.17. Compound 3.17 
was then peracetylated to afford pyranoside 3.18. Selective anomeric 
102 
 
deacetylation of 3.18 gave 3.19, which was subsequently converted to phosphate 
ester 3.20. The latter was then coupled to gulose acceptor 3.16 to yield the 
benzylated disaccharide 3.36 (Scheme 3.6). Disaccharide 3.36 was debenzylated 
and converted to nitrophenylester 3.37. Ester 3.37 on treatment with methylamine 
afforded disaccharide 3.38 with a methylcarbamoyl group at C2 position of the D-
mannose subunit. Disaccharide 3.38 was converted to phosphate ester 3.39 via a 
hydrazine acetate-mediated anomeric deacetylation and subsequent activation 
with diphenyl chlorophosphate in presence of DMAP and Et3N. Attempts to 
convert 3.38 to 3.39 in presence of diphenyl chlorophosphate and n-BuLi as 
described in the literature led to significant loss of material due to competing 
phosphorylation of the methylcarbamoyl moiety. Phosphate ester 3.39 was 
coupled to CBz-protected linker 3.40 to afford linker coupled disaccharide 3.42. 
Disaccharide-linker conjugates 3.41 (synthesized by Chandrabali Bhattacharya, 
Scheme 3.7) and 3.42 were then subjected to sodium methoxide-catalyzed 
deacetylation and subsequent debenzylation to afford the fully deprotected 
disaccharide-linker conjugates 3.43 and 3.44. Disaccharides 3.43 and 3.44 were 
then coupled with the dye succinimidyl ester 3.8 (Figure 3.3) to afford the 
disaccharide-dye conjugates 3.1 and 3.2. 
The synthesis of phosphate ester 3.25 (Scheme 3.3) was also accomplished 
from commercially available α-D-methylmannopyranoside in 13% overall yield 
over five steps. Methylmannopyranoside was converted to the acetal 3.22 by 
regioselective benzylation of the diol 3.21 according to a published procedure. 
The regioselectivity is attributed to the exclusive benzylation of the equatorial C3 
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alcohol of 2,3-O-dibutylstannylene intermediate, derived from the reaction of diol 
3.21 with Bu2SnO. The acid-mediated cleavage and subsequent acetylation of 
3.22 afforded pyranoside 3.23. Selective anomeric deacetylation of 3.23 followed 
by treatment with diphenyl chlorophosphate gave the phosphate ester 3.25. 
Mannose donor 3.25 obtained was then coupled with gulose acceptor 3.16 to 
afford the C3 benzylated disaccharide 3.45 (Scheme 3.8). Compound 3.45 was 
subjected to debenzylation by hydrogenolysis over palladium and converted to the 
nitrophenyl ester 3.46. Incorporation of the methylcarbamoyl group at C-3 
position of the D-mannose moiety was accomplished by treatment of ester 3.46 
with methylamine to afford disaccharide 3.47. Disaccharide 3.47 was converted to 
phosphate ester 3.48 via a hydrazine acetate-mediated anomeric deacetylation and 
subsequent activation with diphenyl chlorophosphate in presence of DMAP and 
Et3N. The latter was coupled with CBz-protected linker 3.40 to afford the linker 
coupled disaccharide 3.49. The linker coupled disaccharide 3.49 was subjected to 
sodium methoxide-catalyzed deacetylation and subsequent debenzylation to 
afford the fully deprotected disaccharide-linker conjugates 3.50 which when 
coupled with the dye succinimidyl ester 3.8 (Figure 3.3) afforded the 
disaccharide-dye conjugates 3.3. 
Phosphate ester 3.28 (Scheme 3.4) was synthesized from commercially 
available α-D-methylmannopyranoside in 9% overall yield over five steps. 
Methylmannopyranoside was first converted to the diol 3.21. The 4,6-O-
benzylidene acetal of the diol 3.21 was subjected to a regioselective borane-
mediated ring-opening reduction and subsequently peracetylated to afford the 
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benzyl pyranoside 3.26. The anomeric acetate of pyranoside 3.26 was selectively 
deacetylated by hydrazine acetate to afford 3.27 which was then converted to the 
phosphate ester 3.28 by treatment with diphenyl chlorophosphate. The mannose 
donor 3.28 with a C4 benzyl group was coupled with gulose acceptor 3.16 to 
afford the disaccharide 3.51 (Scheme 3.9). The latter was then subjected to 
debenzylation by hydrogenolysis over palladium and converted to the nitrophenyl 
ester 3.52. Treatment of the nitrophenyl ester 3.52 with methylamine in THF 
afforded the disaccharide 3.53 containing a methylcarbamoyl group at C-4 
postion of the D-mannose moiety. Hydrazine acetate-mediated selective anomeric 
deacetylation and subsequent activation with diphenyl chlorophosphate in 
presence of DMAP and Et3N afforded the phosphate ester 3.54. The phosphate 
ester was coupled with CBz-protected linker 3.40 to afford linker-disaccharide 
conjugate 3.56. Disaccharide-linker conjugates 3.55 (synthesized by Chandrabali 
Bhattacharya, Scheme 3.10) and 3.56 were then subjected to sodium methoxide-
catalyzed deacetylation and subsequent debenzylation to afford the fully 
deprotected disaccharide-linker conjugates 3.57 and 3.58. Disaccharides 3.57 and 
3.58 were then coupled with the dye succinimidyl ester 3.8 (Figure 3.3) to afford 
the disaccharide-dye conjugates 3.4 and 3.5. 
Disaccharides 3.61 and 3.62 have a carbamoyl group and a 
methylcarbamoyl group respectively at the C-3 position of the D-altrose subunit. 
D-altrose is a C3 epimer of D-mannose subunit present in the natural BLM 
disaccharide. Disaccharides 3.61 and 3.62 would help us to better understand the 
importance of the stereochemistry of the carbamoyl group. Altrose phosphate 
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ester 3.35 was synthesized from commercially available α-D-
methylglucopyranoside in 1% overall yield over seven steps (Scheme 3.5). 
Methylglucopyranoside was first converted to benzyldiene diol 3.29. The reaction 
was carried out in acetonitrile instead of N,N-dimethylformamide as in the case of 
mannose analogues. The change of solvent improved the ease of purification and 
enabled the isolation of the product by recrystallization. The diol 3.29 was then 
converted to oxirane 3.30 according to a published procedure. Regioselective 
opening of the epoxide 3.30 at C3 with sodium benzyloxide afforded the 
altropyranoside 3.31. The regioselective ring opening has been attributed to the 
trans-diaxial effect. Cleavage of the benzyldiene acetal of 3.31 and subsequent 
peracetylation afforded altropyranoside 3.33. Selective hydrazine acetate-
mediated anomeric deacetylation of 3.33 followed by treatment with diphenyl 
chlorophosphate gave the phosphate ester 3.35. The synthesis of the altrose 
phosphate 3.35 was found to proceed in satisfactory yields only in presence of n-
BuLi. The need for a stronger activation conditions required for the synthesis of 
altrose donor as compared to the mannose phosphates is not well understood. The 
altrose donor was coupled with gulose acceptor 3.16 to afford the disaccharide 
3.59 (Scheme 3.11). Disaccharide 3.59 was debenzylated by hydrogenolysis over 
palladium and converted to the nitrophenyl ester 3.60. The nitrophenyl ester 3.60 
was then treated with ammonia or methylamine to incorporate the carbamoyl or 
methylcarbamoyl group at C-3 postion of the D-altrose subunit to afford 
disaccharides 3.61 and 3.62. The anomeric acetate of 3.61 and 3.62 was 
deprotected selectively by hydrazine acetate and treated with diphenyl 
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chlorophosphate in presence of DMAP and Et3N to afford the phosphate esters 
3.63 and 3.64. The use of DMAP/triethylamine mixture for synthesis of phosphate 
ester was essential to suppress the phosphorylation of the amine moiety in the 
methylcarbamoyl group. The phosphate esters 3.63 and 3.64 were coupled with 
CBz-protected linker 3.40 to afford linker-disaccharide conjugate 3.65 and 3.66. 
Disaccharide-linker conjugates 3.65 and 3.66 were then deacetylated and 
debenzylated to afford the fully deprotected disaccharide-linker conjugates 3.67 
and 3.68. The latter were then coupled with the dye succinimidyl ester 3.8 (Figure 
3.3) to afford the disaccharide-dye conjugates 3.6 and 3.7. 
3.3.2 Biological evaluation of fluorescent carbohydrate analogues 
Bleomycin exhibits selective targeting of cancer cells. The initial studies 
(Figure 3.5) monitoring the binding and uptake clearly showed that the 
disaccharide was essential for the selective uptake of the BLM in tumor cells. The 
uptake of the dye itself was extremely low in the cancer as well as normal cells. 
Although the uptake efficiency varied for the different cancer cell lines monitored 
(Figures 3.6−3.8), the uptake profiles of the synthesized disaccharide−dye 
conjugates were similar implying broad specificity of the synthesized 
disaccharides. In all the cell lines tested, decarbamoyl BLM disaccharide 
exhibited low uptake, clearly indicating the importance of the carbamoyl moiety. 
In general, except for 3.5 the disaccharides having a methylcarbamoyl group 
exhibited greater uptake as compared to the disaccharides with the unmodified 
carbamoyl group. The disaccharide−dye conjugates did were not bound to any of 
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the normal human cells tested, further substantiating its role in selective targeting 
of cancer cells by BLM. The disaccharides 3.2 and 3.7, having a modified 
carbamoyl group at C2 and C3 positions, respectively, exhibited the best binding 
and uptake profiles. The fluorescence studies indicate that the modified 
disaccharides if incorporated could potentially enhance the tumor selective 
binding and uptake of BLM. 
3.4. Experimental 
General Methods. The chemicals were all ACS reagent grade and were used 
without further purification. The reactions were carried out under an argon 
atmosphere unless specified. Flash column chromatography was carried out using 
silica gel (Silicycle R10030B, 60 particle size, 230-400 mesh), applying a low 
pressure stream of nitrogen. Analytical thin layer chromatographic separations 
were carried out on glass plates coated with silica gel (60 particle size F254, 
SiliCycle TLG-R10011B-323). The TLC chromatograms were developed by 
immersing the plates in 2.5% potassium permanganate in ethanol or 2% 
anisaldehyde + 5% sulfuric acid + 1.5% glacial acetic acid in ethanol, followed by 
heating, or else visualized by UV irradiation (254 nm). Melting points were 
recorded on a MelTemp apparatus and are uncorrected. Tetrahydrofuran was 
distilled from sodium/benzophenone ketyl and dichloromethane from calcium 
hydride. 1H and 13C NMR spectra were recorded on a Gemini 300 or Varian Inova 
400, or on a Varian Inova 500 spectrometer, using CDCl3 as solvent and internal 
standard, unless otherwise indicated. 1H NMR chemical shifts were reported 
relative to residual CHCl3 at 7.26 ppm, or to residual DMSO-d5 at 2.50 ppm; 13C 
NMR shifts were reported relative to the central line of CDCl3 at 77.16 ppm, or to 
13C DMSO-d6 at 39.51 ppm. Splitting patterns are designated as s, singlet; br s, 
broad singlet; d, doublet; dd, doublet of doublets; dt, doublet of triplets; m, 
multiplet; q, quartet; quin, quintet. Cyanine dyes were obtained from our 
collaborators at General Electric. High resolution mass spectrometric data was 
obtained at the Michigan State Mass Spectrometry Facility or at the Arizona State 
University CLAS High Resolution Mass Spectrometry Facility. 
 
 
2,3,4,5-Di-O-isopropylidene-L-xylose Diethyl Dithioacetal (3.9).163  
To a suspension of 8.00 g (53.3 mmol) of L-xylose in 3.2 mL of conc HCl was 
added, with vigorous magnetic stirring, 11.8 mL (10.1 g, 160 mmol) of 
ethanethiol. Stirring was continued at room temperature until the two layer 
mixture gave a homogenous solution (usually after 15-20 min) which was then 
diluted with 160 mL of acetone. After stirring for 5 h, the solution was neutralized 
with satd aq NH4OH solution and co-evaporated with six 20-mL portions of 
toluene several times to afford a crude residue. The residue was applied to a silica 
gel column (28 × 5 cm). Elution with 1:1 ethyl acetate−hexanes gave 3.9 as a 
colorless syrup: yield 13.4 g (75%); ሾߙሿD + 57.2 (c 1.8, C6H6), lit.163 ሾߙሿD + 51.3 
(c 1.8, C6H6); silica gel TLC Rf 0.59 (3:1 ethyl acetate−hexanes); 1H NMR 
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(CDCl3) δ 1.23-1.28 (m, 6H), 1.36 (s, 3H), 1.41 (s, 6H), 1.45 (s, 3H), 2.68-2.77 
(m, 4H), 3.91 (dd, 2H, J = 9.8 and 4.5 Hz), 4.02-4.06 (m, 1H), 4.13 (dd, 1H, J = 
5.3 and 2.1 Hz) and 4.31-4.34 (m, 2H); 13C NMR (CDCl3) δ 14.26, 14.34, 24.9, 
25.3, 25.6, 26.1, 27.1, 27.3, 53.0, 65.9, 75.2, 78.7, 80.1, 109.5 and 110.0. 
 
 
2,3,4,5-Di-O-isopropylidene-aldehydo-L-xylose (3.10).163 To a stirred solution 
containing 2.60 g (7.70 mmol) of thioacetal 3.9 in 26 mL of acetone diluted with 
2.6 mL of water was added 3.80 g (17.7 mmol) of yellow mercury(II) oxide and 
3.80 g (13.9 mmol) of mercuric(II) chloride. The reaction mixture was stirred at 
55 °C for 2 h and then allowed to cool to room temperature. The solvent was 
filtered through a pad of Celite 545® and concentrated under diminished pressure 
to afford a crude residue. The residue was suspended in three 30-mL portions of 
dichloromethane and filtered through a pad of Celite 545®. The organic layer was 
washed with 40 mL of 1 M aq KI, dried (MgSO4) and then concentrated under 
diminished pressure to afford the crude aldehyde 3.10. The aldehyde was used for 
the next reaction immediately.  
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 2-(Trimethylsilyl)thiazole (3.11).164 A 500-mL, four-necked, round-bottomed 
flask, containing a magnetic stirring bar, was equipped with two 100-mL, 
pressure-equalizing dropping funnels and a low-temperature thermometer. The 
anh apparatus was filled with argon and kept under a slightly positive pressure 
during the entire reaction. The flask was charged with 80 mL of freshly distilled 
Et2O and 42 mL (67 mmol) of a 1.6 M solution of n-BuLi in hexane. One of the 
two dropping funnels was charged with 5.5 mL (10 g, 61 mmol) of 2-
bromothiazole in 20 mL of Et2O and the other with 7.7 mL (6.6 g, 61 mmol) of 
chlorotrimethylsilane in 20 mL of Et2O. The reaction flask was cooled to −78 ºC 
in an anh acetone bath. While the solution in the flask was stirred, 2-
bromothiazole was added dropwise over a period of 1 h. After 20 min of 
additional stirring, chlorotrimethylsilane was added dropwise over 30 min and the 
stirring was continued for a period of 1 h at −78 ºC. The resulting mixture was 
then allowed to warm up to room temperature. A satd aq NaHCO3 was added and 
the mixture was transferred into a 1 L separatory funnel. The organic layer was 
recovered and the aqueous layer was extracted with two 200-mL portions of Et2O. 
The combined organic layer was dried (Na2SO4), filtered, and concentrated under 
diminished pressure with the external bath temperature not exceeding 40 °C. The 
residue was distilled from a 100-mL flask at diminished pressure in a Claisen 
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apparatus. The distillation was carried out under diminished pressure at 45 °C 
after a forerun at 25 °C consisting mainly of bromobutane was collected. The pure 
product 3.11 was isolated as a colorless oil: yield 7.3 g (76%); 1H NMR (CDCl3) 
δ 0.39 (s, 12H), 7.50 (1H, d, J = 3.0 Hz) and 8.09 (1H, d, J = 2.9 Hz); 13C NMR 
(CDCl3) δ 1.03, 127.3, 145.6 and 174.2. 
 
O O O
O OH
S
N
 
111 
 
1,2,3,4-bis-O-(1-Methylethylidene)-5-C-2-thiazolyl-(5S)-D-xylitol (3.12).163 To 
a stirred solution containing 2.22 g (9.65 mmol) of crude aldehyde 3.10 in 38 mL 
of anh dichloromethane cooled to −20 °C was added 2.00 mL (1.97 g, 12.5 mmol) 
of 2-(trimethylsilyl)thiazole (3.11) dropwise over a period of 15 min. The solution 
was stirred at 0 °C for 1 h and then concentrated under dimished pressure to 
afford a crude residue. The residue was dissolved in 38 mL of anh THF and 
treated with 3.00 g (9.65 mmol) of n-Bu4NF•3H2O at 20 °C for 30 min and then 
concentrated under dimished pressure. The residue was diluted by the addition of 
250 mL of dichloromethane. The organic layer was washed with three 50-mL 
portions of water, dried (Na2SO4) and then concentrated under diminished 
pressure to yield compound 3.12 as a crude residue. Recrystallization of the 
residue from cyclohexane afforded alcohol 3.12 as a colorless crystalline solid: 
yield 1.94 g (64% over two steps); ሾߙሿD + 18.2 (c 1.1, CHCl3), lit.163 ሾߙሿD + 18.5 
(c 1.1, CHCl3); silica gel TLC Rf 0.49 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 1.28 (s, 3H), 1.36 (s, 6H), 1.40 (s, 3H), 3.67 (t, 1H, J = 6.6 Hz), 3.79-
3.84 (m, 2H), 4.12 (dd, 1H, J = 7.2 and 3.6 Hz), 4.31-4.34 (m, 1H), 4.56 (br s, 
1H), 5.10 (d, 1H, J = 5.5 Hz), 7.30 (d, 1H, J = 3.2 Hz) and 7.71 (d, 1H, J = 3.2 
Hz); 13C NMR (CDCl3) δ 25.6, 26.1, 27.07, 27.13, 65.7, 71.7, 75.5, 77.4, 79.8, 
109.5, 110.2, 119.7, 142.1 and 170.9. 
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1,2,3,4-bis-O-(1-Methylethylidene)-5-O-(phenylmethyl)-5-C-2-thiazolyl-(5S)-
D-xylitol (3.13).163 To a solution containing 1.94 g (6.15 mmol) of alcohol 3.12 in 
anh DMF cooled to 0 °C was added 0.49 g (60% dispersion in oil, 12.3 mmol) of 
NaH portionwise and the reaction mixture was stirred at 0 °C for 0.5 h. To this 
solution was then added 1.10 mL (1.58 g, 9.20 mmol) of benzyl bromide and the 
reaction mixture was stirred at room temperature for 0.5 h. The reaction mixture 
was quenched by the addition of 1.2 mL of methanol, stirred for 10 min and then 
diluted with 40 mL of distilled water. The aqueous layer was extracted with three 
100-mL portions of ether. The combined organic layer was dried (MgSO4) and 
concentrated under diminished pressure to afford a crude residue. The residue was 
applied to a silica gel column (25 × 4 cm). Elution with 6:1 ethyl acetate−hexanes 
gave ether 3.13 as a colorless solid: yield 2.26 g (91%); ሾߙሿD −32.2 (c 1.1, 
CHCl3), lit.163 ሾߙሿD −32.3 (c 1.1, CHCl3); silica gel TLC Rf 0.36 (9:1 
toluene−methanol); 1H NMR (CDCl3) δ 1.20 (s, 3H), 1.25 (s, 3H), 1.29 (s, 3H), 
1.33(s, 3H), 3.62-3.68 (m, 1H), 3.75-3.80 (m, 1H), 3.89-3.93 (m, 1H), 3.96-3.99 
(m, 1H), 4.35 (dd, 1H, J = 7.3 and 2.5 Hz), 4.44 (d, 1H, J = 12.1 Hz), 4.63 (d, 1H, 
J = 12.1 Hz), 4.80 (d, 1H, J = 4.8 Hz), 7.21-7.28 (m, 5H), 7.32 (d, 1H, J = 3.2 Hz) 
and 7.78 (d, 1H, J = 3.2 Hz); 13C NMR (CDCl3) δ 14.0, 25.5, 26.03, 26.05, 26.7, 
27.0, 65.5, 72.2, 75.5, 77.7, 78.5, 79.4, 109.4, 110.3, 120.1, 127.9, 128.1, 128.3, 
136.8, 142.4 and 168.9. 
 
 
2-O-Benzyl-3,4,5,6-di-O-isopropylidene-aldehydo-L-gulose (3.14).163 A 
solution containing 0.61 g (1.50 mmol) of O-benzyl ether 3.13 and 2.80 g of 
activated 4Å molecular sieves dissolved in 15 mL of anh acetonitrile was stirred 
at 20 °C for 10 min and then 0.22 mL (329 mg, 1.95 mmol) of methyl triflate was 
added dropwise. The suspension was stirred at room temperature for 15 min and 
then concentrated under diminished pressure to afford the crude N-
methylthiazolium salt. To a stirred solution of the crude N-methylthiazolium salt 
in 15 mL of methanol cooled to 0 °C was added 0.12 g (3.30 mmol) of sodium 
borohydride. The reaction mixture was stirred at room temperature for 5 min and 
diluted with 5 mL of acetone. The solvent was filtered through a pad of Celite 
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545® and concentrated under diminished pressure to afford a crude mixture of 
thiazolidines. This was dissolved in 14 mL of acetonitrile and 1.4 mL of water 
and treated under vigorous stirring with 0.96 g (12.0 mmol) of CuO and 0.26 g 
(1.50 mmol) of CuCl2•2H2O. The reaction mixture was stirred at 20 °C for 15 
min, filtered through a pad of Celite 545® and then concentrated under diminished 
pressure to remove acetonitrile and most of the water (bath temperature not 
exceeding 40 °C) to afford a crude residue. The brown residue was triturated with 
four 50-mL portions of ether and the liquid phase was pipetted and filtered 
through a pad of Florisil® (60−100 mesh) to afford a colorless solution. After a 
further washing of Florisil® with 50 mL of ethyl acetate, the combined organic 
layer was concentrated under diminished pressure to yield the crude aldehyde 
3.14 as a brown syrup, which was used immediately for the next reaction. 
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1,3,4,6-Tetra-O-acetyl-2-O-benzyl-L-gulopyranose (3.15).163 A solution 
containing 470 mg (1.34 mmol) of the crude aldehyde 3.14 was dissolved in 7.4 
mL of glacial acetic acid and 1.9 mL of distilled water and stirred at 100 °C for 40 
min. The reaction mixture was then concentrated by co-evaporation three times 
with toluene to afford the crude 2-O-benzyl-L-gulose as a mixture of β-pyranose, 
α-pyranose and furanose forms. A solution of the crude residue and 0.16 g (1.34 
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mmol) of DMAP in 3.4 mL of pyridine and 3.4 mL of acetic anhydride was 
stirred at 20 °C for 12 h and concentrated under diminished pressure to yield a 
brown syrup. The crude residue was applied to a silica gel column (38 × 3 cm). 
Elution with 3:1 ethyl acetate−hexanes gave 3.15 as a yellow oil: yield 1.56 g 
(64% over two steps); silica gel TLC Rf 0.44 (1:1 ethyl acetate−hexanes); 1H 
NMR (CDCl3) δ2.01 (s, 3H), 2.05 (s, 3H), 2.08 (s, 3H), 2.11 (s, 3H), 3.64 (dd, 1H, 
J = 8.3 and 4.9 Hz), 3.98-4.13 (m, 2H), 4.24-4.32 (m, 1H), 4.49 (d, 1H, J = 11.9 
Hz), 4.63 (d, 1H, J = 11.9 Hz), 4.95 (dd, 1H, J = 3.9 and 2.5 Hz), 5.43-5.45 (m, 
1H), 5.89 (d, 1H, J =8.3 Hz) and 7.23-7.34 (m, 5H). 
 
 
1,3,4,6-Tetra-O-acetyl-L-gulopyranose (3.16).163 176To a solution containing 
1.47 g (3.35 mmol) of 3.15 in 23 mL of ethyl acetate was added 0.73 g of 10% 
Pd/C and the reaction mixture was stirred overnight under 1 atm of H2. The 
solvent was filtered through a pad of Celite 545® and concentrated under 
diminished pressure to afford a crude residue. The residue was applied to a silica 
gel column (15 × 4 cm). Elution with 1:1 ethyl acetate−hexanes afforded 3.16 as a 
77:20:3 mixture of α-pyranose, β-pyranose and furanose forms as determined by 
1H NMR: yield 1.02 g (87%); silica gel TLC Rf 0.52 (ethyl acetate); 1H NMR 
(CDCl3) δ 1.91 (s, 3H), 2.00 (s, 3H), 2.03 (s, 6H), 3.22-3.52 (br s, 1H), 3.80 (dd, 
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1H, J = 8.4 and 3.5 Hz), 3.91-3.97 (m, 1H), 3.99-4.04 (m, 1H), 4.14-4.19 (m, 1H), 
4.82-4.88 (m, 1H), 5.19 (t, 1H, J = 3.6 Hz) and 5.70 (d, 1H, J = 8.4 Hz); 13C NMR 
(CDCl3) δ 20.4, 20.5, 20.6, 20.8, 61.6, 66.2, 67.5, 69.5, 70.9, 92.1, 169.4, 169.6, 
169.7 and 170.5. 
 
 
Methyl 4,6-O-Benzylidene-2-O-benzyl-α-D-mannopyranoside (3.17).165 To a 
solution containing 5.00 g (26.0 mmol) of methyl α-D-mannopyranoside and 60.0 
mg (0.26 mmol) of camphor sulfonic acid in 75 mL of DMF was added dropwise 
9.7 mL (9.8 g, 65 mmol) of benzaldehyde dimethyl acetal. The resulting solution 
was heated to 60 °C on a rotary evaporator under a pressure of 250 mbar. After 3 
h, silica gel TLC (1:3 ethyl acetate−hexanes) indicated complete conversion of 
starting material (Rf 0.0) to two products (Rf 0.50 and 0.80). To the reaction 
mixture was then added 4.90 mL (4.90 g, 32.4 mmol) of benzaldehyde dimethyl 
acetal and 30.0 mg (0.13 mmol) of camphor sulfonic acid. The reaction mixture 
was stirred under diminished pressure. After 2 h, silica gel TLC (1:3 ethyl 
acetate−hexanes) indicated the formation of a single product (Rf 0.80). The 
solvent was concentrated under diminished pressure, the residue was co-
evaporated with 50 mL of toluene and then dissolved in 100 mL of 
dichloromethane. The organic layer was washed with 50 mL of satd aq NaHCO3 
and brine. The organic phase was then dried (MgSO4), filtered and concentrated 
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under diminished pressure. The resulting crude mixture of endo and exo 
dibenzylidene derivatives was dissolved in 150 mL of freshly distilled toluene and 
cooled to −40 °C under an argon atmosphere. Then 65 mL of DIBAL (1 M 
solution in toluene, 64.9 mmol) was added slowly to the reaction mixture. The 
reaction mixture was allowed to warm to room temperature slowly. After 2 h, 
silica gel TLC analysis (1:3 ethyl acetate−hexanes) indicated complete 
consumption of starting material (Rf 0.80) and formation of two products (Rf 0.40 
and Rf 0.30). The reaction mixture was quenched by the dropwise addition of 50 
mL of methanol and the mixture was diluted with 250 mL of dichloromethane. 
The organic layer was washed with 200 mL of 10% solution of Rochelle’s salt 
and brine and then dried (MgSO4). The organic layer was filtered and the filtrate 
was concentrated under diminished pressure. The resulting residue was purified 
by flash column chromatography (1:3 ethyl acetate−hexanes) to afford the 
undesired compound methyl 4,6-O-benzylidene-3-O-benzyl-α-D-
mannopyranoside (3.22) (Rf 0.30) and the desired methyl 4,6-O-benzylidene-2-O-
benzyl-α-D-mannopyranoside (3.17) as a colorless crystalline solid: yield 3.0 g 
(41%); silica gel TLC Rf 0.40 (1:3 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
3.34 (s, 3H), 3.79-3.82 (m, 3H), 3.96 (t, 1H, J = 8.0 Hz), 4.10-4.12 (m, 1H), 4.26-
4.27 (m, 1H), 4.72-4.75 (m, 3H), 5.53 (s, 1H), 7.33-7.41 (m, 8H) and 7.42-7.55 
(m, 2H). 
 
 1,3,4,6-Tetra-O-acetyl-2-O-benzyl-α-D-mannopyranoside (3.18).177 To a 
solution containing 3.57 g (9.59 mmol) of acetal 3.17 in 70 mL of Ac2O was 
added a catalytic amount of H2SO4 and the reaction mixture was stirred at 25 °C 
for 40 min. The reaction mixture was poured into a stirring mixture of 100 mL of 
ethyl acetate and 80 mL of satd aq NaHCO3. The organic and aqueous layers were 
separated and the organic layer was washed with 60 mL of brine and dried 
(MgSO4). The organic layer was filtered and concentrated under diminished 
pressure to afford a crude residue. The residue was applied to a silica gel column 
(17 × 5 cm). Elution with 2:1 ethyl acetate−hexanes afforded 3.18 as a yellow oil: 
yield 3.35 g (80%); silica gel TLC Rf 0.66 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 1.98 (s, 3H), 2.04 (s, 3H), 2.08 (s, 3H), 2.12 (s, 3H), 3.82 (dd, 1H, J = 
3.2 and 2.2 Hz), 4.01 (ddd, 1H, J = 10.0, 4.8 and 2.3 Hz), 4.08-4.15 (m, 1H), 
4.23-4.28 (m, 1H), 4.56-4.76 (m, 2H), 5.19 (dd, 1H, J = 10.0 and 3.3 Hz), 5.43-
5.52 (m, 1H), 6.18 (d, 1H, J = 1.9 Hz) and 7.27-7.38 (m, 5H); 13C NMR (CDCl3) 
δ 20.8, 20.90, 20.93, 21.1, 62.4, 66.0, 70.7, 71.1, 73.0, 74.0, 91.3, 128.1, 128.2, 
128.6, 137.3, 168.8, 169.6, 170.4 and 170.9. 
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3,4,6-Tri-O-acetyl-2-O-benzyl-α-D-mannopyranoside (3.19). To a solution 
containing 1.13 g (2.58 mmol) of compound 3.18 in 21 mL of anh DMF was 
added 286 mg (3.10 mmol) of hydrazine acetate. The reaction mixture was stirred 
at room temperature for 1.5 h and quenched by the addition of 100 mL of ethyl 
acetate. The organic layer was washed with three 50-mL portions of brine and 
dried (MgSO4). The solvent was concentrated under diminished pressure to afford 
a crude residue. The residue was applied to a silica gel column (20 × 3 cm). 
Elution with 1:2 ethyl acetate−hexanes afforded pyranoside 3.19 as a colorless oil: 
yield 793 mg (73%); silica gel TLC Rf 0.23 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 1.97 (s, 3H), 2.00 (s, 3H), 2.02 (s, 3H), 3.81-3.87 (m, 1H), 4.05-4.17 
(m, 2H), 4.20 (dt, 1H, J = 9.3 and 4.7 Hz), 4.56-4.63 (m, 3H), 5.21-5.33 (m, 2H), 
5.40 (t, 1H, J = 9.9 Hz) and 7.21-7.36 (m, 5H); 13C NMR (CDCl3) δ 20.57, 20.58, 
20.7, 62.7, 66.6, 68.2, 70.9, 72.8, 75.6, 92.2, 127.70, 127.72, 128.2, 137.6, 169.8, 
170.2 and 171.1; mass spectrum (APCI), m/z 397.1498 (M + H)+ (C19H25O9 
requires 397.1498). 
 
 
3,4,6-Tri-O-acetyl-2-O-benzyl-α-D-mannopyranosyl Diphenyl Phosphate 
(3.20). To a stirred solution containing 793 mg (2.00 mmol) of 3.19 in 120 mL of 
anh dichloromethane was added 305 mg (2.50 mmol) of DMAP, 3.00 mL (2.17 g, 
21.6 mmol) of Et3N and 4.00 mL (5.20 g, 19.2 mmol) of diphenyl 
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chlorophosphate. The reaction mixture was stirred at 0 °C for 2 h and poured into 
a stirring mixture of 300 mL of ethyl acetate and 150 mL of satd aq NaHCO3. The 
aqueous and organic layers were separated and the organic layer was washed with 
three 50-mL portions of water and brine and then dried (MgSO4). The solvent was 
concentrated under diminished pressure to afford a crude residue. The residue was 
applied to a silica gel column (20 × 3cm). Elution with 1:2 ethyl acetate−hexanes 
afforded 3.20 as a colorless oil: yield 508 mg (40%); silica gel TLC Rf 0.44 (1:1 
ethyl acetate−hexanes);1H NMR (CDCl3) δ 2.17 (s, 3H), 2.20 (s, 3H), 2.23 (s, 
3H), 4.10-4.25 (m, 3H), 4.42 (dd, 1H, J = 12.2 and 3.9 Hz), 4.76-4.88 (m, 2H), 
5.49 (d, 1H, J = 8.0 Hz), 5.73 (t, 1H, J = 10.1 Hz), 6.21 (d, 1H, J = 5.7 Hz) and 
7.33-7.62 (m, 15H); 13C NMR (CDCl3) δ 20.39, 20.46, 20.53, 61.7, 65.3, 69.8, 
70.8, 73.1, 74.4, 96.6, 119.9, 120.05, 120.09, 120.14, 124.59, 125.63, 127.8, 
127.9, 128.3, 129.3, 129.8, 136.8, 149.9, 150.1, 150.8, 169.3, 169.8 and 170.53; 
mass spectrum (APCI), m/z 629.1788 (M + H)+ (C31H34O12P requires 629.1788). 
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1,3,4,6-Tetra-O-acetyl-2-O-(3,4,6-tri-O-acetyl-2-O-benzyl-α-D-
mannopyranosyl)-β-L-gulopyranose (3.36). To a stirred solution containing 234 
mg (0.67 mmol) of glycosyl acceptor 3.16 and 508 mg (1.17 mmol) of glycosyl 
donor 3.20 in 4.8 mL of anh dichloromethane at 0 °C, was added 244 µL (300 
mg, 1.35 mmol) of TMSOTf. The reaction mixture was stirred at 0 °C for 10 min 
at which time it was poured into a two phase mixture of 30 mL of ethyl acetate 
and 30 mL of satd aq NaHCO3. The organic and aqueous layers were separated 
and the organic layer was washed with two 20-mL portions of brine and dried 
(MgSO4). The solvent was concentrated under diminished pressure to afford a 
crude residue. The residue was applied to a silica gel column (30 × 3 cm). Elution 
with 2:1 ethyl acetate−hexanes afforded compound 3.36 as a colorless oil: yield 
302 mg (62%); silica gel TLC Rf 0.2 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 1.84 (s, 3H), 1.94 (s, 3H), 1.99 (s, 3H), 2.04 (s, 3H), 2.08 (s, 3H), 2.09 
(m, 6H), 3.51-3.61 (m, 1H), 3.87-4.23 (m, 5H), 4.31 (t, 1H, J = 6.3 Hz,), 4.44-
4.47 (m, 1H), 4.56-4.69 (m, 1H), 4.80-4.97 (m, 2H), 5.02-5.07 (m, 2H), 5.27-5.47 
(m, 2H), 5.78 (d, 1H, J = 8.5 Hz,) and 7.16-7.36 (m, 5H); 13C NMR (CDCl3) δ 
20.61, 20.63, 20.66, 20.67, 20.69, 20.72, 61.3, 62.2, 65.3, 65.7, 66.0, 67.7, 68.8, 
69.2, 70.4, 71.3, 72.2, 73.9, 90.6, 94.2, 127.7, 128.1, 128.2, 137.6, 168.7, 169.36, 
169.37, 169.4, 170.0, 170.3 and 170.6; mass spectrum (APCI), m/z 727.2453 (M 
+ H)+ (C33H43O18 requires 727.2450). 
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1,3,4,6-Tetra-O-acetyl-2-O-(3,4,6-tri-O-acetyl-2-O-((p-
nitrophenyl)carbamoyl)-α-D-mannopyranosyl)-β-L-gulopyranose (3.37). To a 
solution containing 200 mg (0.27 mmol) of disaccharide 3.36 in 38 mL of ethyl 
acetate was added a catalytic amount of Pd(OH)2/C and the reaction mixture was 
stirred overnight under 1 atm of H2. The solvent was filtered through a pad of 
Celite 545® and the filtrate was concentrated under diminished pressure to afford 
a crude residue. The residue was used for the next reaction; silica gel TLC Rf 0.08 
(1:1 ethyl acetate−hexanes).  
To a solution containing 198 mg (0.31 mmol) of the crude residue in 1.2 
mL of anh pyridine was added 151 mg (1.24 mmol) of DMAP and 276 mg (1.24 
mmol) of p-nitrophenyl chloroformate. The reaction mixture was stirred at 40 °C 
overnight at which time it was poured into a mixture of 30 mL ethyl acetate and 
10 mL of H2O. The organic and aqueous layers were separated and the organic 
layer was washed with three 10-mL portions of 1 N HCl and 10 mL of satd aq 
NaHCO3 and then brine. The solution was dried (MgSO4) and filtered and the 
filtrate was concentrated under diminished pressure to afford a crude residue. The 
residue was applied to a silica gel column (25 × 3 cm). Elution with 1:1 ethyl 
acetate−hexanes afforded 3.37 as a colorless foam: yield 211 mg (96% over two 
steps); silica gel TLC Rf 0.30 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) 
δ1.98 (m, 3H), 2.03 (s, 6H), 2.10 (s, 3H), 2.12 (s, 3H), 2.14 (s, 3H), 2.17 (s, 3H), 
3.96-4.18 (m, 2H), 4.19-4.29 (m, 2H), 4.35 (t, 1H, J = 6.5 Hz), 4.96-5.03 (m, 2H), 
5.06-5.23 (m, 3H), 5.27-5.40 (m, 2H), 5.44 (t, 1H, J = 3.0 Hz), 5.88 (d, 1H, J = 
8.4 Hz), 7.39 (d, 2H, J = 8.0 Hz) and 8.26 (d, 2H, J = 9.1 Hz); 13C NMR (CDCl3) 
δ 20.70, 20.72, 20.75, 20.76, 20.9, 61.3, 62.0, 65.5, 65.7, 67.8, 68.8, 69.4, 70.1, 
71.4, 73.5, 90.6, 94.5, 121.7, 125.4, 145.6, 149.8, 151.6, 155.3, 168.7, 169.3, 
169.5, 169.7, 169.7, 170.5 and 170.6; HRMS (APCI), m/z 802.2053 (M + H)+ 
(C33H40NO22 requires m/z 802.2042). 
 
 
1,3,4,6-Tetra-O-acetyl-2-O-(3,4,6-tri-O-acetyl-2-O-(methylcarbamoyl)-α-D-
mannopyranosyl)-β-L-gulopyranose (3.38). To a solution containing 201 mg 
(0.25 mmol) of nitrophenyl ester 3.37 in 6 mL of anh THF was added dropwise at 
0 °C 125 μL (2 M solution in THF, 0.25 mmol) of CH3NH2. The reaction mixture 
was stirred at room temperature for 15 h at which time silica gel TLC analysis 
indicated that the reaction was complete. The solvent was concentrated under 
diminished pressure to afford a crude residue. The residue was applied to a silica 
gel column (25 × 3 cm). Elution with 1:1 ethyl acetate−hexanes afforded 
disaccharide 3.38 as a colorless oil: yield 134 mg (77%); silica gel TLC Rf 0.14 
(1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 1.94 (s, 3H), 1.98-2.15 (m, 18H), 
2.75 (d, 3H, J = 3.7 Hz), 3.93-4.13 (m, 4H), 4.18-4.22 (m, 2H), 4.30-4.33 (m, 
1H), 4.87-5.10 (m, 4H), 5.17-5.21 (m, 2H) and 5.33 (m, 2H); 13C NMR (CDCl3) δ 
123 
 
20.62, 20.63, 20.68, 20.72, 20.75, 20.77, 20.85, 27.6, 61.4, 62.0, 65.9, 67.6, 68.0, 
70.5, 71.4, 90.7, 93.2, 155.38, 155.40, 155.49, 169.24, 169.27, 169.30, 170.50, 
170.51, 170.6 and 170.9; HRMS (APCI), m/z 694.2169 (M + H)+ (C28H40NO19 
requires m/z 694.2195). 
 
 
3,4,6-Tri-O-acetyl-2-O-(3,4,6-tri-O-acetyl-2-O-(methylcarbamoyl)-α-D-
mannopyranosyl)-β-L-gulopyranosyl Diphenyl Phosphate (3.39). To a solution 
containing 108 mg (0.16 mmol) of disaccharide 3.38 in 1.2 mL of anh DMF was 
added 17.0 mg (0.19 mmol) of hydrazine acetate. The reaction mixture was stirred 
at room temperature for 1.5 h and quenched by the addition of 20 mL of ethyl 
acetate. The organic solution was washed with three 10-mL portions of brine and 
dried (MgSO4). The solvent was concentrated under diminished pressure to afford 
a crude residue. The residue was used for next reaction.  
To a stirred solution containing 90.0 mg (0.14 mmol) of the crude residue 
in 8.2 mL of anh dichloromethane was added 21.0 mg (0.17 mmol) of DMAP, 
210 μL (152 mg, 1.49 mmol) of Et3N and 270 μL (351 mg, 1.32 mmol) of 
diphenyl chlorophosphate. The reaction mixture was stirred at 0 °C for 2 h and 
poured into a mixture of 40 mL of ethyl acetate and 20 mL of satd aq NaHCO3. 
The organic layer was washed with three 10-mL portions of water and brine and 
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then dried (MgSO4). The solvent was concentrated under diminished pressure to 
afford a crude residue. The residue was applied to a silica gel column (25 × 3 cm). 
Elution with 2:1 ethyl acetate−hexanes afforded phosphate ester 3.39 as a 
colorless oil: yield 82 mg (56% over two steps); silica gel TLC Rf 0.18 (2:1 ethyl 
acetate−hexanes); 1H NMR (CDCl3) δ 1.67 (s, 3H), 1.94 (d, 6H, J = 7.4 Hz), 2.01 
(s, 3H), 2.11 (s, 3H), 2.16 (s, 3H), 2.76 (s, 3H), 3.89-4.39 (m, 7H), 4.75-5.05(m, 
4H), 5.10-5.30 (m, 2H), 5.44 (s, 1H), 5.68 (s, 1H) and 7.11-7.39 (m, 10H); 13C 
NMR (CDCl3) δ 20.4, 20.70, 20.76, 20.8, 20.9, 27.7, 61.2, 62.0, 65.5, 65.8, 67.5, 
69.1, 69.3, 69.4, 71.4, 71.5, 71.7, 95.9, 96.34, 120.31, 120.33, 125.6, 125.72, 
125.78, 125.83, 129.7, 130.0, 155.4, 169.3, 169.7, 169.8, 170.4, 170.67 and 
170.68; HRMS (APCI), m/z 884.2371 (M + H)+ (C38H47NO19 requires m/z 
884.2378). 
 
 
Benzyl 2-(2-Hydroxyethoxy)ethylcarbamate (3.40).172 To a solution containing 
1.01 g (9.61 mmol) of 2-(2-aminoethoxy)ethanol in 100 mL of THF at room 
temperature was added 1.34 mL (9.61 mmol) of Et3N and 1.49 mL (1.78 g, 10.6 
mmol) of CBzCl. The reaction mixture was stirred for 1 h and was then diluted 
with 250 mL of ethyl acetate. The organic layer was washed with two 250-mL 
portions of H2O, two 250-mL portions of brine, and was then dried (MgSO4) and 
concentrated under diminished pressure. The residue was purified by flash 
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chromatography on a silica gel column (30 × 4 cm). Elution with 9:1 ethyl 
acetate−hexanes afforded alcohol 3.40 as a colorless oil: yield 2.21 g (96%); silica 
gel TLC Rf 0.30 (9:1 ethyl acetate−hexanes); 1H NMR (CDCl3) 3.30 (m, 2H), 
3.45 (m, 4H), 3.52 (s, 1H), 3.62 (m, 2H), 5.03 (s, 2H), 5.86 (m, 1H) and 7.27 (m, 
5H); 13C NMR (CDCl3) 40.5, 61.1, 66.3, 69.7, 72.0, 127.72, 127.75, 128.1, 136.3 
and 156.5. 
 
 
3,4,6-Tri-O-acetyl-2-O-(3,4,6-tri-O-acetyl-2-O-(methylcarbamoyl)-α-D-
mannopyranosyl)-α,β-L-gulopyranosyl Benzyl 2-(2-Ethoxy)ethylcarbamate 
(3.42). To a stirred solution containing 90.0 mg (0.10 mmol) of phosphate ester 
3.39 in 1.1 mL of anh dichloromethane was added a solution of 22.0 mg (0.09 
mmol) of CBz linker 3.40 in 1.1 mL of anh dichloromethane at 0 °C. To the 
cooled reaction mixture was then added 33.0 μL (41.0 mg, 0.18 mmol) of 
TMSOTf and the reaction mixture was stirred at 0 °C for 15 min at which time it 
was poured into a mixture of 20 mL of ethyl acetate and 20 mL of satd aq 
NaHCO3. The aqueous and organic layers were separated and the organic layer 
was washed with three 10-mL portions of water and brine, then dried (MgSO4). 
The solvent was concentrated under diminished pressure to afford a crude residue. 
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The residue was applied to a silica gel column (25 ൈ 3 cm). Elution with 12:12:1 
ethyl acetate−hexanes−methanol afforded disaccharide−linker conjugate 3.42 as a 
colorless oil: yield 56 mg (63%); silica gel TLC Rf 0.20 (12:12:1 ethyl 
acetate−hexanes−methanol); 1H NMR (CDCl3) δ 1.96 (s, 3H), 2.00 (s, 3H), 2.01 
(s, 3H), 2.05-2.08 (m, 6H), 2.10 (s, 3H), 2.78 (d, 3H, J = 4.6 Hz), 3.38 (d, 2H, J = 
4.4 Hz), 3.51-3.70 (m, 4H), 3.78-3.87 (m, 1H), 3.95 (d, 1H, J = 3.5 Hz), 4.00-4.15 
(m, 4H), 4.20-4.30 (m, 2H), 4.45 (t, 1H, J = 6.1 Hz), 4.89-5.12 (m, 6H), 5.20-5.30 
(m, 3H), 5.42-5.49 (m, 1H), 5.46 (s, 1H) and 7.27-7.38 (m, 5H); 13C NMR 
(CDCl3) δ20.71, 20.73, 20.77, 20.80, 20.84, 20.88, 27.7, 62.3, 62.7, 63.9, 66.0, 
66.3, 66.7, 68.7, 68.9, 69.2, 70.1, 70.2, 70.4, 97.2, 97.9, 128.21, 128.23, 128.28, 
128.59, 128.61, 136.7, 155.5, 169.4, 169.80, 169.84, 170.0, 170.66 and 170.69; 
HRMS (APCI), m/z 873.3166 (M + H)+ (C38H53N2O21 requires m/z 873.3141). 
 
 
Methyl-4,6-O-benzylidene-α-D-mannopyranoside (3.21).167 To a solution 
containing 7.00 g (36.0 mmol) of α-D-mannopyranoside in 85 mL of DMF was 
added 5.60 mL (5.68 g, 37.3 mmol) of benzaldehyde dimethyl acetal and a 
catalytic amount of p-TsOH. The reaction mixture was stirred at 60 °C under 
diminished pressure for 1 h, allowed to cool to room temperature and then poured 
into a stirring mixture of 120 mL of ethyl acetate and 100 mL satd aq NaHCO3. 
The organic layer was washed with three 50-mL portions of brine and dried 
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(MgSO4). The solvent was concentrated under diminished pressure to afford a 
crude residue. The residue was applied to a silica gel column (30 × 5 cm). Elution 
with 4:1 ethyl acetate−hexanes afforded acetal 3.21 as a colorless solid: yield 7.13 
g (70%); silica gel TLC Rf 0.31 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
3.38 (s, 3H), 3.78 (m, 2H), 3.87 (m, 1H), 3.98 (m, 2H), 4.25 (m, 1H), 4.72 (d, 
1H), 5.55 (s, 1H), 7.36 (m, 3H) and 7.47 (m, 2H); 13C NMR (CDCl3) δ 55.2, 63.3, 
68.8, 69.0, 71.1, 79.0, 101.6, 102.4, 126.5, 128.6, 129.5 and 137.4. 
 
 
Methyl 4,6-O-Benzylidene-3-O-benzyl-α-D-mannopyranoside (3.22).167 To a 
solution containing 2.00 g (7.10 mmol) of acetal 3.21 in 60 mL of methanol was 
added 1.94 g (7.79 mmol) of Bu2SnO. The solution was heated to reflux for 1.5 h 
affording a clear solution. The solvent was concentrated under diminished 
pressure and the resulting solid was dried under vacuum overnight. The white 
residue was dissolved in 60 mL of DMF and treated with 1.69 mL (2.43 g, 14.2 
mmol) of benzyl bromide and then warmed to 100 °C for 30 min. The cooled 
reaction mixture was poured into a stirred mixture of 90 mL ethyl acetate and 60 
mL satd aq NaHCO3. The organic layer was separated and washed with 60 mL of 
brine and dried (MgSO4). The solvent was concentrated under diminished 
pressure to afford a crude residue. The residue was applied to a silica gel column 
(30 × 5 cm). Elution with 3:7 ethyl acetate−hexanes afforded acetal 3.22 as a 
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colorless oil: yield 1.93 g (73%); silica gel TLC Rf 0.30 (3:7 ethyl 
acetate−hexanes); 1H NMR (CDCl3) δ 3.38 (s, 3H), 3.77 (m, 3H), 4.05 (m, 2H), 
4.27 (m, 1H), 4.70 (m, 2H), 4.84 (m, 1H), 5.62 (s, 1H) and 7.28-7.52 (m, 10H); 
13C NMR (CDCl3) δ 55.2, 60.7, 63.5, 65.4, 69.1, 70.1, 73.2, 75.8, 79.0, 101.3, 
101.8, 126.3, 127.2, 127.8, 128.11, 128.16, 128.5, 128.7, 129.2, 137.8 and 138.2. 
 
 
1,2,4,6-Tetra-O-acetyl-3-O-benzyl-α-D-mannopyranoside (3.23).167 To a 
solution containing 1.93 g (4.40 mmol) of acetal 3.22 in 30 mL of Ac2O was 
added a catalytic amount of H2SO4 and the solution was stirred at room 
temperature for 40 min. The reaction mixture was quenched by the addition of 
120 mL of ethyl acetate and 80 mL of satd aq NaHCO3. The organic and aqueous 
layers were separated and the organic layer was washed with brine and dried 
(MgSO4). The solvent was concentrated under diminished pressure to afford a 
crude residue. The residue was applied to a silica gel column (30 × 5 cm). Elution 
with 2:1 ethyl acetate−hexanes afforded pyranoside 3.23 as a yellow oil: yield 
1.94 g (85%); silica gel TLC Rf 0.34 (3:7 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 2.02 (s, 3H), 2.07 (s, 3H), 2.11 (s, 3H), 2.15 (s, 3H), 3.83 (dd, 1H, J = 
9.7 and 3.4 Hz), 3.90 (m, 1H), 4.04 (m, 1H), 4.19 (m, 1H), 4.41 (m, 1H), 4.64 (m, 
1H), 5.24 (m, 1H), 5.34 (dd, 1H, J = 3.4 and 2.1 Hz), 6.09 (d, 1H, J = 2.0 Hz) and 
7.24-7.37 (m, 5H); 13C NMR (CDCl3) δ 14.4, 20.98, 21.08, 21.13, 62.6, 67.0, 
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67.2, 71.0, 71.7, 74.3, 91.2, 128.0, 128.2, 128.6, 137.6, 168.3, 169.8, 170.2 and 
171.0. 
 
 
2,4,6-Tri-O-acetyl-3-O-benzyl-α-D-mannopyranosyl Diphenyl Phosphate 
(3.25). To a solution containing 1.40 g (3.19 mmol) of acetate 3.23 in 25 mL of 
DMF was added 353 mg (3.83 mmol) of hydrazine acetate. The solution was 
stirred at room temperature for 1.5 h and quenched by the addition of 100 mL of 
ethyl acetate. The organic phase was washed with three 50-mL portions of brine 
and dried (MgSO4). The solvent was concentrated under diminished pressure to 
afford a crude residue. The residue was applied to a silica gel column (20 × 4 cm). 
Elution with 1:2 ethyl acetate−hexanes afforded monosaccharide 3.24 as a 
colorless oil. This material was used for the next reaction immediately: yield 968 
mg (76%); 1H NMR (CDCl3) δ 1.95 (s, 3H), 2.02 (s, 3H), 2.10 (s, 3H), 3.90 (dd, 
1H, J = 9.7 and 3.3 Hz), 4.00-4.11 (m, 2H), 4.16 (ddd, 1H, J = 12.3, 7.7 and 4.6 
Hz), 4.33 (s, 1H), 4.38 (dd, 1H, J = 12.3 and 4.3 Hz), 4.60 (d, 1H, J = 12.2 Hz), 
5.13-5.23 (m, 2H), 5.28-5.33 (m, 1H) and 7.18-7.31 (m, 5H); 13C NMR (CDCl3) δ 
14.2, 20.78, 20.85, 21.0, 60.6, 62.9, 67.5, 68.5, 68.8, 71.4, 74.0, 92.3, 127.78, 
127.83, 128.4, 137.7, 169.9, 170.6 and 171.1. 
To a stirred solution containing 968 mg (2.44 mmol) of pyranoside 3.24 in 
144 mL of anh dichloromethane was added 372 mg (3.05 mmol) of DMAP, 3.67 
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mL (2.66 g, 26.3 mmol) of Et3N and 4.83 mL (6.26 g, 23.4 mmol) of diphenyl 
chlorophosphate. The reaction mixture was stirred at 0 °C for 2h and poured into 
a mixture of 300 mL of ethyl acetate and 150 mL of satd aq NaHCO3. The 
organic layer was washed with three 50-mL portions of water and brine and then 
dried (MgSO4). The solvent was concentrated under diminished pressure to afford 
a crude residue. The residue was applied to a silica gel column (20 × 4 cm). 
Elution with 1:2 ethyl acetate−hexanes afforded 3.25 as a colorless oil: yield 737 
mg (48%); silica gel TLC Rf 0.38 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
1.93 (s, 3H), 1.97 (s, 3H), 2.10 (s, 3H), 3.84 (dd, 1H, J = 9.7 and 3.3 Hz,), 3.89-
4.03 (m, 2H), 4.10-4.20 (m, 1H), 4.33 (d, 1H, J = 12.1 Hz), 4.57 (d, 1H, J = 12.1 
Hz), 5.27 (t, 1H, J = 10.0 Hz), 5.38 (dd, 1H, J = 8.6 and 6.2 Hz), 5.91 (dd, 1H, J = 
6.4 and 1.6 Hz) and 7.16-7.38 (m, 15H); 13C NMR (CDCl3) δ 20.5, 20.62, 20.67, 
61.8, 66.2, 67.2, 67.3, 70.9, 71.5, 73.4, 77.4, 96.5, 119.90, 119.95, 125.67, 125.71, 
127.9, 128.3, 129.85, 137.2, 150.08, 150.15, 169.3, 169.6 and 170.4; mass 
spectrum (APCI), m/z 629.1770 (M + H)+ (C31H34O12P requires 629.1788). 
 
 
1,3,4,6-Tetra-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-benzyl-α-D-
mannopyranosyl)-β-L-gulopyranose (3.45). To a stirred solution containing 340 
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mg (0.98 mmol) of gulose acceptor 3.16 and 737 mg (1.17 mmol) of mannose 
donor 3.25 in 7.0 mL of anh dichloromethane cooled to 0 °C was added 352 µL 
(526 mg, 1.95 mmol) of TMSOTf at 0 °C. The reaction mixture was stirred for 10 
min at which time it was poured into a mixture of 30 mL of ethyl acetate and 30 
mL of satd aq NaHCO3. The organic and aqueous layers were separated and the 
organic layer was washed with two 20-mL portions of brine and dried (MgSO4). 
The solvent was concentrated under diminished pressure to afford a crude residue. 
The residue was applied to a silica gel column (30 × 3 cm). Elution with 2:1 ethyl 
acetate−hexanes afforded disaccharide 3.45 as a colorless oil: yield 407 mg 
(57%); silica gel TLC Rf 0.31 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
1.92 (s, 3H), 2.00-2.01 (m, 6H, J = 2.8 Hz,), 2.04 (s, 3H, J = 5.3 Hz), 2.08 (d, 6H, 
J = 1.9 Hz), 2.12 (s, 3H), 3.61 (ddd, 1H, J = 12.7, 9.6 and 3.3 Hz), 3.84-3.95 (m, 
2H), 3.96-4.20 (m, 4H), 4.26-4.37 (m, 2H), 4.59 (t, 1H, J = 10.4 Hz,), 4.90-5.18 
(m, 4H), 5.39 (dd, 1H, J = 11.1 and 3.3 Hz), 5.86 (d, 1H, J = 8.3 Hz) and 7.24 (m, 
5H); 13C NMR (CDCl3) δ 20.56, 20.59, 20.61, 20.64, 20.65, 20.75, 20.78, 61.4, 
62.3, 65.5, 66.9, 67.2, 67.5, 69.4, 71.3, 73.8, 90.5, 95.1, 127.6, 127.7, 127.9, 
128.3, 137.4, 168.7, 168.8, 168.9, 169.1, 169.4, 169.6, 170.3 and 170.4; mass 
spectrum (APCI), m/z 727.2444 (M + H)+ (C33H43O18 requires 727.2450). 
 
 1,3,4,6-Tetra-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-((p-
nitrophenyl)carbamoyl)-α-D-mannopyranosyl)-β-L-gulopyranose (3.46). To a 
solution containing 470 mg (0.56 mmol) of disaccharide 3.45 in 40 mL of ethyl 
acetate was added a catalytic amount of Pd(OH)2/C and the reaction mixture was 
stirred overnight under 1 atm of H2. The solvent was filtered through a pad of 
Celite 545® and the filtrate was concentrated under diminished pressure to afford 
a crude residue. The residue was used for the next reaction; silica gel TLC Rf 0.16 
(1:2 ethyl acetate−hexanes); mass spectrum (APCI), m/z 637.1993 (M + H)+ 
(C26H37O18 requires 637.1980).  
To a solution containing 338 mg (0.53 mmol) of the crude residue in 2 mL 
of pyridine was added 259 mg (2.12 mmol) of DMAP and 471 mg (2.12 mmol) of 
p-nitrophenyl chloroformate. The reaction mixture was stirred at 40 °C overnight 
at which time it was poured into a mixture of 30 mL of ethyl acetate and 10 mL of 
distilled water. The organic and aqueous layers were separated and the organic 
layer was washed with three 10-mL portions of 1 N HCl and 10 mL of satd aq 
NaHCO3. The organic layer was then washed with brine and dried (MgSO4). The 
solvent was concentrated under diminished pressure to afford a crude residue. The 
residue applied to a silica gel column (25 × 3 cm). Elution with 1:1 ethyl 
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acetate−hexanes afforded the ester 3.46 as a colorless foam: yield 320 mg (71% 
over two steps); silica gel TLC Rf 0.24 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 1.99 (s, 3H), 2.05 (s, 3H), 2.06-2.14 (m, 15H), 3.95 (dd, 1H, J = 8.4 
and 3.0 Hz), 3.99-4.16 (m, 4H), 4.16-4.27 (m, 2H), 4.30 (dd, 1H, J = 15.0 and 8.7 
Hz,), 5.21-5.35 (m, 2H), 5.39 (dd, 1H, J = 14.8 and 11.5 Hz), 4.91-5.08 (m, 2H), 
5.84 (d, 1H, J = 8.4 Hz), 7.33 (d, 2H, J = 9.0 Hz) and 8.21 (d, 2H, J = 9.0 Hz); 13C 
NMR (CDCl3) δ 20.57, 20.63, 20.64, 20.70, 20.71, 20.8, 61.3, 61.9, 65.3, 65.5, 
67.6, 67.7, 69.2, 69.8, 71.3, 74.3, 90.5, 94.9, 122.0, 125.3, 145.6, 151.4, 155.2, 
168.6, 169.2, 169.37, 169.41, 169.7, 170.36 and 170.43; mass spectrum (APCI), 
m/z 742.1841 (M-AcOH)+ (C31H36NO20 requires 742.1831). 
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1,3,4,6-Tetra-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-(methylcarbamoyl)-α-D-
mannopyranosyl)-β-L-gulopyranose (3.47). To a solution containing 320 mg 
(0.40 mmol) of disaccharide 3.46 in 12 mL of THF was added 200 μL (0.4 mmol) 
of 2 M methylamine in THF at 0 °C. The reaction mixture was stirred at room 
temperature for 15 h at which time silica gel TLC analysis indicated that the 
reaction was complete. The solvent was concentrated under diminished pressure 
to afford a crude residue. The residue was applied to a silica gel column (25 × 3 
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cm). Elution with 1:1 ethyl acetate−hexanes afforded disaccharide 3.47 as a 
colorless oil: yield 239 mg (86%); silica gel TLC Rf 0.17 (1:1 ethyl 
acetate−hexanes); 1H NMR (CDCl3) δ 1.98 (d, 6H, J = 7.5 Hz), 2.03-2.11 (m, 
12H), 2.13 (d, 3H, J = 8.8 Hz), 2.69 (d, 3H, J = 4.2 Hz), 3.88-4.22 (m, 6H), 4.31 
(t, 1H, J = 6.0 Hz), 4.67 (d, 1H, J = 4.1 Hz), 4.89-5.01 (m, 2H), 5.00-5.10 (m, 
2H), 5.12-5.20 (m, 1H), 5.38 (s, 1H) and 5.82 (d, 1H, J = 8.3 Hz,); 13C NMR 
(CDCl3) δ 20.66, 20.69, 20.71, 20.79, 27. 6, 61.4, 62.1, 65.4, 66.0, 67.7, 69.17, 
69.27, 69.33, 69.38, 71.31, 77.36, 90.6, 94.8, 155.4, 168.6, 169.2, 169.4, 169.8, 
170.42 and 170.49; mass spectrum (APCI), m/z 694.2206 (M + H)+ (C28H40NO19 
requires 694.2195). 
 
 
3,4,6-Tri-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-(methylcarbamoyl)-α-D-
mannopyranosyl)-β-L-gulopyranosyl Diphenyl Phosphate (3.48). To a solution 
containing 65.0 mg (0.09 mmol) of disaccharide 3.47 in 0.8 mL of anh DMF was 
added 11.0 mg (0.11 mmol) of hydrazine acetate. The reaction mixture was stirred 
at room temperature for 1.5 h and quenched by the addition of 20 mL of ethyl 
acetate. The organic layer was washed with three 10-mL portions of brine and 
dried (MgSO4). The solvent was concentrated under diminished pressure to afford 
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a crude residue which was used for next reaction; mass spectrum (APCI), m/z 
652.2086 (M + H)+ (C26H38NO18 requires 652.2089).  
To a stirred solution containing 43.0 mg (0.07 mmol) of the crude residue 
in 4.0 mL of anh dichloromethane was added 10.0 mg (0.08 mmol) of DMAP and 
100 μL (72.0 mg, 0.71 mmol) of Et3N and 131 μL (170 mg, 0.06 mmol) of 
diphenyl chlorophosphate. The reaction mixture was stirred at 0 °C for 2 h and 
then poured into a mixture of 40 mL of ethyl acetate and 20 mL of satd aq 
NaHCO3. The organic and aqueous layers were separated and the organic layer 
was washed with three 10-mL portions of water and brine and then dried 
(MgSO4). The solvent was concentrated under diminished pressure to afford a 
crude residue. The residue was applied to a silica gel column (25 × 3 cm). Elution 
with 2:1 ethyl acetate−hexanes afforded phosphate ester 3.48 as a colorless oil: 
yield 44 mg (76% over two steps); silica gel TLC Rf 0.25 (3:1 ethyl 
acetate−hexanes); 1H NMR (CDCl3) δ 1.70 (s, 3H), 1.98 (s, 3H), 2.06 (s, 3H), 
2.12 (d, 6H, J = 11.4 Hz), 2.21 (s, 3H), 2.75 (d, 3H, J = 4.5 Hz), 3.93-4.22 (m, 
5H), 4.25-4.40 (m, 2H), 4.56 (d, 1H, J = 4.6 Hz), 4.93-5.05 (m, 2H), 5.12-5.24 
(m, 2H), 5.29 (s, 1H), 5.44 (s, 1H), 5.65-5.73 (m, 1H) and 7.13-7.40 (m, 10H); 
13C NMR (CDCl3) δ 20.5, 20.9, 27.7, 36.7, 61.3, 62.0, 65.7, 67.5, 69.2, 69.4, 69.7, 
71.2, 71.3, 71.7, 95.6, 96.29, 96.34, 120.36, 120.41, 125.7, 125.8, 129.7, 130.0, 
150.2, 150.3, 150.4, 150.5, 155.3, 169.36, 169.42, 169.49, 169.9, 170.5 and 170.7; 
mass spectrum (APCI), m/z 884.2369 (M + H)+ (C38H47O21PN requires 884.2378). 
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3,4,6-Tri-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-(methylcarbamoyl)-α-D-
mannopyranosyl)-α,β-L-gulopyranosyl Benzyl 2-(2-Ethoxy)ethylcarbamate 
(3.49). To a stirred solution containing 44 mg (50 μmol) of the phosphate ester 
3.48 in 0.6 mL of anh dichloromethane was added a solution of 11 mg (40 μmol) 
of the CBz-protected linker 3.40 in 0.6 mL of anh dichloromethane at 0 °C. To 
the cooled reaction mixture was added 16 μL (20 mg, 90 μmol) of TMSOTf and 
the reaction mixture was stirred at 0 °C for 15 min. The reaction mixture was 
poured into a mixture of 10 mL ethyl acetate and 10 mL satd aq NaHCO3. The 
organic and aqueous layers were separated and the organic layer was washed with 
three 10-mL portions of water and brine and then dried (MgSO4). The organic 
layer was concentrated under diminished pressure to afford a crude residue. The 
residue was applied to a silica gel column (25 × 3 cm). Elution with 12:12:1 ethyl 
acetate−hexanes−methanol afforded linker conjugate 3.49 as a colorless oil. The 
product was isolated as a (5:3) mixture of anomers: yield 32 mg (73%); silica gel 
TLC Rf 0.11 (12:12:1 ethyl acetate−hexanes−methanol); 1H NMR (CDCl3) (major 
anomer) δ 2.03 (s, 3H), 2.05 (s, 3H), 2.06-2.15 (m, 12H), 2.71 (d, 3H, J = 4.8 Hz), 
3.40 (s, 1H), 3.51-3.74 (m, 6H), 3.79-3.89 (m, 1H), 3.92-4.01 (m, 1H), 3.99-4.21 
(m, 4H), 4.21-4.41 (m, 2H), 4.55-4.63 (m, 2H), 4.89-5.04 (m, 2H), 5.09 (d, 2H, J 
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= 5.6 Hz), 5.12-5.30 (m, 3H), 5.32-5.41 (m, 1H), 5.65-5.73 (m, 1H) and 7.27-7.39 
(m, 5H); 13C NMR (CDCl3) δ 20.78, 20.83, 20.87, 20.91, 20.93, 20.98, 21.0, 
27.67, 27.69, 40.9, 41.1, 53.6, 61.8, 61.9, 62.3, 62.7, 63.9, 65.6, 65.7, 66.1, 66.4, 
66.7, 67.9, 68.0, 68.6, 68.8, 69.0, 69.3, 69.5, 69.72, 69.76, 70.0, 70.1, 70.3, 70.4, 
70.52, 70.55, 70.7, 72.3, 97.1, 97.2, 120.38, 120.43, 128.2, 128.3, 128.60, 128.65, 
129.8, 130.0, 136.8, 155.7, 156.7, 169.33, 169.37, 169.39, 169.47, 169.54, 169.6, 
170.0, 170.5, 170.6, 170.7, 170.8 and 170.9; mass spectrum (APCI), m/z 
873.3150 (M + H)+ (C38H53N2O21 requires 873.3141). 
 
O OAc
BnO
OAc
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1,2,3,6-Tetra-O-acetyl-4-O-benzyl-α-D-mannopyranoside (3.26).168,178 To a 
stirred solution containing 5.43 g (19.2 mmol) of acetal 3.21 in 50 mL of anh THF 
was added 58.0 mL (57.6 mmol) of a 1 M solution of BH3 in THF and 7.48 g 
(57.6 mmol) of anh CoCl2 at room temperature. The reaction mixture was stirred 
for 15 min at room temperature and quenched by the addition of 100 mL of ethyl 
acetate. The organic phase was filtered and the filtrate was treated with 20 mL of 
a 20% aq solution of NaBH4. The solution was again filtered and washed 
successively with sat aq NaHCO3 and water, and then dried (MgSO4). The 
solution was concentrated under diminished pressure to afford a crude residue. To 
a solution containing 3.44 g (12.1 mmol) of the crude residue in 85 mL of Ac2O 
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was added a catalytic amount of H2SO4. The solution was stirred at room 
temperature for 12 h. The reaction mixture was quenched by the addition of 120 
mL of ethyl acetate and 80 mL of satd aq NaHCO3. The organic and aqueous 
layers were separated and the organic layer was washed with brine and dried 
(MgSO4). The solution was concentrated under diminished pressure to afford a 
crude residue. The residue was applied to a silica gel column (30 × 5 cm). Elution 
with 2:1 ethyl acetate−hexanes afforded pyranoside 3.26 as a yellow oil: yield 
1.17 g (22% over two steps); silica gel TLC Rf 0.26 (2:1 ethyl acetate−hexanes); 
1H NMR (CDCl3) δ 2.00 (s, 3H), 2.08 (s, 3H), 2.13 (s, 3H), 2.15 (s, 3H), 3.87 (t, 
1H, J = 9.7), 3.99 (dt, 1H, J = 9.9 and 3.4 Hz), 4.32 (d, 2H, J = 3.5 Hz), 4.59 (d, 
1H, J = 11.2 Hz), 4.70 (d, 1H, J = 10.8 Hz), 5.26 (dd, 1H, J = 3.3 and 2.1 Hz), 
5.37 (dd, 1H, J = 9.5 and 3.4 Hz), 6.04 (t, 1H, J = 6.1 Hz), and 7.24-7.38 (m, 5H); 
13C NMR (CDCl3) δ 20.92, 20.97, 20.99, 21.04, 62.9, 68.9, 71.6, 71.8, 72.6, 75.2, 
90.8, 127.9, 128.3, 128.7, 137.5, 168.4, 169.8, 169.9 and 170.8. 
 
 
2,3,6-Tri-O-acetyl-4-O-benzyl-α,β-D-mannopyranose (3.27). To a stirred 
solution containing 1.09 g (2.49 mmol) of acetate 3.26 in 20 mL of anh DMF was 
added 274 mg (2.98 mmol) of hydrazine acetate. The reaction mixture was stirred 
at room temperature for 1.5 h and quenched by the addition of 100 mL of ethyl 
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acetate. The organic layer was washed with three 50-mL portions of brine and 
dried (MgSO4). The solvent was concentrated under diminished pressure to afford 
a crude residue. The residue was applied to a silica gel column (20 ൈ 3 cm). 
Elution with 1:2 ethyl acetate−hexanes afforded pyranoside 3.27 as a colorless oil: 
yield 884 mg (90%); silica gel TLC Rf 0.36 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 1.92 (s, 3H), 2.01 (s, 3H), 2.08 (s, 3H), 3.77 (t, 1H, J = 10.0 Hz), 4.11 
(ddd, 1H, J = 9.7, 4.1 and 2.1 Hz), 4.17-4.34 (m, 2H), 4.69-4.48 (m, 3H), 5.09 (s, 
1H), 5.17-5.23 (m, 1H), 5.33-5.38 (m, 1H) and 7.18-7.32 (m, 5H); 13C NMR 
(CDCl3) δ 20.69, 20.73, 63.1, 69.2, 70.5, 71.5, 72.8, 74.6, 77.4, 91.8, 127.6, 
127.8, 128.3, 137.5, 170.0, 170.2 and 171.0; HRMS (APCI), m/z 397.1483 (M + 
H)+ (C19H25O9 requires m/z 397.1498). 
 
 
2,3,6-Tri-O-acetyl-4-O-benzyl-α-D-mannopyranosyl Diphenyl Phosphate 
(3.28). To a stirred solution containing 812 mg (2.05 mmol) of 3.27 in 80 mL of 
anh dichloromethane was added 313 mg (2.56 mmol) of DMAP and 3.10 mL 
(2.25 g, 22.1 mmol) of Et3N, 4.10 mL (5.33 g, 19.7 mmol) of diphenyl 
chlorophosphate. The reaction mixture was stirred at 0 °C for 2 h and then poured 
into a mixture of 300 mL of ethyl acetate and 150 mL of satd aq NaHCO3. The 
aqueous and organic layers were separated and the organic layer was washed with 
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three 50-mL portions of distilled water and brine and then dried (MgSO4). The 
solvent was concentrated under diminished pressure to afford a crude residue. The 
residue was applied to a silica gel column (20 ൈ 4 cm). Elution with 1:2 ethyl 
acetate−hexanes afforded 3.28 as a colorless oil: yield 857 mg (66%); silica gel 
TLC Rf 0.29 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 1.93 (s, 3H), 1.96 
(s, 3H), 2.09 (s, 3H), 3.80 (t, 1H, J = 9.6 Hz), 3.91-4.12 (m, 2H), 4.18 (dd, 1H, J = 
12.2 and 4.2 Hz), 4.50-4.68 (m, 2H), 5.27-5.38 (m, 2H), 5.80 (d, 1H, J = 6.1 Hz) 
and 7.11-7.38 (m, 15H); 13C NMR (CDCl3) δ 20.74, 20.9, 62.4, 69.1, 70.9, 71.8, 
72.1, 75.0, 77.4, 96.3, 120.1, 120.4, 125.7, 125.9, 127.9, 128.2, 128.6, 129.9, 
130.0, 137.3, 150.1, 150.3, 169.5, 169.6 and 170.5; HRMS (APCI), m/z 629.1794 
(M + H)+ (C31H34O12P requires m/z 629.1788). 
 
 
1,3,4,6-Tetra-O-acetyl-2-O-(2,3,6-tri-O-acetyl-4-O-benzyl-α-D-
mannopyranosyl)-β-L-gulopyranose (3.51). To a stirred solution containing 217 
mg (0.62 mmol) of gulose acceptor 3.16 and 471 mg (0.75 mmol) of mannose 
donor 3.28 in 4.5 mL of anh dichloromethane cooled to 0 °C was added 230 µL 
(283 mg, 1.25 mmol) of TMSOTf. The reaction mixture was stirred at 0 °C for 10 
min and then poured into a mixture of 30 mL of ethyl acetate and 30 mL of satd 
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aq NaHCO3. The aqueous and organic layers were separated and the organic layer 
was washed with two 20-mL portions of brine and dried (MgSO4). The solvent 
was concentrated under diminished pressure to afford a crude residue. The residue 
was applied to a silica gel column (30 ൈ 3 cm). Elution with 2:1 ethyl 
acetate−hexanes afforded 3.51 as a colorless oil: yield 330 mg (73%); silica gel 
TLC Rf 0.25 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 1.92 (s, 3H), 2.02 
(s, 3H), 2.07 (t, 6H, J = 3.2 Hz), 2.08-2.11 (m, 6H), 2.15 (d, 3H, J = 3.7 Hz), 
3.70-3.83 (m, 1H), 3.92-4.18 (m, 4H), 4.23-4.40 (m, 2H), 4.50-4.71 (m, 2H), 4.89 
(dd,1H, J = 7.2 and 1.7 Hz), 4.96-4.99 (m, 1H), 5.01-5.10 (m, 2H), 5.10-5.16 (m, 
1H), 5.35-5.45 (m, 1H), 5.85 (d, 1H, J = 8.4 Hz) and 7.18-7.34 (m, 5H); 13C NMR 
(CDCl3) δ 20.68, 20.71, 20.73, 20.79, 20.84, 20.88, 20.9, 61.4, 65.6, 67.7, 69.1, 
69.5, 70.3, 71.3, 71.7, 72.4, 74.8, 90.7, 95.0, 127.6, 127.89, 127.99, 128.46, 
128.49, 137.6, 168.8, 169.32, 169.36, 169.4, 169.7, 170.5 and 170.6; HRMS 
(APCI), m/z 727.2439 (M + H)+ (C33H43O18 requires m/z 727.2450). 
 
 
1,3,4,6-Tetra-O-acetyl-2-O-(2,3,6-tri-O-acetyl-4-O-((p-
nitrophenyl)carbamoyl)-α-D-mannopyranosyl)-β-L-gulopyranose (3.52). To a 
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solution containing 140 mg (0.19 mmol) of disaccharide 3.51 in 13 mL of ethyl 
acetate was added a catalytic amount of Pd(OH)2/C and the reaction mixture was 
stirred overnight under 1 atm of H2. The solvent was filtered through a pad of 
Celite 545® and the filtrate was concentrated under diminished pressure to afford 
a crude residue. The residue was used for the next reaction; silica gel TLC Rf 0.08 
(1:1 ethyl acetate−hexanes).  
To a solution containing 120 mg (0.19 mmol) of the crude residue in 2.0 
mL of anh pyridine was added 92.0 mg (0.76 mmol) of DMAP and 168 mg (0.76 
mmol) of p-nitrophenyl chloroformate. The reaction mixture was stirred at 40 °C 
overnight and then poured into a mixture of 30 mL of ethyl acetate and 10 mL of 
H2O. The aqueous and organic layers were separated and the organic layer was 
washed with three 10-mL portions of 1 N HCl and 10 mL of satd aq NaHCO3 and 
brine. The organic solution was dried (MgSO4) and concentrated under 
diminished pressure to afford a crude residue. The residue was applied to a silica 
gel column (25 ൈ 3 cm). Elution with 1:1 ethyl acetate−hexanes afforded ester 
3.52 as colorless foam: yield 121 mg (78% over two steps); silica gel TLC Rf 0.30 
(1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 1.98 (s, 3H), 2.03 (s, 3H), 2.11 
(d, 6H, J = 5.0 Hz), 2.14 (s, 3H), 2.19 (d, 3H, J = 5.4 Hz), 3.99 (dd, 1H, J = 8.4 
and 3.3 Hz), 4.02-4.25 (m, 4H), 4.27 (d, 1H, J = 2.4 Hz), 4.35 (t, 1H, J = 6.0 Hz), 
4.46-4.55 (m, 2H), 4.93-5.01 (m, 2H), 5.11-5.18 (m, 2H), 5.24 (dd, 1H, J = 10.1 
and 3.3 Hz), 5.32 (dd, 1H, J = 7.7 and 4.3 Hz), 5.43 (t, 1H, J = 3.5 Hz), 5.89 (d, 
1H, J = 8.5 Hz), 7.29-7.39 (m, 2H) and 8.25 (t, 2H, J = 6.0 Hz); 13C NMR 
(CDCl3) δ 20.69, 20.71, 21.0, 61.3, 61.7, 65.6, 67.7, 68.6, 68.8, 70.0, 71.3, 71.4, 
90.6, 95.1, 121.7, 125.4, 145.7, 151.8, 155.2, 168.7, 169.29, 169.33, 169.38, 
169.58, 169.65, 169.7, 169.8, 170.44, 170.46 and 170.58; HRMS (APCI), m/z 
802.2035 (M + H)+ (C33H40NO22 requires m/z 802.2042). 
 
 
1,3,4,6-Tetra-O-acetyl-2-O-(2,3,6-tri-O-acetyl-4-O-(methylcarbamoyl)-α-D-
mannopyranosyl)-β-L-gulopyranose (3.53). To a solution containing 121 mg 
(0.15 mmol) of 3.52 in 3.2 mL of anh THF was added 76.0 μL (0.15 mmol) of a 2 
M solution of CH3NH2 in THF at 0 °C. The reaction mixture was stirred at room 
temperature for 15 h at which time silica gel TLC analysis indicated that the 
reaction was complete. The solvent was concentrated under diminished pressure 
to afford a crude residue. The residue was applied to a silica gel column (25 ൈ 3 
cm). Elution with 1:1 ethyl acetate−hexanes afforded disaccharide 3.53 as a 
colorless oil: yield 90 mg (86%); silica gel TLC Rf 0.14 (1:1 ethyl 
acetate−hexanes); 1H NMR (CDCl3) δ 1.96 (t, 3H, J = 3.4 Hz), 2.04 (d, 3H, J = 
6.4 Hz), 2.11 (dd, 12H, J = 5.4 and 2.8 Hz), 2.17 (d, 3H, J = 2.5 Hz), 2.76 (d, 3H, 
J = 4.8 Hz), 3.97 (dd, 1H, J = 8.4 and 3.2 Hz), 4.00-4.39 (m, 3H), 4.48-4.80 (m, 
1H), 4.93 (d, 1H, J = 7.2 Hz), 4.99 (dd, 1H, J = 7.0 and 4.4 Hz), 5.04-5.10 (m, 
2H), 5.08-5.17 (m, 2H), 5.29 (dd, 1H, J = 13.2 and 9.8 Hz), 5.42 (t, 1H, J = 3.5 
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Hz), 5.87 (d, 1H, J = 8.4 Hz) and 6.28 (d, 1H, J = 4.2 Hz); 13C NMR (CDCl3) δ 
20.68, 20.75, 20.76, 20.80, 20.82, 20.84, 27.8, 61.5, 61.8, 62.5, 62.7, 65.6, 66.0, 
66.3, 66.8, 67.8, 68.9, 69.75, 69.79, 71.4, 90.7, 169.3, 169.59, 169.61, 169.65, 
170.53, 170.55 and 170.7; HRMS (APCI), m/z 694.2199 (M + H)+ (C28H40NO19 
requires m/z 694.2195). 
 
 
3,4,6-Tri-O-acetyl-2-O-(2,3,6-tri-O-acetyl-4-O-(methylcarbamoyl)-α-D-
mannopyranosyl)-β-L-gulopyranosyl Diphenyl Phosphate (3.54). To a solution 
containing 44.0 mg (0.06 mmol) of disaccharide 3.53 in 0.5 mL of anh DMF was 
added 7.00 mg (0.08 mmol) of hydrazine acetate. The reaction mixture was stirred 
at room temperature for 1.5 h and quenched by the addition of 20 mL of ethyl 
acetate. The organic solution was washed with three 10-mL portions of brine and 
dried (MgSO4). The solvent was concentrated under diminished pressure to afford 
a crude residue. The residue was used for the next reaction.  
To a stirred solution containing 43.0 mg (0.07 mmol) of the crude residue 
in 4 mL of anh dichloromethane was added 10.0 mg (0.08 mmol) of DMAP, 100 
μL (72.0 mg, 0.71 mmol) of Et3N and 130 μL (160 mg, 0.63 mmol) of diphenyl 
chlorophosphate. The reaction mixture was stirred at 0 °C for 2 h and then poured 
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into a mixture of 40 mL of ethyl acetate and 20 mL of satd aq NaHCO3. The 
aqueous and organic layers were separated and the organic layer was washed with 
three 10-mL portions of water and brine and then dried (MgSO4). The solvent was 
concentrated under diminished pressure to afford a crude residue. The residue was 
applied to a silica gel column (25 ൈ 3 cm). Elution with 2:1 ethyl acetate−hexanes 
afforded the phosphate ester 3.54 as a colorless oil: yield 38 mg (69% over two 
steps); silica gel TLC Rf 0.48 (2:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
1.95 (s, 3H), 2.00 (s, 3H), 2.09 (s, 3H), 2.12 (s, 3H), 2.15 (s, 3H), 2.21 (s, 3H), 
2.57 (d, 3H, J = 4.0 Hz), 3.70 (s, 1H), 4.03 (s, 2H), 4.15 (d, 2H, J = 9.6 Hz), 4.24 
(d, 2H, J = 12.2 Hz), 4.32-4.38 (m, 1H), 4.99 (d, 2H, J = 12.6 Hz), 5.05-5.25 (m, 
2H), 5.30 (s, 1H), 5.45 (s, 1H), 5.71 (d, 1H, J = 7.4 Hz) and 7.19-7.41 (m, 10H); 
13C NMR (CDCl3) δ 20.77, 20.83, 20.89, 20.93, 27.6, 61.3, 62.3, 65.6, 66.3, 67.5, 
68.8, 69.2, 69.5, 70.7, 70.8, 71.7, 95.1, 96.4, 120.4, 125.7, 129.8, 130.0, 150.4, 
155.4, 169.37, 169.39, 169.6, 169.9, 170.5 and 170.73, 170.76; HRMS (APCI), 
m/z 884.2381 (M + H)+ (C38H47NO21P requires m/z 884.2378). 
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3,4,6-Tri-O-acetyl-2-O-(2,3,6-tri-O-acetyl-4-O-(methylcarbamoyl)-α-D-
mannopyranosyl)-α,β-L-gulopyranosyl Benzyl 2-(2-Ethoxy)ethylcarbamate 
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(3.56). To a stirred solution containing 38.0 mg (0.04 mmol) of phosphate ester 
3.54 in 0.5 mL of anh dichloromethane was added a solution of 10.0 mg (0.04 
mmol) of CBz-protected linker 3.40 in 0.5 mL of anh dichloromethane at 0 °C. To 
the cooled reaction mixture was then added 14.0 μL (17.0 mg, 0.08 mmol) of 
TMSOTf. The reaction mixture was stirred at 0 °C for 15 min and then poured 
into a mixture of 20 mL of ethyl acetate and 20 mL of satd aq NaHCO3. The 
aqueous and organic layers were separated and the organic layer was washed with 
three 10-mL portions of water and brine and then dried (MgSO4). The solvent was 
concentrated under diminished pressure to afford a crude residue. The residue was 
applied to a silica gel column (25 ൈ 3 cm). Elution with 12:12:1 ethyl 
acetate−hexanes−methanol afforded 3.56 as a colorless oil. The product isolated 
as a mixture of anomers: yield 19 mg (51%); silica gel TLC Rf 0.14 (12:12:1 ethyl 
acetate−hexanes−methanol); 1H NMR (CDCl3) δ 1.92-2.14 (m, 18H), 2.71 (t, 3H, 
J = 4.1 Hz), 3.40 (d, 3H, J = 4.9 Hz), 3.52-3.77 (m, 8H), 3.85 (dd,1H, J = 8.4 and 
3.2 Hz), 3.95 (t, 1H, J = 3.9 Hz), 4.27 (dd, 2H, J = 13.4 and 7.3 Hz), 4.40 (t, 1H, J 
= 6.4 Hz), 4.88-5.04 (m, 3H), 5.05-5.22 (m, 6H), 5.25 (dd, 1H, J = 7.3 and 3.6 
Hz) and 7.28-7.40 (m, 5H); 13C NMR (CDCl3) δ 20.78, 20.83 20.85, 20.87, 20.92, 
20.95, 27.7, 61.9, 62.3, 63.1, 63.8, 65.7, 66.8, 66.9, 68.1, 68.7, 68.8, 69.6, 69.8, 
70.2, 71.0, 72.3, 97.2, 97.5, 128.27, 128.33, 128.65, 128.67, 169.5, 169.7, 169.8, 
169.9, 170.57, 170.63 and 170.7; HRMS (APCI), m/z 873.3142 (M + H)+ 
(C38H53N2O21 requires m/z 873.3141). 
 
 
Methyl-4,6-O-benzylidene-α-D-glucopyranoside (3.29).169 To a solution 
containing 10.0 g (51.5 mmol) of α-D-methyl glucopyranoside in 200 mL of 
acetonitrile was added 14.0 mL (14.2 g, 92.7 mmol) of benzaldehyde dimethyl 
acetal and 600 mg (2.57 mmol) of camphor sulfonic acid. The reaction mixture 
was heated to reflux for 20 min and then allowed to cool to room temperature and 
neutralized by the addition of 400 μL of triethylamine. The reaction mixture was 
diluted with 800 mL of ethyl acetate. The organic layer was washed with three 
250-mL portions of water and dried (MgSO4). The organic layer was concentrated 
under diminished pressure to afford a crude residue. The residue was 
recrystallized from 1:7 dichloromethane−hexanes to afford acetal 3.29 as a 
colorless solid: yield 9.48 g (65%); silica gel TLC Rf 0.17 (2:1 ethyl 
acetate−hexanes); 1H NMR (CDCl3) δ 3.45-3.47 (m, 4H), 3.63 (dd, 1H, J = 9.1 
and 3.9 Hz), 3.71-3.85 (m, 2H), 3.93 (t, 1H, J = 9.2 Hz), 4.29 (dd, 1H, J = 9.7 and 
4.3 Hz), 4.80 (d, 1H, J = 3.9 Hz), 5.53 (s, 1H) and 7.33-7.53 (m, 5H); 13C NMR 
(CDCl3) δ 55.7, 62.5, 69.1, 72.0, 73.0, 81.0, 99.9, 102.1, 126.4, 128.4, 129.4 and 
137.2. 
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Methyl 2,3-Anhydro-4,6-O-benzyl-α-D-mannopyranoside (3.30).170,179 To a 
solution containing 2.44 g (60% in oil dispersion, 60.9 mmol) of NaH in 290 mL 
of anh DMF at 0 ºC was added 8.20 g (29.0 mmol) of acetal 3.29 under an argon 
atmosphere. The reaction mixture was stirred at room temperature for 0.5 h. To 
the above stirred solution at 0 ºC was then added 7.10 g (31.9 mmol) of N-
tosylimidazole. The suspension was stirred at room temperature for 1 h. The 
reaction mixture was poured with stirring into 2.5 L of ice−cold water and the 
resulting solid was filtered and washed with water to afford a crude residue. The 
residue so obtained was triturated with methanol to obtain the epoxide 3.30 as a 
colorless solid: yield 1.83 g (24%); silica gel TLC Rf 0.68 (1:1 ethyl 
acetate−hexanes); 1H NMR (CDCl3) δ 3.17 (d, 1H, J = 3.6 Hz), 3.45-3.49 (m, 
4H), 3.64-3.79 (m, 3H), 4.21-4.32 (m, 1H), 4.91 (s, 1H), 5.57 (s, 1H), 7.35-7.53 
(m, 5H); 13C NMR (CDCl3) δ 50.7, 54.0, 55.9, 61.8, 69.6, 75.0, 97.0, 102.6, 
126.3, 128.5, 129.4 and 137.2. 
 
 
Methyl 4,6-O-Benzylidene-3-O-benzyl-α-D-altropyranoside (3.31).171 A 
solution containing 214 mg (9.32 mmol) of sodium metal in 2.9 mL of anh benzyl 
alcohol was heated (~ 100 ºC) until all of the sodium metal had dissolved. The 
cooled solution was treated with 1.07 g (4.05 mmol) of anhydromannopyranoside 
3.30. The reaction mixture was then heated to reflux for 15 min, cooled and 
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diluted by the addition of 20 mL of ether. The solvent was concentrated under 
diminished pressure to afford a crude residue. The residue was applied to a silica 
gel column (20 ൈ 5 cm). Elution with 1:4 ethyl acetate−hexanes afforded acetal 
3.31 as a colorless solid: yield 723 mg (48%); silica gel TLC Rf 0.55 (1:1 ethyl 
acetate−hexanes); 1H NMR (CDCl3) δ 2.30 (s, 1H), 3.42 (s, 3H), 3.77 (t, 1H, J = 
10.3 Hz), 3.84 (t, 1H, J = 2.8 Hz), 3.93 (d, 1H, J = 2.8 Hz), 3.98 (dt,1H, J = 9.3 
and 4.6 Hz), 4.28-4.45 (m, 2H), 4.55 (d, 1H, J = 6.0 Hz), 4.70-4.90 (m, 2H), 5.56 
(s, 1H) and 7.23-7.53 (m, 10H); 13C NMR (CDCl3) δ 55.8, 58.7, 69.4, 70.2, 72.9, 
74.9, 77.2, 102.0, 102.4, 126.3, 127.5, 127.7, 128.30, 128.36, 129.1, 137.7 and 
138.7. 
 
 
Methyl-3-O-benzyl-α-D-altropyranoside (3.32).171 To a solution containing 1.67 
g (4.48 mmol) of acetal 3.31 in 4.2 mL of methanol was added 43.0 mg (0.22 
mmol) of p-toluenesulfonic acid monohydrate at 0 °C. The reaction mixture was 
allowed to warm to room temperature and stirred for 4 h. The reaction mixture 
was quenched by the addition of 1.90 mL (1.38 g, 13.4 mmol) of triethylamine 
and concentrated under diminished pressure to afford a crude residue. The residue 
was applied to a silica gel column (10 ൈ 3 cm). Elution with 5:1 ethyl 
acetate−hexanes afforded methyl pyranoside 3.32 as a colorless oil: yield 1.22 g 
(96%); silica gel TLC Rf 0.17 (ethyl acetate); 1H NMR (CDCl3) δ 3.01 (d, 1H, J = 
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9.3 Hz), 3.33 (s, 3H), 3.53 (d, 1H, J = 15.3 Hz), 3.70-3.77 (m, 2H), 3.80 (dt, 2H, J 
= 8.8 and 4.3 Hz), 3.96 (s, 2H), 4.40-4.78 (m, 4H) and 7.21-7.35 (m, 5H); 13C 
NMR (CDCl3) δ 55.5, 61.9, 63.4, 67.3, 69.2, 72.0, 77.4, 101.5, 127.9, 128.0, 
128.5 and 138.0. 
 
 
1,2,4,6-Tetra-O-acetyl-3-O-benzyl-α,β-D-altropyranoside (3.33). To a solution 
containing 532 mg (1.87 mmol) of methyl pyranoside 3.32 in 13 mL of Ac2O was 
added a catalytic amount of H2SO4. The solution was stirred overnight at room 
temperature. The reaction mixture was then poured into a stirred mixture of 120 
mL of ethyl acetate and 80 mL of satd aq NaHCO3. The organic and aqueous 
layers were separated and the organic layer was washed with brine and dried 
(MgSO4). The solvent was concentrated under diminished pressure to afford a 
crude residue. The residue was applied to a silica gel column (30 × 3 cm). Elution 
with 1:2 ethyl acetate−hexanes afforded the product 3.33 as a 3:2 mixture of α and 
β anomers as determined by 1H NMR; yield 705 mg (86%); silica gel TLC Rf 0.55 
(1:1 ethyl acetate−hexanes); α anomer 1H NMR (CDCl3) δ 2.01 (s, 3H), 2.06-2.09 
(m, 6H), 2.14 (s, 3H), 3.96 (t, 1H, J = 3.2 Hz), 4.11-4.16 (m, 1H), 4.24-4.37 (m, 
2H), 4.55-4.75 (m, 2H), 5.03-5.09 (m, 1H), 5.29 (s, 1H), 5.99 (d, 1H, J = 11.3 Hz) 
and 7.27-7.38 (m, 5H); 13C NMR (CDCl3) δ 20.91, 20.92, 21.04, 21.05, 62.6, 
66.3, 66.6, 68.0, 72.46, 72.49, 91.4, 127.8, 128.1, 128.5, 137.5, 169.0, 169.7, 
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169.8 and 170.9; HRMS (APCI), m/z 379.1387 (M − CH3COO)+ (C19H23O8 
requires m/z 379.1393). 
 
 
2,4,6-Tri-O-acetyl-3-O-benzyl-α,β-D-altropyranoside (3.34). To a solution 
containing 1.93 g (4.40 mmol) of monosaccharide 3.33 in 35 mL of anh DMF was 
added 486 mg (5.28 mmol) of hydrazine acetate. The reaction mixture was stirred 
at room temperature for 1.5 h and quenched by the addition of 100 mL of ethyl 
acetate. The organic layer was then washed with three 50-mL portions of brine 
and dried (MgSO4). The solvent was concentrated under diminished pressure to 
afford a crude residue. The residue was applied to a silica gel column (20 ൈ 4 
cm). Elution with 1:2 ethyl acetate−hexanes afforded 3.34 as a colorless oil. The 
product isolated as a mixture of anomers as analyzed by 1H NMR: yield 837 mg 
(48%); silica gel TLC Rf 0.31 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
1.95 (s, 3H), 1.96 (s, 3H), 2.05 (s, 3H), 2.07 (s, 3H), 2.11 (s, 3H), 2.15 (s, 3H), 
3.73-3.95 (br s, 1H), 3.98-4.05 (m, 1H), 4.09 (d, 1H, J = 8.6 Hz), 4.12-4.27 (m, 
4H), 4.32 (dt, 1H, J = 14.2 and 7.1 Hz), 4.36-4.46 (m, 1H), 4.54-4.75 (m, 4H), 
4.89-4.94 (m, 2H), 4.96-5.08 (m, 4H), 5.24 (t, 1H, J = 12.1 Hz) and 7.41-7.27 (m, 
10H); 13C NMR (CDCl3) δ 20.80, 20.82, 20.86, 20.98, 21.02, 62.9, 63.2, 64.1, 
66.2, 66.9, 68.3, 70.0, 70.3, 72.9, 73.3, 73.8, 74.2, 91.6, 92.8, 128.1, 128.2, 128.4, 
128.5, 128.7, 128.8, 136.2, 137.3, 169.73, 169.78, 169.83, 170.4, 170.95 and 
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170.96; HRMS (APCI), m/z 379.1394 (M − OH)+ (C19H23O8 requires m/z 
379.1393). 
 
 
2,4,6-Tri-O-acetyl-3-O-benzyl-α-D-altropyranosyl Diphenyl Phosphate (3.35). 
To a stirred solution containing 637 mg (1.61 mmol) of pyranoside 3.34 in 2.7 mL 
of anh dichloromethane was added 1.21 mL (1.6 M, 1.93 mmol) of n-BuLi 
solution at −78 °C. The reaction mixture was stirred at this temperature for 10 min 
and 400 μL (520 mg, 1.93 mmol) of diphenyl chlorophosphate was added 
dropwise. The reaction mixture was stirred at −78 °C for an additional 10 min and 
poured into a mixture of 20 mL of ethyl acetate and 10 mL of satd aq NaHCO3. 
The organic and aqueous layers were separated and the organic layer was washed 
with three 10-mL portions of water and brine and then dried (MgSO4). The 
solvent was concentrated under diminished pressure to afford a crude residue. The 
residue was applied to a silica gel column (20 ൈ 3 cm). Elution with 1:2 ethyl 
acetate−hexanes afforded phosphate ester 3.35 as a colorless oil: yield 324 mg 
(32%); 121 mg of unreacted starting material was also recovered; silica gel TLC 
Rf 0.40 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 1.97 (s, 3H), 1.98 (s, 3H), 
2.00 (d, 3H, J = 2.1 Hz), 3.99 (dd, 1H, J = 6.3 and 3.1 Hz), 4.05-4.28 (m, 3H), 
4.50-4.62 (m, 2H), 5.13 (dd, 1H, J = 7.0 and 3.2 Hz), 5.19 (dd, 1H, J = 6.4 and 
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2.2 Hz), 5.96 (dd, 1H, J = 7.1 and 2.2 Hz) and 7.12-7.36 (m, 15H); 13C NMR 
(CDCl3) δ 20.74, 20.76, 20.9, 62.8, 66.9, 68.20, 68.28, 71.6, 72.94, 72.97, 95.5, 
120.30, 120.35, 125.7, 128.0, 128.2, 128.5, 129.8, 129.9, 137.1, 150.2, 150.4, 
169.9 and 170.6; HRMS (APCI), m/z 569.1598 (M − CH3COO)+ (C29H30O10P 
requires m/z 569.1576). 
 
 
1,3,4,6-Tetra-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-benzyl-α-D-
altropyranosyl)-β-L-gulopyranose (3.59). To a stirred solution containing 180 
mg (0.52 mmol) of gulose acceptor 3.16 and 324 mg (0.52 mmol) of altrose donor 
3.35 in 3.7 mL of anh dichloromethane at 0 °C was added 190 µL (234 mg, 1.03 
mmol) of TMSOTf. The reaction mixture was stirred at 0 °C for 10 min at which 
time it was poured into a mixture of 30 mL of ethyl acetate and 30 mL of satd aq 
NaHCO3. The aqueous and organic layers were separated and the organic layer 
was washed with two 20-mL portions of brine and dried (MgSO4). The solvent 
was concentrated under diminished pressure to afford a crude residue. The residue 
was applied to a silica gel column (30 ൈ 3 cm). Elution with 1:2 ethyl 
acetate−hexanes afforded disaccharide 3.59 as a colorless oil: yield 149 mg 
(40%); silica gel TLC Rf 0.24 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
154 
 
1.93 (s, 3H), 1.97 (s, 3H), 2.00 (s, 3H), 2.02 (s, 3H), 2.04-2.06 (m, 6H), 2.08 (s, 
3H), 3.72-3.83 (m, 1H), 3.94-4.16 (m, 2H), 4.16-4.35 (m, 3H), 4.35-4.62 (m, 3H), 
4.79-5.01 (m, 4H), 5.24 (d, 1H, J = 0.4 Hz), 5.35-5.42 (m, 1H), 5.90 (d, 1H, J = 
8.4 Hz) and 7.15-7.30 (m, 5H); 13C NMR (CDCl3) δ 20.7, 20.80, 20.81, 20.86, 
20.89, 21.0, 61.6, 62.6, 65.3, 65.5, 66.4, 67.8, 68.4, 68.8, 72.0, 72.7, 90.6, 95.4, 
127.4, 127.6, 127.9, 128.5, 137.7, 169.0, 169.2, 169.4, 169.5, 169.9, 170.5, 170.7; 
HRMS (APCI), m/z 667.2230 (M − CH3COO)+ (C31H39O16 requires m/z 
667.2238). 
 
 
1,3,4,6-Tetra-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-((p-
nitrophenyl)carbamoyl)-α-D-altropyranosyl)-β-L-gulopyranose (3.60). To a 
solution containing 190 mg (0.26 mmol) of disaccharide 3.59 in 18 mL of ethyl 
acetate was added a catalytic amount of Pd(OH)2/C and the reaction mixture was 
stirred overnight under 1 atm of H2. The solvent was filtered through a pad of 
Celite 545® and the filtrate was concentrated under diminished pressure to afford 
a crude residue. The crude product was used for the next reaction; silica gel TLC 
Rf 0.12 (1:1 ethyl acetate−hexanes). 
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To a solution containing 198 mg (0.31 mmol) of the crude residue in 1.1 
mL of anh pyridine was added 151 mg (1.24 mmol) of DMAP and 280 mg (1.24 
mmol) of p-nitrophenyl chloroformate. The reaction mixture was stirred at 40 °C 
overnight and then poured into a mixture of 30 mL ethyl acetate and 10 mL of 
H2O. The aqueous and organic layers were separated and the organic layer was 
washed with three10-mL portions of 1 N HCl and10 mL of satd aq NaHCO3 and 
brine. The solvent was dried (MgSO4) and then concentrated under diminished 
pressure to afford a crude residue. The residue was applied to a silica gel column 
(25 ൈ 3 cm). Elution with 1:1 ethyl acetate−hexanes afforded ester 3.60 as a 
colorless foam: yield 177 mg (71% over two steps); silica gel TLC Rf 0.28 (1:1 
ethyl acetate−hexanes); 1H NMR (CDCl3) δ 2.02 (s, 3H), 2.04 (s, 3H), 2.09 (s, 
3H), 2.10 (s, 3H), 2.12 (s, 3H), 2.13 (s, 3H), 2.14 (s, 3H), 3.99-4.17 (m, 3H), 4.23-
4.38 (m, 2H), 4.41-4.50 (m, 1H), 4.89-5.02 (m, 2H), 5.02-5.13 (m, 2H), 5.20 (dt, 
1H, J = 10.4 and 5.2 Hz), 5.25-5.34 (m, 1H), 5.43 (t, 1H, J = 3.5 Hz), 5.94 (d, 1H, 
J = 8.4 Hz), 7.42 (t, 2H, J = 7.1 Hz) and 8.22-8.30 (m, 2H); 13C NMR (CDCl3) δ 
20.66, 20.71, 20.72, 20.76, 20.9, 61.5, 62.2, 64.7, 65.1, 65.4, 67.6, 68.1, 68.6, 
71.3, 72.1, 90.5, 94.5, 121.4, 125.4, 136.0, 145.6, 149.8, 151.6, 155.2, 168.8, 
168.9, 169.1, 169.3, 169.5, 170.4 and 170.6; HRMS (APCI), m/z 742.1851 (M − 
CH3COO)+ (C31H36NO20 requires m/z 742.1831). 
 
 1,3,4,6-Tetra-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-carbamoyl-α-D-
altropyranosyl)-β-L-gulopyranoside (3.61). To a solution containing 73.0 mg 
(0.09 mmol) of ester 3.60 in 2 mL of anh THF was added a solution of 0.7 mL of 
anh THF saturated with NH3 at 0 °C. The reaction mixture was allowed to warm 
to room temperature and then stirred for 2.5 h at which time silica gel TLC 
analysis indicated that the reaction was complete. The solvent was concentrated 
under diminished pressure to afford a crude residue. The residue was applied to a 
silica gel column (20 ൈ 3 cm). Elution with 3:1 ethyl acetate−hexanes afforded 
disaccharide 3.61 as a colorless oil: yield 44 mg (71%); silica gel TLC Rf 0.38 
(ethyl acetate); 1H NMR (CDCl3) δ 2.00 (s, 3H), 2.05 (s, 3H), 2.11 (s, 6H), 2.13 
(s, 3H), 2.16 (s, 3H), 2.17 (s, 3H), 3.98 (dd, 1H, J = 8.1 and 3.3 Hz), 4.02-4.38 
(m, 7H), 4.75 (d, 1H, J = 3.3 Hz), 4.82-4.96 (m, 2H), 4.99-5.12 (m, 2H), 5.13 (dd, 
1H, J = 7.8 and 4.4 Hz), 5.44 (t, 1H, J = 3.7 Hz) and 6.11 (d, 1H, J = 8.1 Hz); 13C 
NMR (CDCl3) δ 20.72, 20.75, 20.79, 20.82, 20.83, 20.87, 21.2, 61.8, 62.4, 64.6, 
64.9, 65.5, 66.8, 67.6, 69.0, 69.5, 71.7, 91.0, 94.4, 155.6, 168.9, 169.3, 169.4, 
169.6, 170.2, 170.5 and 170.7; HRMS (APCI), m/z 680.2039 (M + H)+ 
(C27H38NO19 requires m/z 680.2038). 
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 3,4,6-Tri-O-acetyl-2-O-(2,4,6-Tri-O-acetyl-3-O-carbamoyl-α-D-
altropyranosyl)-β-L-gulopyranosyl Diphenyl Phosphate (3.63). To a solution 
containing 44.0 mg (60.0 μmol) of disaccharide 3.61 in 0.5 mL of anh DMF was 
added 7.00 mg (80.0 μmol) of hydrazine acetate. The reaction mixture was stirred 
at room temperature for 1.5 h and then quenched by the addition of 20 mL of 
ethyl acetate. The organic layer was washed with three 10-mL portions of brine 
and dried (MgSO4). The solvent was concentrated under diminished pressure to 
afford a crude residue. The residue was used for the next reaction.  
To a stirred solution containing 41.0 mg (60.0 μmol) of the crude residue 
in 4 mL of anh dichloromethane was added 10.0 mg (80.0 μmol) of DMAP, 100 
μL (72.0 mg, 0.68 mmol) of Et3N and 125 μL (162 mg, 0.61 mmol) of diphenyl 
chlorophosphate at 0 °C. The reaction mixture was stirred at 0 °C for 2 h and then 
poured into a mixture of 40 mL of ethyl acetate and 20 mL of satd aq NaHCO3. 
The aqueous and organic layers were separated and the organic layer was washed 
with three 10-mL portions of distilled water and brine and then dried (MgSO4). 
The solvent was concentrated under diminished pressure to afford a crude residue. 
The residue was applied to a silica gel column (25 ൈ 2 cm). Elution with 2:1 ethyl 
acetate−hexanes afforded phosphate ester 3.63 as a colorless oil: yield 31 mg 
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(55% over two steps); silica gel TLC Rf 0.30 (2:1 ethyl acetate−hexanes); 1H 
NMR (CDCl3) δ 1.83 (s, 3H), 1.98 (s, 3H), 2.04 (s, 3H), 2.12 (d, 3H, J = 2.8 Hz), 
2.15 (d, 6H, J = 3.9 Hz), 3.98-4.09 (m, 2H), 4.09-4.25 (m, 4H), 4.26-4.36 (m, 
2H), 4.66 (d, 1H, J = 9.8 Hz), 4.83 (d, 1H, J = 2.1 Hz), 4.91 (d, 1H, J = 6.4 Hz), 
5.03 (t, 1H, J = 5.7 Hz), 5.09-5.19 (m, 2H), 5.45 (d, 1H, J = 3.2 Hz), 5.74 (t, 1H, J 
= 8.0 Hz) and 7.09-7.41 (m, 10H); 13C NMR (CDCl3) δ 20.62, 20.66, 20.77, 
20.83, 20.88, 61.6, 62.2, 64.5, 64.7, 65.1, 67.1, 67.3, 68.9, 71.7, 94.1, 120.28, 
120.32, 120.37, 125.98, 125.99, 126.23, 126.24, 129.93, 129.94, 130.1, 155.9, 
168.8, 169.0, 169.3, 169.5, 170.4, and 170.8; HRMS (APCI), m/z 870.2230 (M + 
H)+ (C37H45NO21P requires m/z 870.2222). 
 
 
3,4,6-Tri-O-acetyl-2-O-(2,4,6-Tri-O-acetyl-3-O-carbamoyl-α-D-
altropyranosyl)-β-L-gulopyranosyl Benzyl 2-(2-Ethoxy)ethylcarbamate 
(3.65). To a stirred solution containing 31 mg (40 μmol) of phosphate ester 3.63 
in 0.45 mL of anh dichloromethane was added a solution of 8.0 mg (30 μmol) of 
CBz-protected linker 3.40 in 0.45 mL of anh dichloromethane at 0 °C. To the 
reaction mixture was added 12 μL (15 mg, 80 μmol) of TMSOTf and the reaction 
mixture was stirred at 0 °C for 15 min. The reaction mixture was poured into a 
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mixture of 10 mL of ethyl acetate and 10 mL satd aq NaHCO3. The aqueous and 
organic layers were separated and the organic layer was washed with three 10-mL 
portions of water and brine and then dried (MgSO4). The solvent was 
concentrated under diminished pressure to afford a crude residue. The residue was 
applied to a silica gel column (25 ൈ 2 cm). Elution with 12:12:1 ethyl 
acetate−hexanes−methanol afforded 3.65 as a colorless oil: yield 15 mg (48%); 
silica gel TLC Rf 0.17 (11:11:1 ethyl acetate−hexanes−methanol); 1H NMR 
(CDCl3) δ 1H NMR (CDCl3) δ 1.95-2.07 (m, 6H), 2.07-2.15 (m, 12H), 3.41 (t, 
2H, J = 9.5 Hz), 3.59 (d, 2H, J = 5.0 Hz), 3.61-3.71 (m, 3H), 3.87 (dt, 1H, J = 
12.8 and 6.5 Hz), 3.94-4.04 (m, 1H), 4.04-4.20 (m, 3H), 4.21-4.26 (m, 1H), 4.36-
4.48 (m, 1H), 4.49-4.60 (m, 1H), 4.75 (d, 1H, J = 7.5 Hz), 4.84-5.05 (m, 4H), 
5.05-5.20 (m, 4H), 5.21-5.29 (m, 1H), 5.32-5.49 (m, 2H) and 7.27-7.38 (m, 5H) ; 
13C NMR (CDCl3) δ 20.75, 20.77, 20.82, 20.85, 20.88, 20.92, 40.9, 62.1, 62.3, 
62.6, 65.1, 65.2, 66.9, 67.8, 68.1, 68.5, 68.6, 69.2, 70.37, 70.45, 99.5, 128.3, 
128.4, 128.5, 128.7, 136.6, 155.7, 169.0, 169.4, 169.61, 169.65, 170.6, 170.82 and 
170.89; HRMS (APCI), m/z 859.2973 (M + H)+ (C37H51N2O21 requires m/z 
859.2984). 
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1,3,4,6-Tetra-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-(methylcarbamoyl)-α-D-
altropyranosyl)-β-L-gulopyranose (3.62). To a solution containing 86.0 mg 
(0.11 mmol) of ester 3.60 in 2.4 mL of anh THF was added 54.0 μL (0.11 mmol) 
of a 2 M solution of CH3NH2 in THF at 0 °C. The reaction mixture was stirred at 
room temperature for 15 h at which time analysis by silica gel TLC indicated that 
the reaction was complete. The solvent was concentrated under diminished 
pressure to afford a crude residue. The residue was applied to a silica gel column 
(35 ൈ 2 cm). Elution with 2:1 ethyl acetate−hexanes afforded disaccharide 3.62 as 
a colorless oil: yield 31 mg (42%); silica gel TLC Rf 0.13 (3:1 ethyl 
acetate−hexanes); 1H NMR (CDCl3) δ 2.01 (s, 3H), 2.05 (s, 3H), 2.11 (s, 6H), 
2.13 (s, 3H), 2.15 (s, 3H), 2.16 (s, 3H), 2.79 (d, 3H, J = 4.7 Hz), 3.98 (dd, 1H, J = 
8.0 and 3.3 Hz), 4.04-4.30 (m, 4H), 4.33 (dt, 1H, J = 12.1 and 6.1 Hz), 4.71-
4.77(m, 1H), 4.84-4.95(m, 1H), 5.06 (dd, 2H, J = 10.1 and 6.6 Hz), 5.11-5.19 (m, 
1H), 5.21-5.41 (m, 2H), 5.43 (dd, 1H, J = 10.0 and 6.3 Hz) and 6.10 (d, 1H, J = 
8.0 Hz); 13C NMR (CDCl3) δ 20.77, 20.81, 20.82, 20.85, 20.88, 20.9, 21.3, 27.8, 
61.8, 62.5, 64.8, 65.0, 65.5, 66.4, 66.7, 67.6, 69.2, 71.6, 91.1, 94.7, 155.9, 169.0, 
169.3, 169.4, 169.6, 170.1, 170.5 and 170.8; HRMS (APCI), m/z 694.2204 (M + 
H)+ (C28H40NO19 requires m/z 694.2195). 
 
 3,4,6-Tri-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-(methylcarbamoyl)-α-D-
altropyranosyl)-β-L-gulopyranosyl Diphenyl Phosphate (3.64). To a solution 
containing 31.0 mg (40.0 μmol) of disaccharide 3.62 in 0.5 mL of anh DMF was 
added 5.00 mg (50.0 μmol) of hydrazine acetate. The reaction mixture was stirred 
at room temperature for 1.5 h and then quenched by the addition of 20 mL of 
ethyl acetate. The organic solution was washed with three 10-mL portions of 
brine and dried (MgSO4). The solvent was concentrated under diminished 
pressure to afford a crude residue. The residue was used for the next reaction.  
To a stirred solution containing 22.0 mg (30.0 μmol) of the residue in 2 
mL of anh dichloromethane was added 6.00 mg (40.0 μmol) of DMAP, 52.0 μL 
(38.0 mg, 370 μmol) of Et3N and 70.0 μL (91.0 mg, 330 μmol) of diphenyl 
chlorophosphate at 0 °C. The reaction mixture was stirred at 0 °C for 2 h and then 
poured into a mixture of 40 mL of ethyl acetate and 20 mL of satd aq NaHCO3. 
The aqueous and organic layers were separated and the organic layer was washed 
with three 10-mL portions of distilled water and brine and then dried (MgSO4). 
The solvent was concentrated under diminished pressure to afford a crude residue. 
The residue was applied to a silica gel column (25 ൈ 2 cm). Elution with 2:1 ethyl 
acetate−hexanes afforded phosphate ester 3.64 as a colorless oil: yield 7.0 mg 
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(17% over two steps); silica gel TLC Rf 0.28 (3:1 ethyl acetate−hexanes); 1H 
NMR (CDCl3) δ 1.85 (s, 3H), 1.98 (s, 3H), 2.04 (s, 3H), 2.12 (s, 3H), 2.15 (d, 6H, 
J = 2.5 Hz), 2.63 (d, 3H, J = 4.7 Hz), 3.98-4.08 (m, 2H), 4.09-4.26 (m, 3H), 4.30 
(t, 1H, J = 6.1 Hz), 4.63 (d, 1H, J = 10.5 Hz), 4.80 (d, 1H, J = 3.0 Hz), 4.89 (s, 
1H), 5.00-5.06 (m, 1H), 5.13 (dd, 1H, J = 10.5 and 3.1 Hz), 5.18 (d, 1H, J = 3.0 
Hz), 5.45 (d,1H, J = 2.9 Hz), 5.73 (t, 1H, J = 8.0 Hz), 6.46 (d, 1H, J = 4.8 Hz) and 
7.12-7.40 (m, 10H); 13C NMR (CDCl3) δ 20.67, 20.72, 20.77, 20.8, 20.9, 27.4, 
61.6, 62.3, 64.67, 64.72, 65.1, 66.7, 67.2, 69.1, 71.7, 94.2, 96.52, 96.56, 120.1, 
120.2, 120.32, 120.37, 126.0, 126.1, 129.9, 130.1, 156.1, 168.8, 169.0, 169.4, 
169.5, 170.5 and 170.8; HRMS (APCI), m/z 884.2403 (M + H)+ (C38H47NO21P 
requires m/z 884.2378). 
 
 
3,4,6-Tri-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-(methylcarbamoyl)-α-D-
altropyranosyl)-α,β-L-gulopyranosyl Benzyl 2-(2-Ethoxy)ethylcarbamate 
(3.66). To a stirred solution containing 17 mg (19 μmole) of phosphate ester 3.64 
in 0.25 mL of anh dichloromethane was added a solution of 5.0 mg (17 μmole) of 
CBz-protected linker 3.40 in 0.25 mL of anh dichloromethane at 0 °C. To the 
reaction mixture was added 7.0 μL (8.6 mg, 34 μmol) of TMSOTf. The reaction 
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mixture was stirred at 0 °C for 15 min and then poured into a mixture of 10 mL 
ethyl acetate and 10 mL satd aq NaHCO3. The aqueous and organic layers were 
separated and the organic layer was washed with three 10-mL portions of distilled 
water and brine and then dried (MgSO4). The solvent was concentrated under 
diminished pressure to afford a crude residue. The residue was applied to a silica 
gel column (25 ൈ 2 cm). Elution with 12:12:1 ethyl acetate−hexanes−methanol 
afforded 3.66 as a colorless oil: yield 10 mg (59%); silica gel TLC Rf 0.14 
(11:11:1 ethyl acetate−hexanes−methanol); 1H NMR (CDCl3) δ 1.97 (d, 3H, J = 
8.6 Hz), 2.04 (d, 3H, J = 4.2 Hz), 2.07-2.15 (m, 12H), 2.75 (d, 3H, J = 4.7 Hz), 
3.34-3.44 (m, 2H), 3.51-3.70 (m, 8H), 3.72 (dd, 1H, J = 10.3 and 5.6 Hz), 3.82-
3.93 (m, 1H), 3.95-4.25 (m, 3H), 4.26-4.56 (m, 1H), 4.63 (d, 1H, J = 7.2 Hz), 
4.86-5.02 (m, 1H), 4.96-5.28 (m, 6H), 5.33-5.51 (m, 1H), 5.83 (d, 1H, J = 4.7 Hz) 
and 7.27-7.39 (m, 5H); 13C NMR (CDCl3) δ 20.79, 20.84, 20.86, 20.89, 20.93, 
21.0, 29.8, 41.0, 61.9, 62.2, 62.3, 62.7, 62.9, 65.26, 65.33, 66.9, 67.1, 70.2, 70.4, 
70.5, 72.3, 128.3, 128.4, 128.66, 128.67, 136.6, 169.61, 169.65, 169.68, 170.6, 
170.7, 170.8 and 170.9; HRMS (APCI), m/z 873.3150 (M + H)+ (C38H53N2O21 
requires m/z 873.3141). 
 
 Cy5**succinimidyl ester (3.8).174 To a solution containing 0.5 mg (0.6 μmol) of 
Cy5**COOH was added 5.0 mg (16 μmol) of TSTU dissolved in 100 μL of anh 
DMF, followed by 7.5 μL (5.6 mg, 43 μmol) of anh DIPEA dissolved in 75 μL of 
anh DMF. The reaction mixture was stirred at room temperature for 3 h and then 
diluted with 3 mL of ethyl acetate. The solution was then centrifuged at 12000 
rpm for 10 min. The supernatant solution was discarded and the residue washed 
with 1 mL of ethyl acetate. The residue was then dried under vacuum in the dark 
for 30 min to afford the product 3.8 as a dark blue solid: yield 480 μg (86%); 
mass spectrum (MALDI-TOF), m/z 1023.5 (M + H)+ (theoretical m/z 1023.2).  
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Disaccharide-dye Conjugate 3.1.To a solution of 2.20 mg (2.60 mmol) of 
compound 3.41173 in 1 mL of anh methanol was added a freshly prepared solution 
of 0.4 M sodium methoxide in methanol. The reaction mixture was allowed to stir 
at room temperature for 3 h, and the complete consumption of starting material 
was confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was 
then quenched by the addition of 500 mg of Dowex 50x resin, shaken for 15 min 
and filtered. To the solution of the crude product in methanol was added Pd/C and 
H2 gas was bubbled through for 1 h. The complete consumption of starting 
material was confirmed by MALDI-TOF mass spectral analysis. The reaction 
mixture was filtered through Celite 545® and then concentrated under diminished 
pressure to afford 3.43, which was used for the next reaction; HRMS (APCI), m/z 
473.1986 (M + H)+ (C17H33N2O13 requires m/z 473.1983).  
To 101 μg (0.21 μmol) of 3.43 was added a solution of 106 μg (0.11 μmol) 
of Cy5**COOSu (Figure 3.3) in 100 μL of 0.2 M phosphate buffer and the 
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reaction mixture was stirred overnight in the dark. The reaction mixture was 
purified on an Alltech Alltima C18 reversed phase semi-preparative (250 × 10 
mm, 5 μm) HPLC column using aq 0.1% TFA and CH3CN mobile phases. A 
linear gradient was employed (99:1 0.1% aq TFA−CH3CNÆ69:31 0.1% aq 
TFA−CH3CN) over a period of 35 min at a flow rate of 4 mL/min. The fractions 
containing the desired product eluted at 23.5 min and were collected, frozen and 
lyophilized to give 3.1 as a blue solid: yield 48 μg (35% over two steps); HRMS 
(APCI), m/z 669.1883 (M − K − 2H)2− (C55H78N4O26S42− requires m/z 669.1899). 
 
 
Disaccharide-dye Conjugate 3.2.To a solution of 4.40 mg (5.00 mmol) of 
compound 3.42 in 2 mL of anh methanol was added a freshly prepared solution of 
0.4 M sodium methoxide in methanol. The reaction mixture was allowed to stir at 
room temperature for 3 h, and the complete consumption of starting material was 
confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was then 
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quenched by the addition of 500 mg of Dowex 50x resin, shaken for 15 min and 
filtered. To the solution of the crude product in methanol was then added Pd/C 
and H2 gas was bubbled through for 1 h. The complete consumption of starting 
material was confirmed by MALDI-TOF mass spectral analysis. The reaction 
mixture was filtered through Celite 545® and concentrated under diminished 
pressure to afford 3.44, which was used for the next reaction; HRMS (APCI), m/z 
487.2140 (M + H)+ (C18H35N2O13 requires m/z 487.2139).  
To 101 μg (0.21 μmol) of 3.44 was added a solution of 106 μg (0.11 μmol) 
of Cy5**COOSu (Figure 3.3) in 100 μL of 0.2 M phosphate buffer and the 
reaction mixture was stirred overnight in the dark. The reaction mixture was 
purified on an Alltech Alltima C18 reversed phase semi-preparative (250 × 10 
mm, 5 μm) HPLC column using aq 0.1% TFA and CH3CN mobile phases. A 
linear gradient was employed (99:1 0.1% aq TFA−CH3CNÆ69:31 0.1% aq 
TFA−CH3CN) over a period of 35 min at a flow rate of 4 mL/min. The fractions 
containing the desired product eluted at 23.5 min and were collected, frozen and 
lyophilized to give 3.2 as a blue solid: yield 53 μg (37% over two steps); HRMS 
(APCI), m/z 676.1996 (M − K − 2H)2− (C56H80N4O26S42− requires m/z 676.1977). 
 
 Disaccharide-dye Conjugate 3.3. To a solution of 5.80 mg (6.60 mmol) of 
compound 3.49 in 2 mL of anh methanol was added a freshly prepared solution of 
0.4 M sodium methoxide in methanol. The reaction mixture was allowed to stir at 
room temperature for 3 h, and the complete consumption of starting material was 
confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was then 
quenched by the addition of 500 mg of Dowex 50x resin, shaken for 15 min and 
filtered. To the solution of the crude product in methanol was added Pd/C and H2 
gas was bubbled through for 1 h. The complete consumption of starting material 
was confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was 
filtered through Celite 545® and then concentrated under diminished pressure to 
afford 3.50, which was used for the next reaction. HRMS (APCI), m/z 487.2133 
(M + H)+ (C18H35N2O13 requires m/z 487.2139).  
To 87.0 μg (0.18 μmol) of 3.50 was added a solution of 90.0 μg (0.09 
μmol) of Cy5**COOSu (Figure 3.3) in 150 μL of 0.2 M phosphate buffer and the 
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reaction mixture was stirred overnight in the dark. The reaction mixture was 
purified on an Alltech Alltima C18 reversed phase semi-preparative (250 × 10 
mm, 5 μm) HPLC column using aq 0.1% TFA and CH3CN mobile phases. A 
linear gradient was employed (99:1 0.1% aq TFA−CH3CNÆ69:31 0.1% aq 
TFA−CH3CN) over a period of 35 min at a flow rate of 4 mL/min. The fractions 
containing the desired product eluted at 23.9 min and were collected, frozen and 
lyophilized to give 3.3 as a blue solid: yield 27 μg (23% over two steps); HRMS 
(APCI), m/z 676.1984 (M − K − 2H)2− (C56H80N4O26S42− requires m/z 676.1977). 
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Disaccharide-dye Conjugate 3.4. To a solution containing 2.20 mg (2.56 mmol) 
of compound 3.55173 in 1 mL of anh methanol was added a freshly prepared 
solution of 0.4 M sodium methoxide in methanol. The reaction mixture was 
allowed to stir at room temperature for 3 h, and the complete consumption of 
starting material was confirmed by MALDI-TOF mass spectral analysis. The 
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reaction mixture was then quenched by the addition of 500 mg of Dowex 50x 
resin, shaken for 15 min and filtered. To the solution of the crude product in 
methanol was then added Pd/C and H2 gas was bubbled through for 1 h. The 
complete consumption of starting material was confirmed by MALDI-TOF mass 
spectral analysis. The reaction mixture was filtered through Celite 545® and then 
concentrated under diminished pressure to afford 3.57, which was used for the 
next reaction; HRMS (APCI), m/z 473.1972 (M + H)+ (C17H33N2O13 requires m/z 
473.1983).  
To 101 μg (0.21 μmol) of 3.57 was added a solution of 106 μg (0.11 μmol) 
of Cy5**COOSu (Figure 3.3) in 100 μL of 0.2 M phosphate buffer and the 
reaction mixture was stirred overnight in the dark. The reaction mixture was 
purified on an Alltech Alltima C18 reversed phase semi-preparative (250 × 10 
mm, 5 μm) HPLC column using aq 0.1% TFA and CH3CN mobile phases. A 
linear gradient was employed (99:1 0.1% aq TFA−CH3CNÆ69:31 0.1% aq 
TFA−CH3CN) over a period of 35 min at a flow rate of 4 mL/min. The fractions 
containing the desired product eluted at 23.5 min and were collected, frozen and 
lyophilized to give 3.4 as a blue solid: yield 44 μg (32% over two steps); HRMS 
(APCI), m/z 669.1880 (M − K − 2H)2− (C55H78N4O26S42− requires m/z 669.1899). 
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Disaccharide-Dye Conjugate 3.5.To a solution containing 2.70 mg (3.10 mmol) 
of 3.56 in 2 mL of anh methanol was added a freshly prepared solution of 0.4 M 
sodium methoxide in methanol. The reaction mixture was allowed to stir at room 
temperature for 3 h, and the complete consumption of starting material was 
confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was then 
quenched by the addition of 500 mg of Dowex 50x resin, shaken for 15 min and 
filtered. To the solution of the crude product in methanol was added Pd/C and H2 
gas was bubbled through for 1 h. The complete consumption of starting material 
was confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was 
filtered through Celite 545® and concentrated under diminished pressure to afford 
3.58, which was used for the next reaction; HRMS (APCI), m/z 487.2153 (M + 
H)+ (C18H35N2O13 requires m/z 487.2139).  
To 134 μg (0.27 μmol) of 3.58 was added a solution of 90.0 μg (0.09 
μmol) of Cy5**COOSu (Figure 3.3) in 150 μL of 0.2 M phosphate buffer and the 
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reaction mixture was stirred overnight in the dark. The reaction mixture was 
purified on an Alltech Alltima C18 reversed phase semi-preparative (250 × 10 
mm, 5 μm) HPLC column using aq 0.1% TFA and CH3CN mobile phases. A 
linear gradient was employed (99:1 0.1% aq TFA−CH3CNÆ69:31 0.1% aq 
TFA−CH3CN) over a period of 35 min at a flow rate of 4 mL/min. The fractions 
containing the desired product eluted at 24.8 min and were collected, frozen and 
lyophilized to give 3.5 as a blue solid: yield 60 μg (33% over two steps); HRMS 
(APCI), m/z 676.1995 (M − K − 2H)2− (C56H80N4O26S42− requires m/z 676.1977). 
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Disaccharide-Dye Conjugate 3.6. To a solution containing 2.40 mg (2.80 mmol) 
of compound 3.65 in 2 mL of anh methanol was added a freshly prepared solution 
of 0.4 M sodium methoxide in methanol. The reaction mixture was allowed to stir 
at room temperature for 3 h, and the complete consumption of starting material 
was confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was 
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then quenched by the addition of 500 mg of Dowex 50x resin, shaken for 15 min 
and filtered. To the solution of the crude product in methanol was then added 
Pd/C and H2 gas was bubbled through for 1 h. The complete consumption of 
starting material was confirmed by MALDI-TOF mass spectral analysis. The 
reaction was filtered through Celite 545® and then concentrated under diminished 
pressure to afford 3.67, which was used for the next reaction. HRMS (APCI), m/z 
473.1978 (M + H)+ (C17H33N2O13 requires m/z 473.1983).  
To 87.0 μg (0.18 μmol) of 3.67 was added a solution of 90.0 μg (0.09 
μmol) of Cy5**COOSu (Figure 3.3) in 150 μL of 0.2 M phosphate buffer and the 
reaction mixture was stirred overnight in the dark. The reaction mixture was 
purified on an Alltech Alltima C18 reversed phase semi-preparative (250 × 10 
mm, 5 μm) HPLC column using aq 0.1% TFA and CH3CN mobile phases. A 
linear gradient was employed (99:1 0.1% aq TFA−CH3CNÆ69:31 0.1% aq 
TFA−CH3CN) over a period of 35 min at a flow rate of 4 mL/min. The fractions 
containing the desired product eluted at 23.5 min and were collected, frozen and 
lyophilized to give 3.6 as a blue solid: yield 39 μg (33% over two steps); HRMS 
(APCI), m/z 669.1916 (M − K − 2H)2− (C55H78N4O26S42− requires m/z 669.1899). 
 
 Disaccharide-Dye Conjugate 3.7. To a solution containing 1.00 mg (1.10 mmol) 
of compound 3.66 in 2 mL of anh methanol was added a freshly prepared solution 
of 0.4 M sodium methoxide in methanol. The reaction mixture was allowed to stir 
at room temperature for 3 h, and the complete consumption of starting material 
was confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was 
then quenched by the addition of 300 mg of Dowex 50x resin, shaken for 15 min 
and filtered. To the solution of the crude product in methanol was added Pd/C and 
H2 gas was bubbled through for 1 h. The complete consumption of starting 
material was confirmed by MALDI-TOF mass spectral analysis. The reaction 
mixture was filtered through Celite 545® and then concentrated under diminished 
pressure to afford 3.68, which was used for the next reaction. HRMS (APCI), m/z 
487.2143 (M + H)+ (C18H35N2O13 requires m/z 487.2139).  
To 87.0 μg (0.18 μmol) of 3.68 was added a solution of 90.0 μg (0.09 
μmol) of Cy5**COOSu (Figure 3.3) in 150 μL of 0.2 M phosphate buffer and the 
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reaction mixture was stirred overnight in the dark. The reaction mixture was 
purified on an Alltech Alltima C18 reversed phase semi-preparative (250 × 10 
mm, 5 μm) HPLC column using aq 0.1% TFA and CH3CN mobile phases. A 
linear gradient was employed (99:1 0.1% aq TFA−CH3CNÆ69:31 0.1% aq 
TFA−CH3CN) over a period of 35 min at a flow rate of 4 mL/min. The fractions 
containing the desired product eluted at 24.7 and were collected, frozen and 
lyophilized to give 3.7 as a blue solid: yield 57 μg (48% over two steps); HRMS 
(APCI), m/z 676.1967 (M − K − 2H)2− (C56H80N4O26S42− requires m/z 676.1977). 
 
Quantification of the binding/uptake by fluorescence microscopy 
A549 lung carcinoma cells and WI-38 normal lung cells were grown in RPMI 
1640 (Gibco) supplemented with 10% fetal bovine serum (Hyclone) and 1% 
pencillin-streptomycin mix antibiotic supplements (Cellgro). SW480 colon 
carcinoma cells and CCD-112CoN normal colon cells were grown in MEDM 
(Gibco) supplemented with 10% fetal bovine serum (Hyclone) and 1% pencillin-
streptomycin mix antibiotic supplements (Cellgro). Fluorescence images were 
obtained using a Zeiss Axiovert 200M inverted microscope fitted with an 
AxioCam MRm camera equipped with a 300-w xenon lamp, ET-CY5 and CY7 
cyanine filter. Adherent cancer cells were grown on 16-well glass chamber slide. 
Cells were rinsed with phosphate buffered saline when the cell confluence was 
about 70%, then the media was replaced with RPMI 1640 (no phenol red). The 
reporter molecules were subsequently added to afford the final desired 
concentration (25 μM). The cells were incubated at 37 °C for 1 h, washed with 
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phosphate buffered saline and then fixed with 4% paraformaldehyde at 37 °C for 
5 min. The slide was then mounted with Prolong Antifade Gold reagent 
(Invitrogen) and covered with glass coverslip and then dried for 1 h before 
microscope imaging analysis. For comparative studies, the exposure time and 
laser intensity were kept identical for accurate intensity measurements. Pixel 
intensity was quantified using AxioVision Release 4.7 version software, and the 
mean pixel intensity was generated as gray level. Cell lines were maintained at 37 
°C under a humidified atmosphere of 5% CO2 and 95% air. 
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